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ABSTRACT 
 
Luis Fernando Méndez López                                   Graduation date: June 2019 
Universidad Autónoma De Nuevo León 
Facultad De Ciencias Químicas 
 
Title of the study: Metabolomic profile and Bioassay-guided Phytochemical 
analysis of the Stems from Cissus trifoliata, evaluation of their Antibacterial and 
Cytotoxic activity, and determination of the Mechanism of Action of one active 
compound. 
 
Number of pages: 150 Dissertation in partial fulfillment of 
the requirements for the degree of 
Doctor of Science in Pharmacy 
              
Area of study: Natural product chemistry 
 
Objectives and methods: Bioprospecting the metabolic profile of medicinal plants has 
provided a reliable resource for drug discovery and advancements in biomedical research. 
Cissus trifoliata (L.) L belongs to the Vitaceae family and is an important medicinal plant 
used in Mexico for the management of infectious diseases and tumors. The present study 
aimed to identify the metabolic profile of the extracts from the stems of C. trifoliata and 
evaluate their antibacterial and cytotoxic activities. Additionally, to identify the molecules 
that contribute to their biological activity and to explore the mechanism of action of one 
active compound. The hexane, CHCl3-MeOH, and aqueous extracts were prepared from 
the stems of C. trifoliata and their metabolic profile was investigated by column 
VIII 
 
chromatography, NMR, GC-MS, and LC-MS. The antibacterial activity was determined by 
the broth microdilution method and the cytotoxicity against cancer cell lines using the MTS 
proliferation assay. A bioassay-guided study of the CHCl3-MeOH extract was performed 
using WST-1 to identify the active constituents responsible for the antiproliferative effects 
against cancer cells. Additionally, microarrays were used to identify the mechanism of 
action of one active compound against prostate cancer cells.  
Contribution and conclusions: The metabolic profile of C. trifoliata stems was 
constituted of polyphenols (36%), terpenes (28%), fatty acids (18%), simple phenols (9%) 
and alkanes (9%). The pathway analysis indicated the high production of stilbenes, 
flavonoids, and sterols. The extracts showed no antibacterial activity (MIC > 500 µg/ml), 
but high cytotoxic effects against cancer cells (IC50 ≤ 30 µg/ml). The hexane and aqueous 
extracts showed high antiproliferative activity against cancer cells from the liver (Hep3B, 
HepG2) and breast (MCF7). The bioactivity of these extracts was related to the synergistic 
effect of the triterpenes, sterols, flavonols, and stilbenes with cytotoxic, antiproliferative, 
and antiestrogenic activities. The bioassay-guided study of the CHCl3-MeOH extract 
allowed the identification of two active fractions. Both showed significative reduction (p > 
0.05) of cell viability on PC3 and MCF7 cancer cells at a concentration of 100 µg/ml. The 
cytotoxic activity was related to the synergistic anticancer effects of the mixture of 
coumaric acid, kaempferol, apigenin, hydroxyursolic, ursolic, and betulinic acid plus the 
stilbenes resveratrol, piceatannol, and viniferin. The stilbene that characterizes the 
Vitaceae plants is the resveratrol, thus was selected for the study of the mechanism of 
action. To carry out the microarray assay, PC3 cells were exposed to a non-cytotoxic 
inhibitory concentration (IC25) of resveratrol. Results showed that this phenolic compound 
induced significative transcriptional changes (2-fold) in 847 genes. The functional analysis 
IX 
 
suggested that resveratrol influences differentiation and impair cancer stemness by 
induction of the transcription factors POU4F2, KLF14, Hox-A3, and repression of Nanog. 
Resveratrol also affected cellular metabolism by upregulation of SIRT5 and repressed 
genes of the cancer pathways of TGF-β, Notch, PI3K/Akt, insulin/IGF-1, and MDM4/p53. 
Overall, the metabolic profile and biological evaluation of the stems from C. trifoliata 
correlate with high anticancer activity and together with the molecular mechanism of the 
identified bioactive constituents explain its traditional use in the management of tumors. 
 
 
______________________________________________ 
María del Rayo Camacho Corona, Ph.D. 
Thesis Director 
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NCI   National Cancer Institute 
NDN   Necdin 
NDM-1   New Delhi metallo-beta-lactamase 
NDST2  Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 2. 
NF-κB   Nuclear factor-κB 
NIST   National Institute Standard and Technology  
NNT    NAD(P) transhydrogenase  
NMR   Nuclear Magnetic Resonance  
NO   Nitric oxide  
NorA   Protein associated with quinolone resistance in S. aureus 
NP115991  Gap junction alpha-10 protein 
NSCLC  Non-small cell lung carcinoma 
ODS   Octadecylsilane  
oTOF   Orthogonal time-of-flight  
Oxa-48  Carbapenemase-producing Klebsiella pneumoniae strains 
p21  Cyclin-dependent kinase inhibitor 
p27kip1  Cyclin-dependent kinase inhibitor 1B 
PA26   p53-induced protein sestrin 
PARD6G  Partitioning defective 6 homolog gamma 
PBPs   Penicillin-binding proteins  
PBS  Phosphate buffered saline 
PC3   Human prostate cancer cell line. 
PCA   Principal Component Analysis  
PCAF   P300/CBP-associated factor 
PDCD4  Programmed Cell Death 4 
PFK1  Phosphofructokinase  
PGAM   Phosphoglycerate mutase  
PGE2   Prostaglandin E2   
PI3K   Phosphoinositide 3-kinase 
PIK3R2  Phosphatidylinositol 3-kinase regulatory subunit beta  
PKNOX1  PBX/knotted homeobox 1 
PLA2   Phospholipase A2 
PLCG1  Phospholipase C gamma  
PLS-DA  Partial Least Squares Discriminant Analysis  
POR   NADPH P450 reductase  
POU4F2  POU class 4 homeobox 2 
PTPLA   Very-long-chain 3-hydroxyacyl-CoA dehydratase  
Q   Quadrupole  
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QIT-MS  Quadrupole ion traps  
Qnr proteins Quinolone resistance proteins 
QqQ   Triple quadrupoles  
QR-2   Quinone reductase-2  
QTOF   Quadrupole time of flight 
RAW 264.7  Murine macrophage cells 
RBL-2H3  Rat basophilic leukemia cells 
RBPSUH  Recombining binding protein suppressor of hairless 
ReSpect  Spectral database for phytochemicals 
RNAi   RNA interference 
RP   Reversed-phase  
SARDH  Sarcosine mitochondrial dehydrogenase  
SD   Standard Deviation 
SDC2   Syndecan-2 
SETD1B  Histone-lysine N-methyltransferase 
SETD3  SET domain containing 3 
SFB   Serum Fetal Bovine  
SIRT5   NAD-dependent protein deacylase sirtuin-5, mitochondrial. 
SK-OV3  Ovary cancer cells 
SLC25A1  Tricarboxylate mitochondrial transport protein  
SLC27A1  Long-chain fatty acid transport protein 1 ligase  
Smad7   Mothers against decapentaplegic homolog 7 
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STAT3   Signal transducer and activator of transcription 3 
STK17A serine/threonine kinase 17a 
TBX1   T-box 1 protein 
TGF-α   Transforming growth factor alpha 
THRAP3  Thyroid hormone receptor associated protein 3 
TJP2   Tight junction protein ZO-2 
TKT   Transketolase 
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TMS  Tetramethylsilane  
TNF-α   Tumor necrosis factor alpha  
Tp53   Tumor protein p53 
TSG101  Tumor susceptibility gene 101 
UANL   Universidad Autonoma de Nuevo Leon  
UHPLC  Ultra High performance liquid chromatography 
UPLC   Ultra High Performance Liquid Chromatography system 
VEGF   Vascular endothelial growth factor 
Vero   Kidney epithelial cells from green monkey 
WST-1   1-methoxy-5-methyl-phenazinium methyl sulfate 
ZDHHC20  Palmitoyltransferase 
ZDHHC9   Palmitoyltransferase specific for HRAS 
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CHAPTER I 
1. INTRODUCTION 
1.1. Cancer  
Cancer is the second leading cause of morbidity and mortality worldwide, with 
approximately 14 million newly diagnosed cases per year. Almost 9 million people die 
from cancer every year, representing one of every six deaths and one trillion dollars just 
in the United States. Furthermore, the number of diagnosed cases is expected to rise 70% 
over the next two decades because of the increasing longevity and sedentary lifestyle of 
population 1. In Mexico, cancer is the third leading cause of death in adults. The most 
common tissues affected with cancer in males are originated in the digestive (24%) or 
genitourinary (12%) tract whereas in females neoplasia begins in the breast (30%), 
genitourinary (17%) or digestive (14%) tissue 2. Cancer is traditionally defined as the 
uncontrolled growth of abnormal cells that impairs the normal biological process of healthy 
cells. As the tumor progress, the malignant cells spread by the invasion of nearby tissues 
or metastasize distant organs compromising its functions and ultimately might result in 
death. The altered process in cancer cells includes the constant activation of proliferation, 
the evasion of growth suppressors, increased resistance to cell death, the acquisition of 
replicative immortality, genome instability, metabolic changes, invasion, and metastasis. 
Additionally, tumors may induce angiogenesis, inflammation, and immune system evasion 
in the affected tissues fostering cancer progression 3. 
Cancer treatment includes surgery, radiation and systemic treatment with conventional 
cytotoxic therapy, endocrine treatment (in case of hormone-dependent tumors), or 
targeted agents. The selective therapies were developed to target biomarkers of certain 
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tumors, such as oncogenes or tumor suppressors. This therapy includes drugs based on 
RNA interference, kinase inhibitors or monoclonal antibodies with fewer side effects 4. On 
the other hand, cytotoxic therapy lacks selectivity and generates deoxyribonucleic acid 
(DNA) damage or the inhibition of essential enzymes, microtubules, and topoisomerases, 
which ultimately leads to cell death. Therefore, patients may suffer severe side effects 
such as vomits, alopecia, diarrhea, constipation, myelosuppression, infection, cystitis, 
ulcers, lung fibrosis, cardiotoxicity, hepatotoxicity, mucositis and nephrotoxicity 4. Despite 
the adverse side effects, some protocols of cytotoxic therapy remain as the gold standard 
regardless of the little impact offered in overall survival. For example, in ovarian cancer, 
the combination of cyclophosphamide, adriamycin, vincristine, prednisolone, and 
platinum, has been used for twenty years despite the lack of effectiveness. Likewise, in 
lung cancer, survival has increased only two months in the same period, and less than 
5% of patients benefit from the treatment. Similar results in the treatment of breast, colon, 
and head and neck cancers are observed 5. Additionally, radiotherapy and chemotherapy 
regiments might spur the development of secondary tumors. The most common type of 
secondary cancer is leukemia one year after the treatment 6. Moreover, cancer drugs are 
expensive and offer limited results because of the development of tumor resistance 7.  
 
1.1.1. Cancer Drug Resistance 
Major challenges in treating cancer include delayed diagnosis, metastasis and the 
emergence of drug resistance. Over 50% of patients are diagnosed in advanced stages 
or with metastasis in which therapies are almost ineffective. Moreover, on average within 
six months tumors become refractory to therapy as a result of the emergence of drug-
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resistance 8. Modifications to overcome drugs include genetic changes that modify the 
DNA sequence (mutations) or its conformation (epigenetics). Among the molecular 
mechanisms regularly identified as culprits for tumor resistance are gene amplification, 
mutations, silencing, overexpression, downregulation or reactivation 3. The 
overexpression of the ATP-binding cassette (ABC) transporter family of transmembrane 
proteins has been studied extensively for multidrug resistance (MDR). These proteins 
regulate the efflux across the plasma membrane of multiple structurally and 
mechanistically unrelated chemotherapeutic drugs and confer MDR. The family is 
composed of 49 members, but the most studied proteins are the multi-drug resistance 
protein 1 (MRP1); the MDR-associated protein 1 (MRP1); and the breast cancer 
resistance protein (BCRP). They promote the elimination of hydrophobic compounds, 
such as the topoisomerase inhibitors and the antimetabolites 9. Another mechanism 
relevant to drug resistance is the enzymatic inactivation or the lack of drug activation. For 
example, platinum drugs can be inactivated by the enzyme glutathione 10, and 
downregulation of enzymatic activities confers lack of activation of the antimetabolites 5-
fluorouracil and methotrexate 11. Drug response and resistance are affected by alterations 
of the drug target by mutations or increased concentration. Examples include the mutation 
or amplification of the androgen receptor (AR) in prostate cancers that develop resistance 
to therapy of androgen deprivation using leuprolide and AR antagonists such as 
bicalutamide 12. Cancers often develop mutations in the protein kinases targeted by drugs. 
For example, mutations in anaplastic lymphoma kinase (ALK) have been identified in 
neuroblastoma and non-small cell lung carcinoma (NSCLC). For example, the initial tumor 
responses of 60% to the tyrosine kinase, ALK inhibitor crizotinib, disappear in less than 
one year due to mutations in the tyrosine kinase domain and patients relapse 13. In the 
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case of drugs that induce DNA damage, cancer cells increase the production of enzymes 
involved in repair and confer resistance to platinum compounds or topoisomerase 
inhibitors. For example, the mutations in the tumor protein p53 (p53) disrupt the cell cycle 
arrest induced by DNA damage 14 and overexpression of the protein excision repair 1, 
endonuclease non-catalytic subunit (ERCC1) has been linked with poor responses. The 
ERCC1 overexpression allows the efficient nucleotide excision repair mechanisms 
required for the survival of cells exposed to DNA damage 15. Cancer cells often 
overexpress anti-apoptotic proteins such as the members of the B-cell lymphoma 2 (Bcl-
2) family, the inhibitor of apoptosis proteins (IAPs) and the FADD-like IL-1β-converting 
enzyme inhibitory protein the caspase inhibitors (FLIP). Several mechanisms of 
deregulation in these proteins have been associated with various malignancies and drives 
resistance to apoptosis 16. The overexpression of the transcription factors such as, the 
nuclear factor-κappa B (NF-κB) and signal transducer and activator of transcription 3 
(STAT3) is activated by oncogenic mutations in kinases and regulate upstream the anti-
apoptotic pathways that increase survival of cancer cells 17.  It has been estimated that 
90% of failures in cancer therapy are related to tumor resistance. Additionally, toxicity 
produced in normal tissues limits the amount of drug that can be administrated and 
pharmacokinetic effects (absorption, distribution, metabolism, and elimination) limit the 
amount of drug that effectively reach the tumor. Furthermore, several mechanisms 
operate at the same time, and tumor resistance can be intrinsic or acquired throughout 
the treatment. Moreover, tumors are heterogeneous; and resistance can arise by a 
positive selection of tumor cell subpopulations. Thus, tumor resistance and toxicity remain 
the biggest limitations for the survival of cancer patients 18. 
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1.2. Bacterial infections. 
Infectious diseases remain the second leading cause of death worldwide. It has been 
estimated that 15 million deaths each year are directly caused by infectious diseases 19. 
The main causes of death are respiratory infections (3.2 million), diarrhea (1.4 million), 
tuberculosis (1.4 million) and the human immunodeficiency virus infection and the 
acquired immune deficiency syndrome (HIV/AIDS) (1.1 million). Bacterial diseases are 
responsible for more than half of those deaths 20. Bacterial diseases are re-emerging due 
to resistance to antibiotics that is responsible for an increased rate in the costs, morbidity, 
and mortality. The group of bacteria that frequently originates life-threatening nosocomial 
infections is called “ESKAPE”. That name is an acronym for Gram-positive and Gram-
negative bacteria, conformed by Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter species, all of them are characterized by mechanisms of drug-resistance 21.  
 
The most common pathogens causing nosocomial infections in Mexico are Escherichia 
coli (20%), S. aureus (14%) and P. aeruginosa (17%). The rest of the infections are 
produced by A. baunanni, K. pneumoniae, Providencia rettgeri, Stenotrophomonas 
maltophilia, S. epidermidis, S. haemolyticus and E. faecium 22. In Mexico a study showed 
that nearly 70% of E. coli from clinical isolates was resistant to levofloxacin, 28% to 
amoxicillin-clavulanic acid and 40% produced the extended-spectrum beta lactamases 
(ESBLs). In the case of K. pneumoniae from clinical isolates, 32% were resistant to 
levofloxacin and 28% produced ESBLs. In the same study, half clinical isolates of S. 
aureus were resistant to oxacillin (MRSA), and to levofloxacin. In the case of P. 
aeruginosa 40% were resistant to ceftazidime, imipenem, levofloxacin, and 20% to 
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amikacin. Isolates from E. faecium were resistant to vancomycin  (33%) and A. baumannii 
presented resistance to amikacin (40%), ceftazidime (70%), levofloxacin (50%), and 
piperacillin-tazobactam (50%) 23. Additionally, authors report that nearly 70% of 
Streptococcus pneumoniae samples were resistant to penicillin, cotrimoxazole, and 
clindamycin and 30% of H. influenzae clinical isolates were resistant to cotrimoxazole, 
ampicillin and clarithromycin 24.  
 
It is considered that Mexico possesses conditions that foster antibiotic resistance, such 
as abuse of antibiotics in animal production, self-prescription and the use of low-quality 
drugs. Additionally, in the clinical setting, the overcrowded facilities, poorly trained staff, 
and low equipped hospitals allow the rapid spread and slow detection of MDR infections. 
Moreover, patients are often in malnourished conditions with scarce access to medical 
services and drugs, thus MDR infections frequently become fatal 23. 
 
1.2.1. Mechanisms of Antibiotic Resistance 
Resistance to antibiotics is the expected result of the interaction of many organisms with 
their environment during evolution. Most antibiotics are naturally metabolic products 
derived from fungi and bacteria. Thus, microorganisms are intrinsically endowed with a 
mechanism to evade them and survive. However, in the clinical setting the main concern 
is the acquired antibiotic resistance of bacteria that was originally susceptible 25. The 
mechanism by which bacteria become antibiotic-resistant is generally through mutations 
in the genes that codify for the targets of the antibiotics or by the acquisition of foreign 
DNA that codify for proteins of resistance through horizontal gene transfer (HGT) 25.  
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Mutations that result in antimicrobial resistance can origin from the modification of the 
target. Thus, variations decrease drug affinity or decrease drug uptake. Additionally, the 
activation of drug pumps allows the clearance of antibiotics by expelling antibiotics outside 
the cells. The acquisition of foreign DNA through HGT is one of the most important factors 
driving MDR. Bacteria can acquire external genetic material through transformation 
(incorporation of DNA), transduction (phage mediated) and bacterial conjugation 26. 
 
Antibiotic resistance can be triggered by different mechanisms and at the same time in 
bacteria. For example, fluoroquinolone resistance can be induced by mutations in the 
genes of DNA gyrase that modifies the target site, and by the expression of Qnr proteins 
(quinolone resistance proteins), that protects the target site, while over-expression of 
efflux pumps can pull-out fluoroquinolone from the cells 27. In other cases, bacteria seem 
to prefer some mechanisms of resistance over others. For example, the predominant 
mechanism of resistance to β-lactams in gram-negative bacteria is the production of β-
lactamases, whereas gram-positive organisms prefer the production of the penicillin-
binding proteins (PBPs) 28.  
 
1.3. Antibiotic resistance in cancer patients. 
Cancer patients are at risk of bacterial infections in the bloodstream due to chemotherapy-
induced neutropenia, especially hematological patients undergoing hematopoietic stem 
cell transplantation 29. Immunosuppressed patients with cancer suffer from that 
complication and increase the morbidity, mortality and economic costs. According to the 
US Centers for Disease Control and Prevention (CDC), every year, about 650 000 patients 
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with cancer receive chemotherapy and 10% will acquire an infection that requires 
hospitalization 30. Chemotherapy produces oral mucositis and the use of central venous 
catheters, plus the antimicrobial prophylaxis against enteric gram-negative bacilli leads to 
infections with gram-positive cocci, especially the viridans group, streptococci, and 
coagulase-negative staphylococci. Despite that antibiotic therapy is used in neutropenic 
febrile cancer patients, half of the patients become infected with antibiotic-resistant 
bacteria that increase eleven times their mortality rate from infection 30.  
 
1.4. Plants as a potential source of new drugs 
Plants have evolved for over 350 million years mechanisms that allow them to survive a 
wide range of stressors. They are continuously exposed to environmental stresses that 
include abiotic factors (a nutrient deficiency, hypoxia/anoxia, drought, salinity, lack of 
oxygen, temperature fluctuations and light intensity) and biotic factors (bacteria, fungi, 
viruses, nematodes, insects and herbivore pests). Plants can trigger immune responses 
and reinforce their cell walls, biosynthesize lytic enzymes, and produce secondary 
metabolites as a response of stressors 31. Secondary metabolites refer to a broad array 
of chemical defenses, produced constitutive or inducible in response to pathogens or 
stressors. Phytoanticipins (include saponins, cyanogenic glycosides, and glucosinolates) 
are present in the plant before microorganism attack or produced after infection from pre-
existing precursors. They are usually found at the plant surface while others are present 
in vacuoles or organelles and are released through a hydrolyzing enzyme after pathogen 
challenge. On the other hand, phytoalexins (including terpenoids, glycosteroids, 
flavonoids, and polyphenols) are small molecules (molecular weight < 500) which are both 
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synthesized and accumulated in the plant after induction. Phytoalexins showed several 
medicinal properties against cancer, diabetes, inflammation, malaria, bacteria, 
nematodes, insecticide and nematodes 32. Thus, plants are excellent candidates for drug 
discovery. Medicinal plants are typically collected and identified by a trained botanist. In 
other cases, the plant is generally used in traditional medicine but often the chemical 
content is unknown. A plant can also be selected based on the genetic relationship 
(chemotaxonomy) with a recognized medicinal plant. Once plants are collected the 
phytochemist is the professional that performs the extraction process and the fractionation 
to isolate and characterization the active compounds through chromatographic and 
spectroscopic techniques. The molecular biologist also plays a major role in drug 
discovery, they select the pharmacologically relevant assays, to find the compounds that 
possess the biological activity. Furthermore, pure compounds can be tested to find the 
relevant molecular target or to explore the mechanism of action that underlies the 
therapeutic effects 33. 
 
Pharmacognosy is the science that studies the physical, chemical, biochemical and 
biological properties of drugs, drug substances, or potential drugs of natural origin as well 
as the search for new drugs from natural sources. Despite the recent interest in molecular 
modeling, combinatorial chemistry, and other synthetic chemistry techniques, natural 
products derived from plants remain as one of the most important sources of new drugs, 
new drug leads, and new chemical entities 34. 
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1.4.1. Drugs derived from plants to treat cancer and bacterial infections  
Drug discovery from medicinal plants has played an important role in cancer therapy. Sixty 
percent of clinically approved anticancer drugs were isolated from medicinal plants. Most 
of them belong to four classes of phycompounds: the vinca alkaloids, epipodophyllotoxins, 
taxanes, and camptothecins. Vinblastine and vincristine were isolated from Catharanthus 
roseus and have been used clinically for over 50 years. Podophyllotoxin was isolated from 
the resin of Podophyllum peltatum (Berberidaceae) and the first derivative approved for 
clinical use was the etoposide. Paclitaxel was originally isolated from Taxus brevifolia 
(Taxaceae) and camptothecin was isolated from Camptotheca acuminate, both were 
clinically introduced in the mid-1990s. Currently, derivatives of all four compound classes 
remain in clinical use 35. The initial screenings of plants for anticancer drug discovery 
include the use of established cancer cell lines, in which the cytotoxic effects of plant 
extracts or the isolated compounds are measured. According to the National Cancer 
Institute (NCI), plant extracts and pure compounds are considered cytotoxic active if their 
half-maximal inhibitory concentration (IC50) is ≤30 µg/ml or ≤4 µg/ml, respectively 36. In 
the case of antibacterial drugs approved by the FDA, only 3% are derived from plants. 
The 97% were isolated or derived from microbes (51% from bacteria and 46% from fungi). 
In 1968 the aminosalicylate became the first antibacterial FDA approved derived from 
plants (Salix alba) and the azelaic acid, isolated from cereals like rye and barley was last 
marketed in 1995 37. The evaluation of the antibacterial activity in vitro of plant extracts or 
isolated compounds relies in the methods of disk-diffusion and broth or agar dilution. 
Dilution methods are the most appropriate for the determination of the minimum inhibitory 
concentration (MIC) value, which is the lowest concentration of the assayed antimicrobial 
agent that inhibits the visible growth and it is usually expressed in µg/ml or mg/l. The 
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concentration of the extracts evaluated should not exceed the range of 1 mg/ml for 
extracts and 0.1 mg/ml for isolated compounds 38. An extract is considered active if the 
MIC is ≤ 30 µg /ml, and isolated compounds when the MIC is ≤ 8 µg/ml 39, 40. 
 
1.4.2. Targeting drug-resistance with phytochemicals.  
The toxic effects derived from cancer chemotherapy and the emergence of drug 
resistance limits cancer survival. Regarding bacterial infections, the spread of multidrug-
resistant strains of bacteria represents a big threat to their successful treatment. Medicinal 
plants potentially contain new compounds with diverse chemical structures and 
mechanisms of action. Some of them might be more effective, selective or can inhibit the 
resistance mechanisms. Compounds that showed inhibition of the resistance 
mechanisms, and restore the sensitivity to drugs are called chemo-sensibilizators in 
cancer 41, and resistance modulators in bacteria 42. The use of a compound that inhibits 
bacteria resistance was marketed by the name of Augmentin. The drug is a combination 
of amoxicillin (a beta-lactam antibiotic) and clavulanic acid, a microbially derived inhibitor 
of beta lactamases. Resistance modulators may also inhibit multidrug resistance (MDR) 
in bacteria, a process that generates intracellular ineffective concentration of drugs. 
Epicatechin gallate is a weak antibacterial (MIC = 280 µg/ml), but reverse the methicillin-
resistance by inhibiting the synthesis of PBPs in methicillin-resistant S. aureus (MRSA) 
43. The diterpenes totarol showed strong antibacterial activity (MIC = 2 µg/ml) against S. 
aureus but also potentiate methicillin activity against MRSA via interference of PBPs. 
When incorporated into the medium at 1 µg/ml, it caused an eight-fold increase in 
methicillin activity against MRSA 44. The 5´-methoxyhydnocarpin and berberine can inhibit 
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the NorA (protein associated with hydrophilic quinolone resistance in S. aureus), which is 
a drug efflux pump in S. aureus 45. Kaempferol did not display relevant antibacterial activity 
against MRSA (MIC = 256 µg/ml), however, also inhibits the expression of NorA. In 
combination with antibiotics a reduction in the MIC was observed for norfloxacin (16-fold), 
ciprofloxacin (16-fold), lomefloxacin (four-fold) and ofloxacin (two-fold) 46. On the other 
hand, phytochemicals can sensitize tumor cells to chemotherapeutic agents by inhibiting 
pathways that lead to resistance. Additionally, those compounds protect from therapy-
associated toxicity 42. For example, treatment with genistein before docetaxel or cisplatin 
administration enhanced tumor cell death in pancreatic cancer cell lines compared with 
the treatment with drugs alone. This effect may have been mediated by the inhibition of 
NF-κB, causing increased apoptosis. In liver and colon cancer cell lines, genistein plus 
dexamethasone resulted in enhanced expression of the CDK-interacting protein 1 
(p21CIP1), halting cell cycle progression 47. Resveratrol administered before (10 µM for 3 
days) paclitaxel increased p21CIP1 expression approximately four-fold, lowering the 
threshold of cell death by paclitaxel in non-small cell lung cancer cells (EBC-1). 
Additionally, the combination increase the expression of the cyclin-dependent kinase 
inhibitor 1B (p27kip1), and the cell-cell adhesion molecule of epithelial tissues the E-
cadherin, the epidermal growth factor receptor (EGFR), and Bcl-2 48. Curcumin 
potentiated the cytotoxic effects of doxorubicin, fluorouracil, and paclitaxel in prostate 
cancer cells, and suppressed activation of NF-κB. Curcumin has also been shown to 
modulate the activity of the MDR genes, suppressing MDR1 protein leading to 
chemosensitization 49. Another two examples of inhibition of MDRs are the effects of 
flavopiridol in enhancing the cytotoxic effects of paclitaxel, cytarabine, topotecan, 
doxorubicin, and etoposide in non-small cell lung cancer cells 50, and the flavonols 
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quercetin and kaempferol markedly increasing the sensitivity of the multidrug-resistant 
human cervical carcinoma KB-V1 cells to vinblastine and paclitaxel in a dose-dependent 
fashion 51. 
 
1.4.3. Cell differentiation by phytochemicals for cancer treatment. 
The strategies that relay in the suppression of the hallmarks of cancer (proliferation, de-
differentiation, immune avoidance, inflammation, angiogenesis, etc,) instead of inducing 
the cell death of tumor cells remain as a relatively new field. The description of the 
mechanism behind the effects of the phytochemicals on those processes will provide 
insights into their potential therapeutic value as drugs or chemopreventive agents. One of 
the most promising and powerful approaches in cancer treatment is the therapy called 
cytoeducation, which is the induction of differentiation of cancer cells. In general, 
differentiation means structural and functional changes that lead to the maturation of cells 
throughout development pathways into lineages or to a cell phenotype 52. Cancer cells 
are unable, to varying degrees, to achieve maturation, and thus malignant neoplastic cells 
show a lack of, or only partial evidence of differentiation, known as anaplasia. Since the 
basic underlying cause for the failure to differentiate can be attributed to structural 
changes in the cell’s DNA, i.e. mutations, which are essentially irreversible, it is 
remarkable that some compounds can induce several types of malignant cells to undergo 
differentiation toward more mature phenotypes 53.  
Examples of differentiation therapy in cancer include the treatment of acute promyelocytic 
leukemia (APL) and other leukemias with all-trans retinoic acid (ATRA), a vitamin A 
derivative 54, 55 and the induction of differentiation of myeloid leukemia cells to monocytes 
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with 1α,25-dihydroxyvitamin D3, which also can induce differentiation of prostate and 
breast cancer cells lines 53. Phytochemicals with empirical evidence of induction of 
differentiation in cancer cells belong to the class of coumarins and flavonoids. The 
coumarin daphnetin (7,8-dihydroxycoumarin), showed potent anti-proliferative effects in 
the A-498 (human renal carcinoma) cell line at 50 μM, by inhibition of the constitutively 
active ERK1/ERK2 kinases and induce differentiation (increased expression of 
cytoskeletal proteins such as the cytokeratins, an epithelial marker) plus concomitant S 
phase accumulation by inhibition of the cell cycle in the G1-S phase transition (the stage 
in the cell cycle in which the cell grows) 56. Other coumarins, the 5-methoxy-6,7-
methylenedioxycoumarin, and 5-(3-methyl-2-butenyloxy)-6,7-methylenedioxycoumarin, 
induce the differentiation human leukemia U-937 to monocytes at doses of 42.75 μM , 
and 22.16 μM, respectively 57. Procyanidin (oligomers of flavan-3-ols, such as catechin 
and epicatechin) also causes irreversible growth-inhibitory in the MDA-MB468 breast 
carcinoma cell line by induction of accumulation in G1 phase of the cell cycle in a dose-
dependent manner and showed an increased expression of cytokeratin 8 (a marker of 
differentiation). These effects were accompanied by inhibition of the mitogen-activated 
protein kinase (MAPK)/extracellular signal-regulated protein kinase1/2 (ERK1/ERK2) in a 
dose-dependent manner after 72 h of treatment at doses of 75-μg/ml 58. Other flavonoids 
such as wogonin and, apigetrin showed induction of differentiation on various leukemia 
cells. Moreover, a newly semisynthetic flavonoid, designated III-10, induced differentiation 
of human U937 leukemia cells via PKCδ (Protein kinase C delta) activation. It was 
designed to improve the oral bioavailability and block the metabolism of flavonoids at its 
hydroxyl groups via introducing the hydrophilic pyrrolidinyl group and the benzyl group to 
the hydroxyl position. Results showed that exerts growth inhibition on the cell lines U937, 
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NB4 (acute promyelocytic leukemia cells), HL-60 (acute myeloid leukemia cells) and K-
562 (erythroleukemia cells). And the flow cytometry showed that III-10 could induce U937 
cells to differentiate into monocyte-like cells at a concentration of 2µM 59. The mechanisms 
underlying the effect of phytochemicals on cell proliferation and differentiation will allow 
the identification of key molecular targets for this group of compounds to facilitate the 
development of new pharmacological tools with potential therapeutic value for the 
management of cancer with minor side effects. 
 
1.5. Plant metabolomics 
The metabolome is defined as the total quantitative collection of compounds with small 
molecular weight present in a cell, tissue or organism. The use of high-throughput 
analytical strategies for the large-scale identification and quantification of metabolites is 
termed metabolomics. Metabolomics evolves from the pioneering work of metabolite 
profiling by GC-MS in the early seventies. Metabolic profiling is used when the aim of the 
study is the identification and quantification of the metabolites present in an organism. On 
the other hand, metabolomics refers to the identification and quantification of the 
metabolites in a biological system in a certain physiological state. Other approaches in 
metabolomics include the targeted analysis, that studies the changes in certain groups of 
metabolites by optimizing their separation and detection. This method is only possible for 
a limited number of compounds and relies on the discriminate analysis or on molecular 
relationships based upon molecular pathways/networks 60. The use of metabolomics in 
the study of plants differs from the classical or traditional targeted phytochemical analysis 
in various aspects, such as being a data-driven approach that aims to assess all 
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measurable metabolites without any pre-conception or pre-selection. The advance in 
analytical tools with a higher degree of sensitivity, selectivity, and reproducibility allowed 
the emergence of plant metabolomics as a type of large-scale phytochemistry 61. 
Phytochemistry in natural product discovery focuses on identifying individual, bioactive 
metabolites, while plant metabolomics seeks to extract meaning from complex data sets. 
Those fields evolve independently however, both use the same equipment for metabolite 
analysis and evaluation of the qualities of medicinal plants 62. 
 
1.5.1. Mass spectrometry-based plant metabolomics platforms 
Mass spectrometry approaches allow the comprehensive profiling of the metabolome of 
medicinal plants. The quantitative and qualitative measurements of large numbers of 
cellular metabolites provide a broad view of the biochemical status of a plant. It is 
considered that metabolomic approaches provide the most functional information from all 
the omics technologies. Estimations indicate that number of plant metabolites oscillates 
between 100,000 and 200,000 ranging from relatively simple primary compounds to highly 
complex and chemically diverse secondary products. To obtain the most comprehensive 
visualization of the metabolome of a medicinal plant the use of multiple combinations of 
solvents, extractions, chromatographic, and spectrometric techniques is necessary 62. A 
typical metabolomic analysis comprises three main experimental stages; the preparation 
of the sample, the acquisition of the data using analytical methods and data mining using 
chemometric methods followed by compound identification. Plant metabolites are 
structurally diverse, forming a highly complex spectrum of compounds of different size, 
solubility, volatility, polarity, quantity and stability. Any extraction method would certainly 
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produce an inherently multidimensional sample arising from the chemical and physical 
differences of the constituents. Several methods may be employed to extract metabolites. 
The choice of method depends on a variety of factors, such as the physicochemical 
properties of the target metabolites, the biochemical composition of the system under 
investigation and the properties of the solvent used 63. Chromatography-mass 
spectrometry is the most applied analytical techniques in metabolomics. GC-EI-MS is a 
good approach for targeted analysis of known primary metabolites, whereas LC-ESI-MS 
is applied for the untargeted analysis of secondary metabolites 64. To date, gas 
chromatography coupled to mass spectrometry (GC-MS) is the most widely accepted 
analytical technique used in studies of plant metabolomics. GC-MS is used for the analysis 
of very complex matrices such as those of plant extracts. GC-MC provides efficient 
metabolite separations, resolution, detection, and quantification of metabolites even at low 
concentrations. The high reproducibility achieved with GC-MS analyses is the result of the 
electron ionization (EI) method generally employed in GC-MS. In EI, molecules interact 
with kinetically activated electrons with an accepted average standard energy of 70 eV. 
Therefore, reproducible mass spectra allowed the building of mass spectral libraries for 
comparison and identification. Quadrupole (Q) and orthogonal time-of-flight (oTOF) are 
the most used mass analyzers for GC-MS. TOF-MS analyzers provide higher mass 
accuracy, higher duty cycles, and faster acquisition times than quadrupole mass 
analyzers. Those parameters are deconvoluted if necessary in overlapping GC peaks in 
complex plant extracts. GC-MS technology is used for the analysis of volatile and 
thermally stable metabolites or metabolites that can be chemically modified to produce 
volatile derivatives 65. 
18 
 
The most-important complementary technology to GC-MS is the liquid chromatography 
coupled to mass spectrometry (LC-MS). This technique is used to analyze thermolabile, 
polar metabolites, and high-molecular weight compounds. Most LC-MS applications use 
reversed-phase (RP) stationary phases of silica particles functionalized with hydrophobic 
alkyl chains; such octadecylsilane (ODS). In RP separations the most used mobile phases 
are mixtures of organic solvents and water. Thus, less polar compounds interact more 
with the stationary phase and are more retained than polar molecules. Ultra-high 
performance liquid chromatography (UHPLC) is a related HPLC technique that uses sub-
2 mm particles, smaller diameter columns (1-2.1 mm), and higher pressures around 
16,000 psi (compared to ca. 6,000 psi for traditional HPLC systems) 66. Thus, UHPLC 
provides better resolution and faster analysis. Applications of LC-MS use ESI to allow the 
analysis of biomolecules directly from the liquid phase and is suitable for LC coupling. ESI 
is a soft-ionization technique, which introduces little internal energy. Thus, few fragments 
are generated and provide few structural information of compounds. To obtain detailed 
structural information from intact ionized species, fragmentation can be achieved by the 
collision of the analyte ions with inert gas molecules (e.g., He, Ar, or N2). This process is 
carried out on a tandem MS instrument that allows two or more sequential stages of mass 
spectrometric analysis 67. The most common tandem in time instruments is the ion 
trapping mass spectrometers such as quadrupole ion traps (QIT-MS), the Orbitrap, and 
the Fourier-transform ion cyclotron resonance mass spectrometers (FT-ICR-MS). Ion trap 
instruments are particularly useful for unknown plant metabolites because of the multiple 
MS stages and the provided information for structural elucidation. Tandem-in-space 
instruments have two mass analyzers separated by a collision cell and allow two 
sequential stages of mass spectrometric analysis (MS2). MS2 is achieved through the 
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spatial separation of the precursor and fragment ions. Examples of these instruments 
include triple quadrupoles (QqQ) and quadrupole time-of-flight instruments (qTOF). The 
study of plant metabolomics by LC-ESI-MS methods present co-eluting interfering 
compounds due to the complexity of the plant extracts. The presence of multiple 
metabolites influence the ionization and the transfer of analytes from liquid to the gas 
phase and potentially compromise the accurate quantification of metabolites. 
Consequently, the optimization of chromatography is essential to reduce the impact of 
matrix-induced effects in the mass spectrometer. One major limitation of the target 
metabolite analysis with LC-MC is the requirement of reference compounds for the 
identification and quantification of the measured metabolites. Thus, the analysis is limited 
to compounds commercially available 68. 
 
1.5.2. Data analysis and compound identification 
The mass spectral data provides a pattern that is characteristic of specific compounds. 
Additionally, the identification of analytes uses the accuracy of the mass in the elucidation 
of metabolites. The procedure for metabolite assignments from MS data consists of the 
acquisition of accurate mass measurement and the fragmentation patterns, calculation of 
the elemental composition formula and the spectral comparison in a database for 
comparison of the fragmentation pattern or with authentic pure standards (when 
commercially available) 69. According to recommendations of the Metabolomics 
Standards Initiative (MSI), the identification of a compound at the highest level of 
confidence (MSI level 1) requires the comparison of orthogonal parameters of the 
unknown to an authentic standard measured in the same laboratory and under the same 
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conditions. The MSI level 2 (“putatively annotated compound”) is for identification by 
comparison with parameters available in databases. The MSI level 3 (“putatively 
characterized compound classes”) is for comparison with chemical literature and spectral 
databases 70.  
 
Various databases have been developed to assist in the assignment of the spectral peaks 
observed in metabolomics experiments 71. METLIN is a database that contains about 
62,000 MS2 spectra for more than 12,000 metabolites. All spectra were acquired under 
standardized conditions (electrospray ionization, positive and negative polarity, high mass 
accuracy, four different collision energies) on a quadrupole time of flight (QTOF) mass 
spectrometer 72. ReSpect is an MS2 database specific for plant metabolites. Spectral 
records are annotated with taxonomic information about the species from which the 
metabolite has been extracted and the chemical class of the metabolite. Flavonoids are 
the best-represented class (1,360), followed by terpenoids (519), phenylpropanoids (341), 
alkaloids (256), amino acid derivatives (236), and glucosinolates (93) 73. The Human 
Metabolome Database (HMDB) identifies mainly human metabolites. It is used for 
metabolomics, clinical chemistry and biomarker discovery. It contains information of 2280 
drugs, 3670 toxins and 28,000 food components 74. PhytoHub is a database that contains 
detailed information about dietary phytochemicals and their metabolites. Around 1,200 
polyphenols, terpenoids, alkaloids and other plant secondary metabolites present in foods 
75. The LIPID MAPS Structure Database (LMSD) is a database with structures of and 
annotations of biologically relevant lipids. The LMSD contains 43307 lipid structures, 
among them fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol, lipids, 
saccharolipids, and polyketides 76. 
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1.5.3. Data mining and data processing 
A single GC-MS analysis can identify 500 molecules and provide abundant information 
that requires simplification and interpretation. Specialized software provides the tools for 
the statistical analysis to identify differences or similarities in samples, reduction in the 
dimensionality of data and their visualization. The most popular approaches include 
unsupervised methods such as principal component analysis (PCA), hierarchical 
clustering (HCA) and K-means clustering 77. The PCA is the most used multivariate 
technique and describe the variance in a set of multivariate data in terms of a set of 
underlying orthogonal variables (principal components). The original variables can be 
expressed as a linear combination of the principal components. PCA is a linear additive 
model, in the sense that each principal component (PC) accounts for a portion of the total 
variance of the data set. Often, a small set of principal components (2 or 3) account for 
over 90% of the total variance, and in such circumstances, one can resynthesize the data 
from those few PCs and thus reduce the dimension of the data set. Then, data is plotting 
in the space defined by the two or three largest PC and provides an easy method for 
visualizing the similarities in the data sets 77. Hierarchical cluster analysis (HCA) is a 
method for grouping samples in a data set by their similarity. HCA involves a progressive 
pair-wise grouping of samples by distance. Several distance measures can be used in 
HCA, such as Euclidean distance, Manhattan distance, or correlation. The result of 
hierarchical clustering is visualized as a dendrogram. Branch lengths can be made 
proportional to the distances between groups. This can provide a visualization of the 
similarities of samples within data sets. Clustering is most useful to classify samples in 
groups. It is often applied to the data after transformation with PCA, in which case it 
becomes a means of identifying groups in the reduced dimension data space 77. These 
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types of methods are unsupervised because they require no other information than the 
original data set. A different set of methods called supervised, create a calibration using 
a training data set, i.e. a set of observations that have been classified by independent 
means. An example of a supervised method is the use of standards to calibrate a protein 
concentration assay. Supervised methods can thus only be carried out if one is able to 
provide known examples 77. 
The tools of visualization allow the identification of the properties of the data sets. 
Metabolites can be related by their molecular structure, the polarity of the solvent 
employed in the extraction, or the plant from which they were extracted, etc. Diagrams 
representing the networks or metabolic pathways of the biosynthesis of metabolites have 
been used as a powerful tool for visualizing relationships between metabolites. Such 
metabolic network diagrams are also useful to visualize metabolomic data and can be 
combined with data from genomics or proteomics. Metabolic networks can identify the 
chain of causality that led to the observed metabolic profile 77. 
 
MetaboAnalyst is a web-based system that supports comprehensive metabolomic data 
analysis, visualization and interpretation. This platform identifies peaks from raw data, 
align the peaks among different samples and replicates, and identify and quantify each 
metabolite. The statistical analysis can be carried with the same software and provides 
graphical results. In MetaboAnalyst data sets from metabolic studies are processed to 
obtain the PCA, HCA, K-means clustering, metabolite set enrichment analysis, metabolic 
pathway analysis, and spectra analysis tools 78. 
Currently is technologically impossible to extract and analyze all the metabolite content in 
a plant. Most metabolomic studies characterized a very small fraction of the whole 
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metabolome of a certain plant. Moreover, the lack of universal metabolite-specific libraries 
or known reference compounds represents a major limitation to the definitive identification 
of metabolites. Another major technological challenge encountered in metabolomics is the 
dynamic range, which is the presence of some excessive metabolites that cause 
significant chemical interferences that limit the range in which other metabolites may be 
successfully profiled. Finally, plants present many biological variations that represent 
another problem for reproducibility in the results. The goal of a comprehensive quantitative 
and qualitative analysis of all the metabolites present in a medicinal plant remains an 
ambitious goal far from reality, but substantial analytical progress was made in the last 
decade 79. 
 
1.6. Bioassay-guided study of medicinal plants 
The ethnobotanical knowledge often leads to the targeted evaluation of the plant extracts 
or bioassay-guided studies to characterize or isolate the active compounds. Then, using 
complementary techniques the mechanism of action can be elucidated increasing the 
understanding of the biological effects of the medicinal plants. Together, those techniques 
help in the validation of the ethnomedical use of the plant and provide useful lead 
compounds for further drug development. The characterization of the metabolomic profile 
of a medicinal plant by chromatography-mass spectrometry techniques allows the fast 
identification of biologically active constituents 80, however, for the isolation of the 
biologically active molecules, a bioassay-guided fractionation of the plant extracts linked 
to column chromatography should be carried out. The bioassay-guided study refers to the 
isolation of the pure chemical agent from the complete plant extract by the fractionation 
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of the sample. The separation of the extracted components is based on differences in 
their physicochemical properties, and the results in biological activity. After several rounds 
of separation and biological tests, the therapeutically active phytocompounds can be 
isolated. The field of natural products has provided many effective drugs based on this 
rationale 81. However, a common problem with this approach is the loss of activity during 
the fractionation. The reason obeys to several factors that include but are not limited to 
next possibilities: an extract may contain a large amount of only moderately active 
compounds and be very active, may contain small amounts of highly active compounds, 
and synergistic interactions may be responsible for the bioactivity 80. Traditionally methods 
for drug discovery from medicinal plants have additional drawbacks, such as their 
complexity and the long timescales, and the use of a big amount of solvents need it before 
an active compound from the complete extracts will finally emerge, and that most 
compounds obtained by this method are already characterized 82.  
The use of the metabolomic profile in combination with a bioassay-guided study provides 
an overview of the chemical complexity of the active fractions without the need for the 
time-consuming isolation procedures 60. This approach enables the profiling of the entire 
metabolome of the extracts or specific fractions before testing for biological activity. 
Additionally, allow the rapid analysis of the active fractions and the assessment of the 
characterization and quantification of the chemical constituents. Recent algorithms can 
also infer the bioactivity of a medicinal plant based on its metabolic profile 83. This method 
is currently employed in drug discovery research due to its effectiveness to directly link 
the metabolomic profile with bioactivity results and the advantages that represent in cost-
effectiveness 81, 84.  
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CHAPTER II 
2. BACKGROUND 
2.1. Cissus trifoliata 
Plants of the genus Cissus belong to the Vitaceae family that includes the common fruit 
grapes (Vitis vinifers). The tribe Cisseae is monogeneric, with about 300 species widely 
distributed in the tropical and subtropical regions in Asia (85 spp.), the Americas (70 spp.), 
Africa (135 spp.), and Australia (12 spp.) 85. These plants are lianas, sometimes succulent, 
with climbing tendrils, hermaphrodite or polygamomonoecious. Branches contain 
adherent bark; tendrils unbranched or 2-branched or occasionally 3-6 branched, without 
adhesive discs. The leaves are simple or ternate, usually succulent with flowers mostly 
perfect, 4-parted, cymose or corymbose. The ovary is two-celled and fruits with one to 
four seeds. In the case of C. trifoliata, plants are glabrous or sparsely pubescent; leaves 
mostly trifoliolate, the leaflets of two to nine cm long, usually broadly cuneate, coarsely 
dentate or lobate; cymes equaling or longer than the leaves; fruit purple or nearly black, 
with five to eight mm long. Some of the Mexican specimens have been referred to as C. 
incisa (Nutt.) Des MouL, but is doubtfully distinct from C. trifoliata 86. Recent studies 
confirm no genetic differences between herbariums specimens of C. incisa and C. trifoliata 
87. Based on phylogenetic relationships, molecular (plastid, nuclear ribosomal sequences) 
and morphological characters (leaf shape) C. trifoliata is closer to C. descoingsii and C. 
verticillate, than C. quadrangularis, C. repens and C. assamica which lay in different 
clusters 85, 88.  
The accepted botanical name is C. trifoliata (L.); although it is also referred to as C. acida 
(L.), C. carnifolia, C. incisa, C. parvifolia, Kemoxis acida, Sicyos trifoliatus, Vitis acida, 
Vitis incisa, Vitis trifoliata, possum-grape, and vine-sorrel 86.  
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C. trifoliata is widely distributed in tropical America and the Mexican territory. It is native 
of Baja California, Chihuahua, Coahuila, Durango, Nuevo Leon, San Luis Potosi, Sinaloa, 
Sonora, Tamaulipas, Puebla, Michoacan, Veracruz, Oaxaca, Quintana Roo and Yucatan. 
Is also present in the United States, Venezuela, Colombia and Ecuador 89 and dispersed 
in the Caribbean islands such as Bahamas, Cuba, Haiti, Jamaica and Puerto Rico 86.  
 
In Mexico, this plant is also known as “Hierba del buey” in Spanish and called Xbolontibi 
in Maya. C. trifoliata is an important medicinal plant for the Mayan tribes in Yucatan for 
the management of gastrointestinal illnesses, sores, cutaneous infections and tumors 90, 
91. The plant is macerated with salt and applied as poultices in the affected site, or 
prepared as infusion 92. In Nuevo Leon, at the Northeastern of Mexico, is used for the 
native population to treat skin infections, inflammation, abscesses and tumors 93. 
Ethnobotanical uses documented for C. trifoliata in the rest of America include caustic, 
poison (tubers), burns, sore and tumors 86. The chemical content of C. trifoliata remains 
unknown; however, in murine models showed anti-inflammatory activities 94. 
 
2.2. Medicinal properties of plants from the genus Cissus  
Cissus plants are considered medicinal as they have been used in all the continents for 
the management of several diseases that include arthritis, menopause, obesity, pain, 
infections, cancer and diabetes 95 (Table 1). Thus, C. trifoliata is a potential source of 
bioactive compounds as suggested by its chemotaxonomic relationship with other 
medicinal plants, and with its ethnobotanical use in the Mexican traditional medical 
systems 33. 
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Table 1. Medicinal properties of Cissus plants in different countries 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several extracts of Cissus species have been tested in relation to the traditional uses. In 
this regard, hypoglycemic activities have been found for C. assamica 114 and C. sicyoides 
115. C. pteroclada and C. repens showed antioxidant, anti-inflammatory and analgesic 
activities 102 respectively. C. quadrangularis demonstrates anti-inflammatory, analgesic, 
anti-oxidant and hepatoprotective properties 104 and anti-osteoporotic activity 116. 
 
2.2.1. Antibacterial and cytotoxic activity of Cissus extracts 
Reports in relation to their antibacterial and cytotoxic properties of plants from the genus 
support the search of bioactive molecules in C. trifoliata. The ethyl acetate and petroleum 
Country Specie Traditional use 
Australia C. hypoglauca Sore throats 96. 
Brazil C. sicyoides C. verticillata 
Diabetes 97. 
Sore throats 98. 
Cameron C. aralioides Infections 99. 
Congo C. rubginosa Diarrhea 100. 
China 
C. assamica 
C. pteroclada 
C. repens 
Diabetes 101. 
Pain 102. 
Arthritis 103. 
India 
C. quadrangularis 
C. ibuensis 
C. hamaderohensis 
Bone healer, menopause, obesity 104. 
Infections 105. 
Infections 106. 
Nigeria 
C. cornifolia 
C. populnea 
C. ibuensis 
Infections 107. 
Fertility and malaria 108. 
Infections, arthritis 109. 
Mexico C. trifoliata C. verticillata 
Infections 110 
Tumors 90. 
Tanzania C. rotundifolia Headaches, infections 111. 
Trinidad C. verticillata C. debilis 
Diabetes, infections112. 
Headaches 113. 
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ether extracts of the stem part of C. quadrangularis showed zone of inhibition against S. 
aureus, B. cereus, E. coli and S. typhi at a concentration of 1000µg/ml. At a concentration 
of 250 µg/ml, no significative activity was founded and the ethyl acetate extract was the 
most active, against S. aureus and S. typhi 117. Another study of the antibacterial activity 
of the extracts from the stems of C. quadrangularis by the determination of the MIC with 
broth microdilution method found the positive activity of the ethyl acetate extract against 
B. subtilis (0.9 mg/ml), P. aeruginosa (1.8 mg/ml), S. typhi (3.7 mg/ml), S. aureus (0.9 
mg/ml), and S. pyogenes (3.7 mg/ml). For the acetone extract against the estimated MICs 
were against P. aeruginosa (3.1 mg/ml), S. typhi (6.2 mg/ml), and S. aureus (1.5 mg/ml). 
The methanolic extract show activity against B. subtilis (0.4 mg/ml), P. aeruginosa (3.1 
mg/ml), S. typhi (1.2 mg/ml), S. aureus (0.4 mg/ml), and S. pyogenes (0.9 mg/ml) 118.  
Extracts from the leaf and roots from C. welwitschii showed MIC values of 2 mg/ml and 
0.5 mg/ml against B. cereus and E. coli respectively. The range of concentrations used 
for antibiotics ranged from 1 µg/ml to 4 mg/ml. They include ampicillin, kanamycin, and 
norfloxacin, showing that strains used were drug-sensitive and that extracts are not as 
effective as antibiotics. Authors claim that the interactions between compounds may 
reduce the effectiveness of the plant extracts 119. The antibacterial activity of extracts from 
the stems of C. quadrangularis was also tested against drug-resistant bacteria from 
clinical isolates by the method of agar well diffusion. However, the concentrations used 
for the assay were 1g/ ml and 1.5 g/ml. The hexane, ethyl acetate, and methanol extracts 
were evaluated against E. coli resistant to ciprofloxacin, K. pneumoniae resistant to 
amoxycillin and ciprofloxacin, and P. aeruginosa resistant to Amoxycillin, Ciprofloxacin, 
and Cephaloridine. All of the extracts showed positive inhibition of bacterial growth, and 
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the zone of inhibition range between 8 and 19 mm, but Klebsiella was the most sensitive 
bacteria 120. Several extracts from Cissus plants have also shown antimicrobial activity in 
vitro against B. subtilis, K. pneumonia, S. aureus, E. coli, and P. aeruginosa. Those 
species include C. pallida 121, C. welwitschii 119, C. cornifolia 122, C. rotundifolia 106, C. 
ibuensis 123, and C. rubiginosa 100.  
Regarding the activity of Cissus plant extracts against cancer cell lines, cytotoxic activity 
was found by the MTT technique in extracts from the stems of C. quadrangularis. They 
estimate an IC50 of 200 μg/ml for the hexane extract against the skin carcinoma cell line 
A431 124, and 48 μg/ml for the acetone extract against the epidermic carcinoma cell line 
KB 124. The ethyl acetate extract from the stems of C. sicyoides showed an IC50 of 43 μg/ml 
against the liver carcinoma cells HepG2 125 and the ethanolic extract from their leaves 
showed activity against lung carcinoma NCI-H292 and mouth KB carcinoma cell lines with 
an IC50 of 50 µg/ml 126. Finally, the methanolic extract from the stems of C. debilis caused 
proliferative inhibition in the carcinoma cell line from colon CaCo-2 with an estimated IC50 
of 50 µg/ml 127. Even though extracts are not as effective as antibiotics or cytotoxic agents 
is important to mention that side-effects are minimum for human consumption. Studies 
showed that at doses as high as 5 g/kg for humans 128 and animals 129 there are no signs 
of any adverse side effects at least for C. quadrangularis extracts. 
 
2.2.2. Bioactive compounds isolated from Cissus plants 
Some of the properties of Cissus plants are attributed to bioactive compounds such as 
flavonoids, triterpenes, sterols, coumarins and stilbenes with anti-inflammatory, 
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antimicrobial 130 and anticancer activities 131 (Table 2). They exert their action mechanism 
through the modulation of enzymes as phospholipases, cyclooxygenases, lipoxygenases 
132, and steroid and kinase pathways 133. Some of the isolated and characterized 
compounds on Cissus plants possess both, antibacterial and cytotoxic activities. For 
example, kaempferol induced the apoptosis via cell cycle arrest in the cell line of breast 
carcinoma MDA-MB-453 134 and inhibits the function and expression of the MDR1 in S. 
aureus 46. Eugenol inhibits MCF7 cell growth, and, in dose and time-dependent manner 
originates cell shrinkage, membrane changes, and apoptotic body formation. Eugenol 
downregulates the cyclins D1 and B, the antiapoptotic protein Bcl-2 whereas increases 
the expression of p21 and p53 135. Eugenol has also been shown to be inhibitory for the 
E. coli that produces shigatoxin (O157:H7) through membrane disruption 136. Ellagic acid 
induces antiproliferative effects in human prostatic cancer cell lines (PC3) through 
downregulation of the insulin growth factor II (IGF-II) and the induction of p53/p21 
expression 137. Ellagic acid also shows antibacterial activity against Aeromonas hydrophila 
through unknown mechanisms 138. Friedelin is another example of a compound with 
inhibitory activities against E. faecalis, S. aureus, P. aeruginosa and Vero cells (kidney 
epithelial cells extracted from an African green monkey Chlorocebus) although the 
mechanism of action is not well understood 139. Other compounds isolated in Cissus plants 
with both, in vitro activities against cancer and bacterial cells are resveratrol 140, quercetin 
141, daucosterol 142, ursolic acid 143, purpurogallin 144, myrecitin 145 and lupeol 146. Several 
species of the plants of the genus Cissus still lack phytochemical characterization and 
biological evaluation to support their use as traditional medicine. In Mexico, some 
communities continue to practice Maya medicine and include the use of C. verticillata and 
C. trifoliata for the management of gastrointestinal, skin diseases and tumors 110. 
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Moreover, according to the chemotaxonomic relationship it is probable that more Cissus 
species from Mexico possess bioactive compounds with anticancer and antibacterial 
properties 95. 
Table 2. Bioactive compounds isolated from the stems of Cissus plants 
Plant  Solvent Compounds 
C. assamica  BuOH Ursolic acid, lupeol, isolariciresinol, daucosterine, 
ellagic acid, β-sitosterol and bergenin 147. 
C. pteroclada EtOH Stigmasterol, β-sitosterol, daucosterol, taraxerone, 
eugenol, bergenin, myricetin, gallic acid and oleanolic 
acid 148. 
C. quadrangularis EtOH 
MeOH 
δ-amyrin, resveratrol, δ-amyrone, piceid, β-sitosterol, 
kaempferol, quercetin, phytol, lupeol, piceatannol, 
pallidol, quadrangularin and parthenocissin 116, 120, 133. 
 
2.2.3. Compounds isolated and evaluated from Cissus plants  
Few reports evaluate the biological activity of compounds isolated in Cissus plants. 
Examples include the isolation of ascorbic acid from the methanolic extract from the stems 
of C. quadrangularis. The administration of the compound produced a significant 
protection against aspirin-induced gastric toxicity by showing a significant increase in 
prostaglandin E2 (PGE2), the transforming growth factor alpha (TGF-α ), the vascular 
endothelial growth factor (VEGF), expression accompanied by an inhibition of nitric oxide 
and regulation of the levels of cytokines in rats. These findings suggest that ascorbic acid 
from C. quadrangularis prevents gastric ulcer formation due to its immunomodulatory 
effect, antioxidant activity and prostaglandin synthesis modulation 149. In addition, the new 
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flavonoid cissusin isolated from the methanolic extracts of C. sicyoides stems show 
inhibitory effects of mast degranulation in the rat basophilic leukemia cells (RBL-2H3) cells 
150. Likewise, the triterpene lupeol isolated from the methanolic extract of C. 
quadrangularis stems showed five times more potent melanin promotion activity when 
compared with the standard control compound; 3-isobutyl-1-methylxanthine 151. 
Moreover, bergenin a phenolic compound isolated from the ethanolic extract of C. 
pteroclada stems exerted in vitro anti-inflammatory effects in lipopolysaccharide (LPS) 
stimulated murine macrophages (RAW 264.7). The molecular effects consist of the 
inhibition in the production of the pro-inflammatory molecules such as the nitric oxide 
(NO), PGE2 and the expression of NF-κB, TNF-α, interleukin 1 beta (IL-1β), inducible 
nitric oxide (iNOS) and cyclooxygenase-2 (COX-2) 102. Finally, it was recently discovered 
a new benzolactone from the ethyl acetate extracts of C. cornifolia roots. The compound 
(4,6-dihydroxy-5-methoxy-3-(1,2,3,4,5-pentahydroxypentyl)-2-benzofuran-1(3H)-one) 
showed antimicrobial activity against six of ten clinical isolates of S. aureus, S. typhi, and 
C. albicans. The inhibition zones ranged between 17 and 25 mm 152. 
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CHAPTER III 
3. HYPOTHESIS AND OBJECTIVES 
3.1. HYPOTHESIS  
The stems of Cissus trifoliata possess bioactive compounds with antibacterial or cytotoxic 
activities with a mechanism of action different from the reported in the literature. 
 
3.2. General Objective 
To perform a metabolomic profile and a bioassay-guided phytochemical analysis of 
Cissus trifoliata stems, to evaluate their antibacterial and cytotoxic activities, and to 
elucidate the mechanism of action of one active compound. 
 
3.2.1. Specific Objectives  
 To investigate the ethnomedical uses, chemical composition, and biological 
evaluation of the plants from the genus Cissus. 
 To identify the chemical composition of the hexane, CHCl3-MeOH and aqueous 
extracts from the stems of C. trifoliata. 
 To study the metabolomic profile of C. trifoliata stems. 
 To assess the antibacterial and cytotoxic activity of each extract. 
 To perform a Bioassay-guided fractionation of the CHCl3-MeOH extract. 
 To characterize the metabolomic profile of the active fractions. 
 To identify the mechanism of action of one compound present in the most active 
fraction. 
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CHAPTER IV 
4. MATERIALS AND METHODS 
4.1. Phytochemistry 
Phytochemistry was carried out in the Pharmaceutical Chemistry Laboratory at the 
Postgraduate Studies Division of the School of Science in Chemistry, of the UANL. 
 
4.1.1. Plant material 
The plant selected for this study was collected in Rayones, Nuevo León and identified by 
the Biologist Mauricio González Ferrara. A sample of reference was deposited in the 
Department of Botany, Faculty of Biological Sciences, UANL (voucher 027499).  
 
4.1.2. Fractionation of the extracts and isolation of solids.  
Dried and ground stems (756 g) were subjected to exhaustive extractions by maceration 
with hexane (4 L, 48 h), CHCl3-MeOH (1:1) (9 L, 4 times, 24h each), and distilled water (4 
L, 24 h). Solvents used were chloroform (CHCl3) purity 98.8%, methanol (MeOH) purity 
99.9%, and hexane purity 98.99% (Baker, USA). The organic extracts were filtered and 
concentrated using rotavapor (V300, Buchi, Switzerland), at 40 °C and the aqueous 
extract was lyophilized. The fractionation of the extracts was performed by column 
chromatography, using silica gel (63-200 μm) (Sigma Aldrich) in a 1:20 relation. 
Fractionation and purification of compounds were monitored with thin layer 
chromatography (TLC) of silica gel 60F-254 (Fluka Analytical) using visible and ultraviolet 
(UV) light at 254 nm and 365 nm (Spectroline, EF160C) and revealed with cerium sulfate. 
Melting points were calculated using the Fisher-Johns equipment (00590Q).  
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4.1.2.1. Fractionation of the hexane extract 
The hexane extract (3.5 g) was subjected to column chromatography, using silica gel (70 
g) as stationary phase and hexane/ethanol in gradient as mobile phase. A total of 224 
fractions of 20 ml each were collected. Fractions were pooled in four according to their 
similarity on TLC (Table 3). 
Table 3. Fractionation of the hexane extract 
Fractions Mobile phase Pooled Fractions  Weight (g) 
1-84 Hex 100 I 0.1306 
85-98 Hex / EtOH 96:4 II 2.5837 
99-144 Hex / EtOH 93:7 III 0.0902 
145-224 EtOH 100 IV 0.0941 
  
4.1.2.2. Fractionation of the CHCl3-MeOH extract 
The CHCl3-MeOH extract (24 g) was subjected to column chromatography, using silica 
gel (480 g) as the stationary phase and hexane, ethylacetate and methanol in gradient as 
mobile phase. A total of 210 fractions of 20 ml each were collected. Fractions were pooled 
in fourteen according to their similarity on TLC (Table 4). 
 
4.1.3. Isolated solids from the fractionation of hexane extract 
4.1.3.1. Solid one (CIR1) 
Solid one crystallized out from pooled fraction I, eluted with hexane 100% as a white 
amorphous solid. The solid was filtrated and washed with cold acetone to remove 
impurities. The process afforded 50 mg (0.006614%) of a waxy solid. TLC analysis shows 
that CIR1 was not active under visible or UV light, but stain as a brown spot with cerium 
sulfate.  
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Table 4. Fractionation of the CHCl3-MeOH extract 
Fractions Mobile phase Pooled Fractions Weight (g) 
1-28 Hex 100 A 0.1499 
29-36 Hex / AcOEt 85:15 B 1.8797 
37-45 Hex / AcOEt 80:20  C 0.9695 
46-54 Hex / AcOEt 70:30 D 0.4827 
55-72 Hex / AcOEt 60:40 E 2.1402 
73-78 Hex / AcOEt 30:70 F 0.4285 
79-108 AcOEt 100 G 1.1653 
109-117 AcOEt / MeOH 80:20 H 0.4561 
118-128 AcOEt / MeOH 80:20 I 0.6795 
129-144 AcOEt / MeOH 70:30 J 1.3392 
145-168 AcOEt / MeOH 50:50 K 4.1135 
169-186 AcOEt / MeOH 30:70 L 3.7527 
187-198 AcOEt / MeOH 20:80 M 1.5929 
199-210 MeOH 100 N 1.2244 
 
4.1.3.2. Solid two (CIR2) 
From pooled fraction II (hexane-ethanol 96:4) precipitated a cream amorphous solid. Its 
filtration with cold acetone yields 28 mg (0.003703%) of a white solid, soluble in hexane. 
CIR2 exhibited a single brown spot in TLC stained with cerium sulfate.  
 
4.1.3.3. Solid three (CIR3) 
The pooled fraction II (hexane-ethanol 96:4) was re-chromatographed over silica gel 
(2.35g), eluting with hexane-ethyl acetate (Column II). The subfractions with identical TLC 
patterns were combined. From subfraction 30-37 (90:10) precipitated a solid, which was 
washed with methanol yielded 39 mg (0.005158%) of a white solid. CIR3 was soluble in 
hexane and appear as a brown spot on a TLC stained with cerium sulfate. 
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4.1.3.4. Solid four (CIR4)  
Subfractions 56-63 (hexane-ethyl acetate 85:15) from column II afford a solid that was 
purified by successive recrystallization with acetone. The process yields 35 mg 
(0.004629%) of crystals, which were soluble in chloroform and acetone. CIR4 on TLC 
stains as a single purple spot with cerium sulfate. 
 
4.1.3.5. Solid five (CIR5)  
The solid five precipitated in the mother liquor of CIR3. The white solid was filtered by 
vacuum and washed with hexane. The process recovered 30 mg (0.003968%) of solid 
soluble in chloroform. The TLC analysis showed a brown spot with the cerium sulfate 
stain.  
 
4.1.4. Nuclear Magnetic Resonance (NMR) spectroscopy 
The chemical structure of the solids was analyzed by 1H and 13C NMR spectroscopy 
performed in BRUKER NMR 400 MHz equipment using as solvent deuterated chloroform 
(CDCl3), and tetramethylsilane (TMS) as a reference. The software Mestrenova version 
12.0.2 was used for processing the spectral data. 
 
4.1.5. Gas chromatography-mass spectrometry  
The GC-MS analysis was performed in a gas chromatograph 6890 equipped with an MSD 
5973 mass detector, both from Agilent technologies, using helium as the carrier gas. A 
volume of 1μl of samples was injected in split mode (1:15), at an injector temperature of 
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270 ºC. The quadrupole mass spectrometer was operated in EI mode at 70 eV in scan 
mode (m/z 50 to 600). Data acquisition and processing were performed using Agilent MSD 
Chemstation software. The solids and the hexane extract were analyzed by GC-MS, the 
instrumental conditions are described in table 5.  
Table 5. Conditions of GC-MS analysis for the solids and the hexane extract 
GC-MS engine model Agilent. GC 6890, MSD 5973N 
GC column HP-5 (30 m *0.25 mm x 0.25 µm) 
Injector Split 1:15 
Carrier gas  Helium 
Carrier gas flow 1 ml/min 
Injector temperature 270 °C 
Source temperature 230 °C 
Detector temperature 250 °C 
Initial temperature 70 °C, 2 min 
Temperature program 70 to 200 °C ,10 °C/min, 200 to 310 °C, 10 °C/min. 
Final temperature 310 °C, 5 min. 
 
4.1.6. Liquid Chromatography-Mass spectrometry  
Samples were diluted in 50% with LC-MS grade MeOH (Fisher Scientific), filtered using 
the Supelco (54145-U) Iso-disc, N-4-2 nylon, 4 mm x 0.2 µm filters (Sigma-Aldrich), and 
transferred to high-recovery amber vials (Agilent Technologies, Inc., Santa Clara, CA). 
Reverse-phase liquid chromatography was performed using an Agilent 1290 Infinity Ultra 
High-Performance Liquid Chromatography system (UHPLC). The mobile phase was 
delivered by a binary pump at a flow rate of 0.250 ml/min using two mobile phases: solvent 
A was composed of LC-MS grade water and 0.1% v/v formic acid (Proteochem Loves 
Park, IL) and solvent B was of LCMS grade MeOH and 0.1% v/v formic acid (Proteochem). 
The solvents were dispensed over a gradient: 0-6 min, 100% solvent B; 10 min, 100% B; 
11 min, 30% B. The autosampler was set with an injection volume of 5 µl. The flush port 
was set to clean the injection needle for 30s intervals. The stationary phase was a C18 
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column (ZORBAX Rapid Resolution High Throughput (RRHT), 2.1 x 50 mm, 1.8 µm, 
Agilent Technologies, Inc.) was used. The column was maintained at an isothermal 
temperature of 38 °C (Table 6). 
Table 6. UPLC Parameters 
Instrument Agilent 1290 Infinity Binary LC 
Mobile phases A) 0.1% formic acid in water B) 0.1% formic acid in methanol 
 Initial 100% B 
Gradient Gradient 
 
Time (min)  
%A 
6 min 0% 
10 min 0% 
11 min 70% 
 
%B 
100% 
100% 
30% 
Flow rate 0.250 ml/min 
Column 
A ZORBAX Rapid Resolution High Throughput (RRHT), 2.1 x 50 mm, 
1.8 µm C18 column (Agilent Technologies, Inc.) with an Agilent 2.1 mm 
× 5 mm, guard column (p/n 821725-911) 
Post run time 4 minutes at initial mobile phase 
Temperature 38 °C 
Injection volume 5 µl 
 
Mass spectrometric analysis was performed by an Agilent 6530 QTOF LC-MS with an ESI 
source set for detection mass range from mass-to-charge ratio (m/z) 100 to 1000. A 
dedicated isocratic pump continuously infused a mix of reference standards (Agilent 
Technologies, Inc.) at a flow rate of 0.5 ml/min to achieve accurate mass correction. The 
nebulizer pressure was set at 35 psi with a surrounding sheath gas temperature of 350 
°C and a gas flow rate of 11 l/min. Drying gas temperature was set at 300 °C with a flow 
rate of 10 l/min. Default settings were used to set a voltage gradient for nozzle at 1000 V, 
skimmer at 65 V, capillary (VCap) at 3500 V, and fragmentor at 175 V (Table 7). The 
active fractions from the CHCl3-MeOH extract were dissolved in a (50:50 v/v) solution of 
methanol and water at the concentration of 1000 mg/l. Their analyses were carried out by 
reverse phase HPLC on an Agilent 1200 series system fitted with an Agilent, Zorbax C18 
(4.6 × 100 mm, 3 μm). 
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Table 7. Q-TOF LC/MS Parameters 
Instrument Agilent 6530 Accurate-Mass Q-TOF LC/MS 
Ionization mode Negative electrospray with Agilent Jet Stream technology 
Acquisition rate  1.0 spectra/s 
Mass range  100-1,000 m/z 
Drying gas temperature  225 °C 
Drying gas flow rate  10.0 l/min 
Sheath gas temperature  350 °C 
Sheath gas flow rate  11.0 l/min 
Nebulizer gas  35 psi 
Skimmer voltage  65 V 
Octopole RF  750 V 
Fragmentor  175 V 
Capillary  2.5 kV (negative mode) 
 
The HPLC conditions were as follows: flow rate, 0.4 ml/min; solvent A, 0.1% formic acid 
in water; solvent B, methanol; gradient, solvent B 20-100% over 10 min and kept at 100% 
for 5 min. The extract was injected (4 μL) in the HPLC system and analyzed by ESI-QTOF-
MS in the negative mode using an Agilent 6520 time-of-flight mass spectrometer. Mass 
spectral data were acquired in the range m/z 100-3000, with an acquisition rate of 1.35 
spectra/s, averaging 10,000 transients. The source parameters were adjusted as follows: 
drying gas temperature 250 °C, drying gas flow rate 5 L/min, nebulizer pressure 45 psi, 
and fragmentor voltage 150 V. Data acquisition and processing were done using Agilent 
Mass Hunter Workstation Acquisition v. B.02.00 software. 
 
4.1.7. Identification of plant metabolites and data analysis 
Record of LC-MS data was achieved using Agilent MassHunter Acquisition SW Version, 
6200 series TOF/6500 series Q-TOF B.05.01 (B5125.1). Agilent MassHunter Qualitative 
Analysis B.06.00 was used to analyze data and to generate the total ion chromatogram 
(TIC), extracted ion chromatogram (EIC), the extracted compound chromatogram (ECC), 
and mass spectra. MS acquisition was performed with three replicate injections to allow 
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column conditioning and examine reproducibility. The putative compound identification 
was based on the correct elemental composition generated using the accurate m/z and 
the molecular formula generator tool (Agilent Technologies). Data were queried against 
the online METLIN, HMDB, LMSD and Phytohub databases. 
 
4.1.8. Antibacterial activity. 
4.1.8.1. Bacterial strains. 
The tested bacteria include seven bacteria from the ATCC (American Type Culture 
Collection, Manassas, VA, USA) and nine resistant strains isolated in the University 
Hospital of the Universidad Autonoma de Nuevo León (Monterrey, Nuevo León, Mexico). 
The bacteria from the ATCC include 3 three gram-positive bacteria; Staphylococcus 
aureus (ATCC, 29213), Staphylococcus epidermidis (ATCC,14990) and Enterococcus 
faecium (ATCC, 2127) and four gram-negative bacteria, Acinetobacter baumanni (ATCC, 
13883), Escherichia coli (ATCC, 25922), Pseudomonas aeruginosa (ATCC, 27853), and 
Klebsiella pneumoniae (ATCC, 19606). The drug resistant gram-positive bacteria were 
methicillin-resistant S. aureus (14-2095), linezolid-resistant S. epidermidis (14-583), and 
vancomycin-resistant E. faecium (10-984). The drug resistant gram-negative bacteria 
were, carbapenem-resistant A. baumannii (12-666), extended spectrum β-lactamase 
(ESBL) E. coli (14-2081), carbapenem-resistant P. aeruginosa (13-1391), oxacillin-
resistant (OXA-48) K. pneumoniae (17-1692), and New Delhi metallo-β-lactamase 1 
(NDM-1+) K. pneumoniae (14-3335).  
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4.1.8.2. Microdilution method. 
The MIC of the extracts and the positive control levofloxacin were determined in duplicate 
by the micro-dilution broth method in 96-well microplates 153. The aqueous extract was 
dissolved in distilled water, while organic extracts and levofloxacin were dissolved in 
dimethyl sulfoxide (DMSO). The solutions were then diluted in Mueller-Hinton broth (Difco, 
Detroit, MI, USA), in order to achieve concentrations ranging from 500, 250, 125, 62.5, 
31.2, 15.6 and 7.8 µg/ml for extracts and 200, 100, 50, 25, 12.5, 6.25 and 3.12 µg/ml for 
levofloxacin according to literature 154. The range of concentrations used for DMSO was 
from 6% to 0.09% (v/v) and this solution was used as a negative control. The strains were 
inoculated on plates prepared with 5% blood agar and cultured for 24 h at 37 °C. The 
strains of P. aeruginosa and S. epidermidis were incubated for 48 h at 37 °C. One to three 
colonies from the blood agar plate were selected and transferred to a tube containing 5 
ml of sterile saline solution. The suspension was adjusted to 0.5 MacFarland standard 
(1.5 x 108 CFU). Then, 10 µl of this suspension was transferred into 11 ml Mueller Hinton 
broth to achieve 1.5 × 105 CFU/ml. One hundred microliter of Mueller Hinton broth was 
added into each well of the 96-well plate. Further, 100 µl of each solution to be tested was 
added to the wells of line A. Then, a serial dilution (1:2) was carried out through the plate 
until line G. Then, 100 µl of bacterial suspension (1.5 x 108 CFU) was added to all the 
wells except line H which was the sterility control. Plates were incubated at 37 °C for 24 
or 48 h depending on the bacteria. After the incubation, the turbidity or bottom deposition 
was visually evaluated to determine the microorganism viability. The MIC values were 
determined as the lowest concentration which inhibits the microorganism growth. 
According to the National Committee for Clinical Laboratory Standards extracts with a MIC 
value ≥30 µg/ml were considered negative for antibacterial activity 154
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4.1.9. Cytotoxic activity 
4.1.9.1. Cells and culture of MTS assay 
The cytotoxic activity was investigated on the human cancer cell lines PC3 (prostate), 
Hep3B, and HepG2 (hepatocellular), MCF7 (breast), A549 (lung) and HeLa (cervical) 
human cancer cell lines, obtained from the ATCC (American Type Culture Collection, 
Manassas, VA, USA) 155. PC3 cells were grown in RPMI-1640 medium (Sigma Aldrich, 
St. Louis, MO, USA), and the rest in DMEM medium (Invitrogen, Thermo Fisher Scientific, 
Inc., Waltham, MA, USA), supplemented with fetal bovine serum 10% (SFB, Invitrogen) 
and with 2 mM glutamine. All cultures were incubated at 37 °C in an atmosphere of 5% 
CO2. For the evaluation in the MTS assay, 4000 cells per well were cultured in a 96-well 
plate. The concentrations used for the extract, the pure compounds, and the positive 
control paclitaxel were 100, 10, 1, 0.1, 0.001 µg/ml for a dose/response curve, and 
incubated at 37 °C in 5% CO2 atmosphere for 72 h according to recommendations 36. The 
number of viable cells in proliferation was determined by using CellTiter 96 AQueous One 
Solution Cell Proliferation Assay kit (Promega, Madison, WI, USA), following the 
manufacturer's instructions. Cell viability was determined by absorbance at 450 nm using 
an automated ELISA reader. The experiments were conducted by triplicate in three 
independent experiments. The concentrations assayed allowed the determination of the 
half-maximal inhibitory concentration (IC50) by regression analysis with the statistical 
program Prism5. The recommendations of the National Cancer Institute were used as a 
guideline. Thus, the extracts were considered cytotoxic when the IC50 ≤ 30 μg/ml 36.  
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4.1.10. Bioassay-guided cytotoxicity of the CHCl3-MeOH extract by WST-1  
The hexane extract (3.5g) was completely processed by column chromatography during 
the purification of the solids. Thus, the bioassay-guided study was done in the CHCl3-
MeOH (21g). The assays were performed in MCF7 and PC3 cell lines. When cells reached 
a confluence of 80%, were washed twice with phosphate-buffered saline (PBS) solution, 
followed by 500 μl of 0.25% trypsin for each vial with medium, and incubating for 5 min at 
37 °C in 5% atmosphere of CO2 in an incubator (model 3403 Thermo Scientific ®). After 
incubation, cells were detached and resuspended in 1 ml of EMEM (Eagle modified 
essential medium) medium supplemented with 10% fetal bovine serum (SFB) and 1% of 
an antibiotic (10000 units of penicillin/10 mg streptomycin /ml). The cell suspension was 
centrifuged at 13000 rpm for 10 min in a refrigerated centrifuge (Sorval Thermo 
Scientific®). The supernatant was removed, and the pellet was resuspended with 5 ml of 
EMEM medium, 10 μl of the cell suspension was transferred in the Neubauer chamber to 
perform the cell counting. The cell suspension was adjusted to 5x104 cells/ml. For the 
assay, approximately 5x103 cells per well were incubated for 24 h. Then, fractions under 
study and the controls were added to the 96-well plates. The concentrations of the 
fractions used were 100, 50, and 25μg/ml. The stock solution of each extract was made 
of 1 mg of extract and 250 μl of DMSO. From the stocks, 20 μl were transferred to an 
Eppendorf tube, and 480 μl of EMEM medium were added. Then, 100 μl of the solution 
was taken and placed in the first well of the plate and subsequently carry out a serial 
dilution. The procedure was carried out for each fraction and controls in triplicate. The 
plate was incubated for 48 h at 37 °C. At the end of the incubation period, the supernatant 
of the plate was substituted with 10 μl of WST-1 and 90 μl of EMEM medium and incubated 
for 2 h. At the end of the incubation period, the optical density was measured at 450 nm 
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with an ELISA reader (ELX800, Biotek®). The paclitaxel was used as the reference drug 
at the same concentrations, and as positive control 1% of triton X in PBS. As negative 
controls, the cells without any treatment, the solvent/medium EMEM at the same 
concentrations for the dilutions of the fractions, and 95 μl of EMEM medium and 5 μl of 
WST-1 other as target of the reaction of wells without cells.  
 
4.1.10.1 Determination of the IC50 for pure compounds  
Phytochemicals identified in the active fractions are widely distributed in the plant 
kingdom, except for stilbenes with a narrow distribution that includes the Vitaceae. Thus, 
resveratrol derivatives were chosen for the determination of the cytotoxic activity and the 
microarray study. The pure compounds purchased in Sigma Aldrich were the resveratrol 
(R5010) and piceid (R15721). The IC50 was calculated against the PC3 and MCF7 cell 
lines by the WST-1 protocol previously used in the evaluation of the cytotoxic activity of 
the fractions. Cells were exposed to 6.25, 12.5, 25, 50 and 100 (µg/ml) of resveratrol or 
piceid for 24 h. Stocks were prepared with DMSO, and assays were carried out in triplicate 
and repeated 3 times on different days. The IC50 was calculated with Quest Graph™ (AAT 
Bioquest, Inc. USA).  
 
4.1.11. Microarrays 
4.1.11.1 RNA isolation 
Traditional methodologies to discover anticancer drugs are based on the determination of 
the cytotoxic effects of a certain molecule over cancer cells in vitro exposed to its IC50. 
However, recent literature has shown that the exposition to IC20-30 156 or lower 
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concentrations, but longer incubation periods 157 are useful in the determination of novel 
anticancer mechanisms of well-known phytocompounds. Thus, PC3 cells were exposed 
to resveratrol at IC25 for 24 h to explore antitumor effects non-related with apoptosis. The 
concentration of resveratrol used for the assays was 27 µg/ml (115 µM). Cells were 
counted, and 10 µl were added to the Neubauer chamber to reach a cell suspension of 
2x106 of cell/ml. In each flask 1 ml of cell suspension was added in 3 ml of EMEM and 
incubated for 24 h, at 37 °C in an atmosphere of 5% of CO2. Further, cells were exposed 
for 24 h with resveratrol. For the RNA isolation, the media was discarded, and cells were 
washed with PBS, and 1 ml of trypsin was added to each flask and incubated for 3 min. 
Then 2 ml of EMEM was added in each flask. Cells were transferred to 15 ml Falcon tubes 
and centrifugated for 10 min at 1300 rpm.  
The supernatant was discarded, and 1 ml of PBS was added to the pellet. Centrifugated 
8 min at 13300 rpm at 4 °C. The supernatant was discarded and 500 µl of trizol was added 
and vortexed for 15 s, followed for incubation of 2 min at room temperature. Then, 500 µl 
of CHCl3 were added, and vortexed for 15 s, and incubated 3 min at room temperature. 
Another centrifugation step of 8 min at 13300 rpm was carried out. The aqueous phase 
was recovered by micropipette and included in 500 µl of isopropanol and mixed by 
immersion. The centrifugation step was repeated in the same conditions, and the 
supernatant was discarded. The pellet was washed with 500 µl of ethanol 70% and 
centrifugated in the same conditions for 5 min. The pellet was left to dry for 5 min at room 
temperature. Then, 50 µl of Mili-Q water was added to dissolve the RNA pellet. Samples 
were kept at 4 °C. RNA integrity was evaluated in 1% agarose gel in TBE 1X buffer, run 
at 80 V for 5 minutes, followed by 120 V for 25 min. RNA was quantified by 
spectrophotometry, adding 2 µl of each sample in nanodrop 2000 (Thermo Scientific, 
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USA). The optical density relationship 260/280 was assessed to evaluate RNA purity. 
Finally, the RNA was precipitated and transferred to cryotubes, adding 5 µl of sodium 
acetate 3M at pH 5.2 and vortexed. Cold ethanol was added (138 µl) in each sample and 
mixed by immersion. RNA samples were kept in -80 °C.  
 
4.1.11.2 RNA tagging 
For RNA tagging, deoxynucleotides of thymine were marked with fluorescence molecules, 
Alexafluor 555 for the control and Alexafluor 647 (Thermo Fisher Scientific, MA, USA) for 
the sample. The RNA of the samples was centrifugated at 14000 rpm for 15 min. The 
supernatant was discarded, and the pellet washed with 500 µl of ethanol 70%, it was 
centrifugated and allowed to dry 15 min. Then was resuspended in 15 µl of water treated 
with diethylpyrocarbonate (DEPC). Tagging was performed by retrotranscription 
employing mixtures. Mixture A contained Oligo dT 1 µl, random primers 1 µl and water 
treated with DEPC. The final volume of the mixture was 19 µl and was incubated at 70 °C 
for 10 min and placed on ice for 5 min. Mixture B consisted in reaction buffer 5X RT (8 µl, 
MgCl 25 mM, 2 µl, aminoalil-DNTP 4 µl, ditiotreitol (DTT) 0.1 M 4 µl, transcriptase reverse 
superscript II (200U/ µl) 3 µl. Mixture B was mixed with A, and centrifugated e incubated 
for 10 min at 25 °C, followed by overnight incubation at 42 °C. After retrotranscription, 
RNA was hydrolyzed with 5 µl of NaOH 1 N and 1 µl of EDTA 0.5 M and incubated 10 min 
at 65 °C, then 24 µl of (4-(2-hidroxietil)-1-ácido piperazineetanosulfonico) (HEPES) 1 M, 
pH 7.5 were added. The cDNA purification consisted of the addition of 7 µl of sodium 
acetate 3 M and 400 µl of union buffer, mixed and was subjected to column Qiagen. It 
was incubated 5 min, and centrifugated at 1400 rpm one min, it was washed in triplicated 
with 500 µl of ethanol at 80%, and centrifugated at 14000 rpm. Finally, ethanol was 
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evaporated. New tubes were used to recover cDNA of the column with 30 µl of H2O/DEPC. 
The sample was centrifugated at 9000 rpm for 1 min in a vacuum centrifuge (Integrated 
Speedvac system model ISS110, Thermo). Samples were resuspended in 4.5 µl sodium 
bicarbonate 100 mM, 9.0 pH, vortexed and allowed to rest 10 min.  
 
4.1.11.3 Microarray hybridization  
Microarrays used was the H35K, which contains the entire human genome sequence as 
a blueprint (Arrayit, CA, USA). The microarray chip was hydrated in water vapor at 60 °C 
for 10 s, tree times. Chip was fixed with ultraviolet light for 1 min, 2x, in the Sprectrolinker 
(XL-1500). To perform hybridization, the complementary DNA (cDNA) was quantified with 
Nanodrop. Each sample was adjusted and led to dry, to dissolve them in hybridization 
solution containing 17.5 µl of saline-sodium citrate (SSC) 5X, 7 µl of Sodium dodecyl 
sulfate (SDS) 0.1%, 45.5 µl and Tris EDTA buffer (TE). Denaturalization was performed 
at 94 °C for 5 m and 30 s at 65 °C. The mixture was added to the microarray and covered. 
The incubation was allowed for 18 h in a water bath at 42 °C. Afterward, the microarrays 
were washed 3 times with the SSC 1X buffer at room temperature. The microarrays were 
centrifugated (model Allegra 6, Beckman) at 1500 rpm for 2 min. Once dry, microarrays 
were read it with the scanner GenePix 4100 (Molecular Devices, CA, USA).  
 
4.1.11.4. Bioinformatic analysis of Microarrays 
For the bioinformatic analysis, the upregulated and downregulated genes considered 
were those with a z-score of ± 2 SD. The database employed for the interpretation was 
DAVID version 4.0 (The database for Annotation, Visualization, and Integrated Discovery) 
to identify the functional roles of the affected genes. 
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4.1.12. Statistical analysis 
The analysis of the metabolic profile was carried out using MetaboAnalyst version 4. All 
data were log-transformed and normalized before statistical analysis. Principal 
Component Analysis (PCA) was used to determine the metabolomic variation in individual 
extracts and the hierarchal clustering to visualize the relationship among samples 
(Euclidean distances). The metabolic pathways analysis employed the library of 
Arabidopsis thaliana. The one-way ANOVAs and the post-hoc analysis (Tukey HSD test) 
were performed to determine significative differences (p > 0.05). Data from experiments 
of cell proliferation were analyzed by ANOVA-LSD test (Fisher's least significant 
difference) in the IBM SPSS Statistics Version 20. 
 
4.1.13. Waste disposal 
Hazardous waste material was properly collected, stored and disposed in line with the 
recommendations of the department of waste management of the FCQ, UANL. 
Accordingly, the halogenated solvents and their mixtures were collected in container D, 
and non-halogenated solvents in collector C. Waste material generated during the assays 
of microbiology and cell cultures were disposed in a biohazard red bags and autoclave it 
before discarding in line with the guideline of the microbiology lab of the University 
Hospital, and INGEN, UANL. Disposal of organic substances produced during the 
chromatographic analysis was processed according to the instructions of the department 
of Medical Toxicology of Cagliari University, Italy. 
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CHAPTER V 
5.1. RESULTS AND DISCUSSION 
 
 
5.1.1. Plant material and extraction 
The sequential maceration of the grounded stems (756 g) yields 3.5 g (0.423%), 24 g 
(3.201%) and 8.24 g (1.084%) of dry extracts of hexane, CHCl3-MeOH (1:1) and aqueous 
solvents, respectively.  
 
5.1.2. Structural elucidation of solids from the hexane extract 
5.1.2.1. Physic and spectral data of solid 1 (CIR1) 
White waxy solid, melting point (MP) 60-62 °C. The 1H NMR of CIR1 (Figure 1) shows the 
presence of a triplet at δ 0.88 (t, J = 6.8 Hz, H1, H31) integrating for six methyl protons 
and a singlet of methylenes at δ 1.25 (H2 to H30) integrating for 58 protons which suggest 
a long chain linear alkane. The 13C NMR spectra (Figure 2) shows five-carbon signals at 
δ 31.95 (C3, C29), 29.72 (C5 to C27), 29.38 (C4, C28), 22.71 (C2, C30), 14.12 (C1, C31), 
which corresponds to the observed five resonances for a hydrocarbon chain of 
(αCH3)2(βCH2)2(γCH2)2(δCH2)2(εCH2)2. The terminal αCH3 groups, and four CH2 groups 
(β, γ, δ, and ε), at 14.3 ppm (αCH3), 23.0 ppm (βCH2), 32.2 ppm (γCH2), 29.7 ppm (δCH2) 
and 30.0 ppm (εCH2) 158. Thus, CIR1 was assigned as hentriacontane C31H64, MW = 
436.85 g/mol, according to its NMR signals and previous reports 159.  
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 Figure 1. 1H NMR (400 MHz, CDCl3) spectra of CIR1.  
 
 Figure 2. 13C NMR (100 MHz, CDCl3) spectra of CIR1.  
 
The solid 1 was subsequently analyzed by GC-MS and its chromatogram (Figure 3) 
showed that it was a mixture of long-chain alkanes, and squalene. The retention times, 
abundance, molecular weight, and molecular formula of the identified compounds are 
summarized in Table 8. 
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 Figure 3. GC-MS chromatogram of CIR1. 
 
90% of the identified compounds corresponds with long-chain alkanes. The GC-MS 
analysis confirmed the presence of hentriacontane as the most abundant constituent in 
CIR1. The hentriacontane is a common constituent of plant extracts identified by 
hyphenated gas chromatography-mass spectrometry 160.  
 
Table 8. GC-MS analysis of CIR1 
Peak RT (min) Abundance (%) Compound Molecular weight Molecular formula 
1 3.289 0.95 Pentacosane  352.6804 C25H52 
2 87.794 0.41 Pentatriacontane 492.9462 C35H72 
3 91.532 0.19 Octacosane 394.7601 C28H58 
4 95.217 2.52 Cyclooctacosane 392.7442 C28H56 
5 98.481 0.33 Squalene 410.7180 C30H50 
6 99.454 1.09 Nonacosane 408.7867 C29H60 
7 102.547 30.26 Dotriacontane 450.8664 C32H66 
8 109.241 52.35 Hentriacontane 436.8399 C31H64 
9 114.804 10.75 Triacontane 422.8133 C30H62 
 
The EI mass spectrum of hentriacontane is typical for linear saturated hydrocarbons 
(figure 4). It shows smooth transitions of carbenium ion signal intensities from peak to 
peak, starting from propyl [C3H7+] m/z 43, then intensities rise to butyl [C4H9+] m/z 57, then 
falls notably fall to the molecular ion peak at m/z 436 [M+.], in line with the reported 
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spectrum 159, 161. GC-EIMS m/z (rel. int.) = 436, C31H64, M+ (15), 99 (27), 97 (35), 85 (50), 
71 (65), 57 (100), 43 (70). 
Figure 4. Mass spectrum of Hentriacontane 
 
5.1.2.2. Physic and spectral data of solid 2 (CIR2) 
White solid of mp 74-75 °C. The 1H NMR of CIR2 exhibited the existence of one triplet at 
δ 0.88 (t, J = 6.6 Hz, H1, H48) integrating for six methyl protons and a singlet of 
methylenes at δ 1.25 (H2 to H47) integrating for 92 protons, suggesting the presence of 
a long-chain linear alkane (Figure 5).  
Figure 5. 1H NMR (400 MHz, CDCl3) spectra of CIR2. 
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In the 13C NMR spectra are recognized signals of a long hydrocarbon chain, the five-
carbon signals at δ 31.95 (C3, C46), 29.72 (C5 to C43), 29.38 (C4, C45), 22.71 (C2, C47), 
14.12 (C1, C48) (Figure 6). Based on NMR spectral data the proposed structure for solid 
2 has been characterized as octatetracontane, C48H98 162 in mixture with other minority 
compounds. 
 Figure 6. 13C NMR (100 MHz, CDCl3) spectra of CIR2. 
 
 
The results of the GC-MS analysis support the presence of long-chain aliphatic 
compounds and allowed the identification of other components in the solid 2. The GC-MS 
chromatogram is presented in Figure 7, the retention times, abundance, molecular weight, 
and molecular formula of the ten identified molecules were summarized in Table 9. The 
solid 2 resulted in a mixture of hentriacontane, octacosane, tricosane, heneicosane, 
nonacosane, heptacosane, the triterpene squalene, and other unknown compounds.  
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 Figure 7. GC-MS chromatogram of CIR2. 
 
Approximately 60% of the identified compounds correspond to alkanes and 
hentriacontane was the majoritarian long-chain aliphatic compound present in the solid. 
The mass spectrum of squalene, the next most abundant identified compound in solid 2 
is showed in figure 8.  
Table 9. GC-MS analysis of CIR2 
Peak RT (min) Abundance (%) Compound Molecular weight Molecular formula 
1 71.425 3.11 Heneicosane 296.5741 C21H44 
2 75.754 0.87 Docosane 310.6006 C22H46 
3 80.129 7.92 Tricosane 324.6272 C23H48 
4 84.017 1.39 Pentatriacontane 492.9462 C35H72 
5 88.149 12.97 Octacosane 394.7601 C28H58 
6 91.447 0.78 1-Hexacosene 364.6911 C26H52 
7 91.677 1.95 Heptacosane 380.7335 C27H56 
8 99.020 2.41 Nonacosane 408.7867 C29H60 
9 99.940 37.76 Squalene 410.7180 C30H50 
10 108.932 27.11 Hentriacontane 436.8399 C31H64 
 
The EI-MS spectrum of squalene exhibits a fragmentation pattern typical of cleavage of 
isoprene units [C5H9]+ m/z 69 , in consistency with literature 163. GC-EIMS: m/z (rel. int.)= 
410(3),C30H50 [M+], 137(40), 121(17), 95(17), 81(100), 69(90), 57(19), 55(17) 163. 
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 Figure 8. Mass spectrum of squalene. 
 
 
 
5.1.2.3. Physic and spectral data of solid 3 (CIR3) 
White waxy solid of mp 64-65 °C. The NMR data of CIR3 (Figure 9) shows a triplet at δ 
0.88 (t, J = 6.7 H, H28) attributed to three methyl protons, and at 1.25 (H4 to H27) a singlet 
integrating for 48 protons, which corresponds to 24 units of methylenes, downfield at 1.63 
(H3) a multiplet integrating two protons corresponding to a methylene protons beta, in 
respect to a carbonyl, and at 2.35 (t, J = 7.5 Hz, H2) a triplet integrating for two protons 
corresponding to an alpha carbonyl methylene protons. The 13C NMR gave signals at δ 
178.47 that corresponds to a carboxylic carbon at C1, along with the signals at 33.79 (C2) 
of the alpha carbonyl methylene, and 31.94 (C26), 29.69 (C4 to C25), 24.72 (C23), 22.70 
(C27) and 14.12 (C1). (Figure 10). Overall, the spectral data and the literature comparison 
suggest the structure of the octacosanoic acid C28H56O2; MW = 424.75 g/mol 164.  
The solid 3 was also subjected to GC-MS analysis that revealed four majoritarian 
compounds from which two were identified. The chromatogram is shown in figure 11 and 
table 10 summarizes the retention times, abundance, molecular weight, and molecular 
formula of the identified compounds. 
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 Figure 9. 1H NMR (400 MHz, CDCl3) spectra of CIR3. 
 
 
 
 
 Figure 10. 13C NMR (100 MHz, CDCl3) spectra of CIR3. 
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 Figure 11. GC-MS chromatogram of CIR3. 
The major compound present in solid 3 corresponds to 1,30-triacontanediol, followed by 
the 2-heptadecyloxirane and other unidentified constituents. Both compounds commonly 
identified by GCMS analysis of plant extracts 160, 165. The mass spectrum of 1,30 
triacontanediol corresponds with the reported in literature 166 (Figure 12). 
Table 10. GC-MS analysis of CIR3 
Peak RT (min) Abundance (%) Compound Molecular weight Molecular formula 
1 99.854 15.32 2-heptadecyloxirane 282.5110 C19H38O 
2 112.932 84.69 1,30-Triacontanediol 454.8120 C30H62O2 
 
The spectrum lacks the molecular ion peak (typical of aliphatic alcohols). Instead, the [M-
36] ion, from the loss of two molecules of water is observed at m/z 418. GC-EIMS: m/z 
(rel. int.)= 454 (0), C30H62O2 [M+], 418(15), 96 (68), 82 (90), 69 (74), 55 (100), 43 (70).  
 Figure 12. Mass spectrum of 1,30 triacontanediol. 
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5.1.2.4. Physic and spectral data of solid 4 (CIR4) 
Needle shape crystals, mp 135-136 °C. The 1H NMR shows six singlets methyl signals 
that appeared at δ 1.01 (s, 3H, H19), 0.92 (d, J= 6.5 Hz, 3H, H21), 0.86 (t, J = 7.3 Hz, 3H, 
H29), 0.84 (d, J = 7.2 Hz, 3H, H26), 0.81 (d, J = 7.2 Hz, 3H, H27), and 0.68 (s, 3H, H18). 
The spectrum further revealed the presence of a signal at δ 5.53 (psd, J = 4.7Hz, 1H, H6), 
and δ 3.53 (m, 1H, H3) and less intense signals at δ 5.15 (dd, J = 9, 15 Hz), and 5.01 (dd, 
J = 9, 15 Hz). Overall, most of the CIR4 1H NMR spectrum is consistent to the reported 
literature values for β-sitosterol 167 (Figure 13). The 13C NMR spectra of solid 4 showed 
twenty-nine carbon signals, including six methyls, two olefinic carbons, and the carbon 
adjacent to the hydroxyl group. The signals were assigned accordingly to the reported 
spectra for β-sitosterol 168; at δ 140.78 (C5), at 121.73 (C6), and 71.83 (C3) for the ring 
motifs. The methyls were assigned as: at δ 21.10 (C26), 19.83 (C19), 19.41 (C27), 19.05 
(C21), 12.00 (C29) and 11.87 (C18) (Figure 14). Thus, based on the spectroscopic data 
of CIR4 and literature comparison the solid four appears to be composed mainly by β-
sitosterol, and the presence of signals at δ 5 in the 1H NMR spectrum indicates a mixture 
with stigmasterol (the double bond between C22 and C23) 167 169.  
 
Consistent with the spectral data, the GC-MS analysis revealed that solid 4 was a mixture 
composed mainly of β-sitosterol (73%), stigmasterol (17%) and campesterol (9%). The 
GC-MS chromatogram of CIR4 is presented in Figure 15. The compound assignment was 
based on their mass spectra, compared with the NIST database166. Table 11 summarizes 
the retention times, abundance, molecular weight, and molecular formula of the identified 
compounds. 
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Figure 13. 1H NMR (400 MHz, CDCl3) spectra of CIR4. 
 
 
 
 
 
 Figure 14 .13C NMR (100 MHz, CDCl3) spectra of CIR4. 
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 Figure 15. GC-MS chromatogram of CIR4. 
 
The mass spectrum of β-sitosterol is presented in figure 16. The parent molecular ion 
peak at m/z 414 corresponds with the molecular formula C29H50O 168 and the 
fragmentation pattern that is characteristic for sitosterols 169.  
Table 11. GC-MS analysis of solid 4 
Peak RT (min) Abundance (%) Compound Molecular weight Molecular formula 
1 106.495 0.51 5α-Cholest-5-en-3-β-ol 386.3548 C27H46O 
2 109.497 0.22 (22E)-Ergosta-5,22-dién-3-ol 398.6642 C28H46O 
3 111.514 9.17 Campesterol 400.6801 C28H48O 
4 112.722 17.09 Stigmasta-5,22-dien-3-ol 412.6908 C29H48O 
5 114.982 73.01 β-Sitosterol 414.7067 C29H50O 
 
It shows a peak at m/z 396 resulted from the loss of water molecule from the molecular 
ion which will further dealkylate to yield peak at m/z 381. Fragments at m/z 273 for 
fragmentation of C17-C20 cleavage [M-side chain]+, the dehydration of m/z 273 fragment 
will yield m/z 255 and the peak 231 comes from [273-42 (ring D)]+, 161 [273-70 (ring C)]+, 
107 [161-54 (ring B)]+, 92 [107-15 (CH3)]+ 168.GC-EIMS m/z (rel. int.) = 414, C29H50O, 
M+(40), 396 (20), 381 (14), 329 (18), 303 (25), 255 (18), 213 (23), 145 (30), 107 (47), 95 
(48), 81 (50), 43 (100). 
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 Figure 16. Mass spectra of β-Sitosterol. 
 
 
5.1.2.5. Physic and spectral data of solid 5 (CIR5) 
White solid of mp 62-63 °C. CIR5 1H NMR had peaks characteristics of aliphatic esters 
isolated from plant apolar extracts 170. The spectrum shows the presence of two triplets 
integrating for two protons each, at δ 4.05 (t, J= 6.7 Hz, H25), and 2.29 (t, J = 7.5 Hz, H2), 
corresponding with methylene protons adjacent to the carbonyl group of the ester function, 
and a multiplet at δ 1.60 (H3, H26) integrating for 4 protons corresponding for a couple of 
methylenes beta position relative to the ester, a singlet at 1.25 (H4 to 23, and H27 to H45) 
integrating for 80 protons corresponding to a long methylene chain, and a triplet at δ 0.88 
(t, J = 6.7 Hz, 6H) for six methyl protons (H24, H47) (Figure 17). The 13C NMR shows the 
characteristic carbonyl ester at δ 174.04 (C1), and the carbon alpha in respect to the 
oxygen of the ester at δ 64.41 (C25), subsequently appear a signal of a carbon alpha to 
the carbonyl at δ 34.44 (C2), and a signal at 31.94 (C22, C45) corresponding to the 
gamma carbons respect to the terminal methyls, then, appears a signal of a carbon chain 
at 29.71 (C27 to C44, and C27 to C21. After the methylene chain appears at 25.95 (C26), 
25.05 (C3), 22.70 (C46, C23), and at 14.12 (C24, C47) (Figure 18). NMR spectral data 
suggest the presence of a long chain saturated ester 170, the trycosyl tetracosanoate, with 
a molecular formula of C47H94O2; MW = 690 g/mol.  
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 Figure 17. 1H NMR (400MHz, CDCl3) spectra of CIR5. 
 
 
 
 
 
  
Figure 18.13C NMR (100MHz, CDCl3) spectra of CIR5. 
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The GC-MS analysis of CIR5 revealed a mixture of fatty alcohols, alkanes, and other 
unidentified compounds. The chromatogram of solid 5 is reported in Figure 19.  
 Figure 19. GC-MS chromatogram of CIR5 
 
 
Based on their mass spectra, and comparison with the NIST database five compounds 
were identified as major constituents of CIR5, the 1,30-triacontanediol, 1-triacontanol, 
cyclooctacosane, dotriacontane, and nonacosane. Those constituents are usually 
identified by GCMS analysis of plant extracts 160 The retention time, abundance, molecular 
weight molecular formula is presented in Table 12.  
Table 12. GC-MS analysis of solid 5 
Peak RT (min) Abundance (%) Compound Molecular weight Molecular formula 
1 101.996 5.78 Nonacosane 408.7867 C29H60 
2 108.433 11.62 Dotriacontane 450.8664 C32H66 
3 111.980 16.47 Cyclooctacosane 392.7442 C28H56 
4 112.847 36.34 1,30-Triacontanediol 454.8120 C30H62O2 
5 117.885 29.80 1-Triacontanol 438.8127 C30H62O 
 
 
The mass spectrum of 1-triacontanol is typical of aliphatic alcohols with an absence of 
molecular ion peak, instead, the [M-18] ion (loss of water) is observed at m/z 392 166. 
GC-EIMS: m/z (rel. int.) = 438(0), C30H62O [M+], 420(25), 392(3), 125(25), 97(70), 83(70), 
57(100). (Figure 20). 
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 Figure 20. Mass spectra of 1-triacontanol. 
 
 
5.1.2.6. Isolation of compounds from hexane extract of Cissus plants. 
The most abundant compounds present in the solids according to NMR signals, 
correspond with the hentriacontane and octatetracontane, which are unsaturated linear 
hydrocarbons present in dominant proportions in plant waxes 162, 171. The octacosanoic 
acid is a long-chain saturated fatty that is also a common constituent of plant waxes 172. 
In the case of the long chain saturated ester suggested for the NMR spectral data as 
trycosyl tetracosanoate, there are no previous reports, however, similar aliphatic esters 
have been characterized in the lipid constituents of plants 170. Moreover, the chain length 
of wax esters in plants range from C32 to C64, which is also consistent with the chemical 
composition of plant cuticular waxes 173. The mixture of sterols such as the present in solid 
4 are also constituents in plant cuticular waxes 173. Furthermore, similar compounds have 
been isolated from the hexane extract of C. quadrangularis. For example, the 
heptacosane, the pentatriacontane, the isopentacosanoic acid, the β-sitosterol, and the 
eicosyl eicosanoate 149, 174. Overall, the GC-MS and NMR spectroscopy of solids from the 
hexane extract of C. trifoliata corresponded with the main constituents of plant cuticular 
waxes (mixtures of alkanes, alcohols, fatty acids, esters, triterpenes, and sterols) 175. 
Accordingly, compounds present in the solids are widely distributed in the plant kingdom 
173 and their further purification and biological evaluation were discarded. 
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5.1.3. GC-MS analysis of hexane extract 
The volatile contents of the hexane stem extract of C. trifoliata were analyzed by GC-MS. 
The chromatogram is shown in Figure 21. The name, retention time, abundance, 
molecular weight, and the molecular formula of the compounds are listed in table 13.  
Figure 21. GC-MS chromatogram of hexane stem extract of C. trifoliata. 
 
The hexane extract contained sixteen major compounds including alkanes (18.7%), fatty 
acids (31.3%), terpenes (37.5%), alcohols (6.25%) and esters (6.25%). Overall, the 
compounds identified in the hexane extract are common constituents of cuticles and 
membranes in most plants, composed of C16 and C18 esterified fatty acids and waxes 
(mixtures of homologous series of long-chain aliphatics, such as alkanes, alcohols, 
aldehydes, fatty acids, and esters, together with variable amounts of triterpenes), 
glycerolipids, sterols, and sphingolipids 175. Previous reports of the GC-MS analysis of the 
hexane extracts of C. quadrangularis stems identified as the main components the 
hexadecanoic acid ethyl ester, the octadecanoic acid ethyl ester and phytol 176. The alkane 
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hentriacontane has been previously reported in C. quadrangularis stems 177, while the 
nonacosane in C. cornifolia 178. In agreement, the nonacosane and hentriacontane, are 
predominant cuticular wax components in plants 179.  
 
Table 13. GC-MS analysis of hexane extract from the stems of C. trifoliata 
Peak RT (min) 
Abundance 
(%) 
Molecular 
weight 
Molecular 
formula Compound 
1 66.472 14.39 256.4241 C16H32O2 Hexadecanoic acid 
2 66.623 5.35 284.4772 C18H36O2 Hexadecanoic acid ethyl ester 
3 74.039 12.60 280.4455 C18H32O2 9Z,12Z-octadecadienoic acid 
4 74.328 4.63 282.4614 C18H34O2 9Z-Octadecenoic acid 
5 75.294 4.42 284.4772 C18H36O2 Octadecanoic acid 
6 83.176 2.01 312.5304 C20H40O2 Eicosanoic acid 
7 89.609 1.94 394.7601 C28H58 Octacosane 
8 95.271 3.15 410.7180 C30H50 Squalene 
9 102.377 10.45 408.7867 C29H60 Nonacosane 
10 108.871 12.82 436.8399 C31H64 Hentriacontane 
11 111.546 1.81 400.6801 C28H48O Campesterol 
12 112.571 1.91 412.6908 C29H48O Stigmasterol 
13 113.143 1.73 454.4749 C30H62O2 1,30-triacontanediol 
14 114.588 11.23 414.7067 C29H50O Beta sitosterol 
15 116.401 6.53 426.7174 C30H50O Lupeol 
16 118.246 5.03 412.6908 C29H48O Stigmast-4-en-3-one 
 
The hexadecanoic and the octadecanoic acid were also the major fatty acids in the hexane 
extract from the stems of C. quadrangularis 176. They are structural constituents in the 
cellular membranes of higher plants 180. In the case of the n-hexadecanoic acid ethyl ester, 
it was found as the major constituent of hexane extract from the roots of C. quadrangularis 
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176. This is one of the most common esters founded in plant waxes 181. The eicosanoic 
acid, is also a major constituent of the hexane extract from the roots in C. quadrangularis 
176, but in general is a minor constituent of plant cell membranes 181. The unsaturated fatty 
acids present in the hexane extract of C. trifoliata were the (Z,Z) 9,12-octadiecadienoic 
acid and the (Z)-9-octadecenoic acid. The former was reported for the first time in the 
methanolic extract from stems 182 and the other as a major constituent in the hexane 
extracts from the roots 176 of C. quadrangularis. Both fatty acids, the linoleic acid, and the 
oleic acid play roles in increasing the fluidity of plant membranes 183. This is the first report 
of the presence of the alcohol 1,30-triacontanediol in plants from the genus Cissus, 
however, is an alcohol common in the cuticular wax of plants 179 acting as a growth 
regulator 184. Among the terpenes identified, the squalene is the simplest and the most 
abundant in the hexane extract from the stems of Cissus plants 116. Lupeol was the only 
pentacyclic terpene and was reported as a major constituent in the hexane extract from 
the stems and roots in C. quadrangularis 116, 176. Its biosynthesis is induced by pathogens 
and exerts antimicrobial activities 185. The β-sitosterol, stigmasterol, and campesterol were 
previously isolated in the hexane extract from the stems of C. quadrangularis 116, 176. In 
the case of stigmast-4-en-3-one was previously isolated in the ethanolic extract from the 
stems C. quadrangularis 186. Although all sterols share a structural role in the fluidity of 
plant membranes 187, changes in plant sterol structure, such as the observed in stigmast-
4-en-3-one are associated with infestation with insects, and its biological activity showed 
to disrupt their metabolism and growth 188.  
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5.1.4. UPLC-QTOF-MS analysis 
5.1.4.1. UPLC-QTOF-MS characterization of the CHCl3-MeOH extract  
The total compound chromatogram (TCC) of the CHCl3-MeOH extract of C. trifoliata stems 
is presented in Figure 22. The compounds tentatively identified are summarized in Table 
14, with numbers showing the elution order, retention time, the experimental m/z and the 
molecular formula. All the compounds were characterized based on accurate m/z, the 
calculation of the molecular formula and data provided by the literature and databases. 
Eighteen compounds were identified and included simple phenolics (16.6%), fatty acids 
(22.2%), flavonoids (44.6%), and stilbenes (16.6%).  
 
Figure 22. Chromatogram of the UPLC-QTOF-MS analysis of the CHCl3-MeOH stem extract of C. trifoliata 
 
 
Most of the compounds identified by LC-MS were phenolic compounds. The gallic acid 
derivatives such as the protocatechuic acid, trigallic acid, and methyl digallate are 
secondary metabolites widely distributed in the plant kingdom. They play a role in the 
interaction with pathogens 189. Flavonoids are also widely distributed in plants and were 
the main chemical class identified. Apigenin, kaempferol and quercetin have been 
reported on alcoholic extracts from C. ibuensis 106, C. digitate 190 and C. quadrangularis 
191.  
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Table 14. UPLC-QTOF-MS analysis of the CHCl3-MeOH stem extract of C. trifoliata 
Peak RT  
(min) 
Experimental 
m/z [M-H]- 
Molecular 
Formula 
Tentatively identified 
compound 
1 0.612 593.1497 C27H30O15 Kaempferol-O-α-rhamnosyl-glucopyranoside 
2 2.419 625.1436 C27H30O17 Myricetin 3-O-rutinoside 
3 2.857 507.1147 C23H24O13 Syringetin 3-O-galactoside 
4 3.226 405.1198 C20H22O9 Piceatannol glucoside 
5 3.547 595.1341 C26H28O16 Quercetin 3-O-glucosyl-xyloside 
6 3.774 310.2052 - Unknown 
7 4.042 315.0717 C13H16O9 Protocatechuic acid hexoside 
8 4.807 433.1140 C21H22O10 Dihydrokaempferol 3-O-rhamnoside 
9 5.090 389.1249 C20H22O8 Resveratrol 3-O-glucoside 
10 5.813 473.0362 C21H14O13 Trigallic acid 
11 5.895 431.0939 - Unknown 
12 6.180 335.0403 C15H12O9 Methyl digallate 
13 6.423 433.0760 C20H18O11 Quercetin arabinoside 
14 6.531 336.1840 - Unknown 
15 6.592 615.1869 C34H32O11 Pallidol-3-O-glucoside 
16 6.763 447.0938 C21H20O11 Kaempferol 3-O-galactoside 
17 7.169 615.0988 C28H24O16 Myricitrin O-gallate 
18 7.191 297.3810 - Unknown 
19 7.417 253.2161 C16H30O2 Hexadecenoic acid 
20 7.534 279.2348 C18H32O2  Octadecadienoic acid 
21 7.595 255.2345 C16H32O2 Palmitic acid 
22 7.852 283.2649 C18H36O2 Stearic acid 
23 8.272 653.2235 - Unknown 
24 9.480 535.1650 - Unknown 
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Stilbenes were the second most common class of polyphenolic compounds identified in 
the stems of C. trifoliata. Previously, resveratrol, piceatannol, and pallidol were isolated 
and characterized in ethanolic extracts from the stems of C. quadrangularis 133. 
Additionally, stilbene glucosides have been found in C. repens 103 and C. sicyoides 150. 
 
 
5.1.4.2. UPLC-QTOF-MS characterization of the aqueous extract  
The chromatogram of the aqueous extract of C. trifoliata stems is presented in Figure 23. 
The compounds tentatively identified are summarized in Table 15, showing the elution 
order, retention time, the experimental m/z and the molecular formula. All the compounds 
were characterized based on accurate m/z, the calculation of the molecular formula and 
data provided by the literature and databases, these include flavonoids (83%) and 
stilbenes (17%). 
 
Figure 23. Chromatogram of the UPLC-QTOF-MS analysis of the aqueous stem extract of C. trifoliata 
 
The flavonoid glucosides of apigenin, kaempferol, and quercetin were identified in the 
aqueous extract. Additionally the glucosides of the stilbenes piceatanol and E-viniferine 
were identified. Those resveratrol derivatives were previously reported in C. 
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quadrangularis 133 and C. repens 103, whereas the anthocyanidins cyanidin and delphinidin 
were identified in the methanolic extract of C. sicyoides 192.  
 
Table 15. UPLC-QTOF-MS analysis of aqueous stem extract of C. trifoliata 
Peak RT  
(min) 
Experimental 
m/z [M-H]- 
Molecular 
Formula 
Tentatively identified 
compound 
1 0.612 592.9786 C27H30O15 Apigenin-6,8-di-C- glycoside 
2 2.781 563.0218 C26H28O14 Kaempferol rhamnosyl xyloside 
3 3.180 405.1198 C20H22O9 Piceatannol glucoside 
4 3.497 595.1341 C26H28O16 Quercetin 3-O-glucosyl-xyloside 
5 3.689 609.1451 C27H30O16 Kaempferol 3,7-O-diglucoside 
6 4.457 374.4914 - Unknown 
7 4.665 593.1497 C27H30O15 Kaempferol-O--rhamnosyl-glucopyranoside 
8 5.078 453.1356 C28H22O6 E-viniferin  
9 5.395 400.3705 - Unknown 
10 5.973 755.2030 C33H40O20 Kaempferol 3-O-glucosyl-rhamnosyl-galactoside 
11 6.179 594.1627 - Unknown 
12 6.423 433.0760 C20H18O11 Quercetin arabinoside 
13 6.779 448.1011 C21H21O11 Cyanidin 3-O-galactoside 
14 6.954 464.0960 C21H21O12 Delphinidin 3-O-glucoside 
15 7.384 447.0930 C21H20O11 Kaempferol hexoside 
16 7.465 576.4380 - Unknown 
17 7.645 302.0060 - Unknown 
18 7.851 426.7290 - Unknown 
 
Overrall, the phytochemical characterization of the organic and aqueous extracts from the 
stems of C. trifoliata highlighted its taxonomic relationship with Vitaceas. Based on plastid 
markers Cissus plants were founded genetically related to vitis plants 193, additionally, the 
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metabolomic studies of Vitaceas showed overrepresentation of flavonoid and stilbene 
metabolites 194. Moreover, stilbene derivatives accumulate and characterize the lignified 
stem tissues of Vitaceae 195, which is consistent given the macerated plant material in the 
present study.  
 
5.1.4.3. Metabolic profile of stems from the medicinal plant C. trifoliata  
The metabolic profiling of plants refers to the analysis of the plant extracts by hyphenated 
techniques such as the gas chromatography-mass spectrometry (GC-MS) and liquid 
chromatography-mass spectrometry (LC-MS) 196. The plant extracts are very complex 
matrices and the identification of metabolites requires the use of specific algorithms. Using 
the accurate mass and the spectral data the molecular formula is recovered. The 
combined information is then compared with available databases and metabolites are 
identified 64. Metabolic profiling has been useful to understand the chemical diversity of a 
medicinal plant 84, 196. The information is then used to compare it with taxonomically related 
studied plants and to infer their bioactivity 82, 83. Following this approach, forty-six 
metabolites were identified. The metabolic profile of extracts from the stems of C. trifoliata 
included alcohols, alkanes, esters, fatty acids, terpenes, and phenolic compounds. With 
the use of MetaboAnalyst tools, the obtained chemical content was processed to perform 
the PCA, and the metabolic pathway analysis. 
 
5.1.5. Principal Component Analysis  
The PCA showed that extracts are three different chemical entities. The polarity of the 
solvents employed for the extractions may underlie the observed differences 197 (Fig 24).  
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Figure 24. PCA of the metabolomic composition of extracts from the stems of C. trifoliata. 
 
 
5.1.6. Pathway Analysis  
The Pathway Analysis module in Metaboanalyst combines results from pathway 
enrichment analysis with topology analysis to identify the most relevant pathways involved 
in the production of the metabolites that were identified. Over-representation analysis 
tests if a group of compounds was present more than expected by chance, and the impact 
was calculated from pathway topology analysis. The results suggested (figure 25) that 
extracts from the stems of C. trifoliata were overrepresented by the pathways of the 
biosynthesis of flavone, flavonols (0.8) and stilbene (1.0). Stilbenes occur within a limited 
distribution in the plant kingdom. Consistent with the results of the pathway analysis, C. 
trifoliata belongs to the Vitaceae family of plants that produce stilbenes in great amounts 
198. Vitis vinifera is the most studied Vitaceae, and recent metabolic and molecular studies 
are consistent with its high production of flavonoid and stilbenes 199. Stilbene derivatives 
act as phytoalexins under the elicitation of biotic and/or abiotic agents through the 
activation of the stilbene synthase gene. The production of stilbenes by Vitis spp. as a 
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response to fungal infection was first reported in 1976. Resveratrol is the most abundant 
stilbene and accumulates at high levels at the sites of infection 194. 
 
 Figure 25. Pathway analysis of the constituents from the stems of C. trifoliata 
 
 
Quantification of stilbene derivatives in Vitis stems showed that the most abundant 
stilbenes are trans-ε-viniferin, resveratrol, cis-resveratrol, and piceid, and their 
accumulation is higher in the lignified organs such as stems 200. The finding of stilbenes 
as the metabolites with high impact in the extracts from the stems of C. trifoliata is also 
consistent with the isolation of stilbene derivatives from the stems of C. quadrangularis, 
C. repens and C. sycioides. As previously suggested, the metabolic profiling of a medicinal 
plant by GC-MS, and LC-MS, is useful to infer its bioactivity 83. Accordingly, bioactivity 
against cancer cells can be inferred from the metabolic profile of C. trifoliata that was high 
in sterols, stilbenes and flavonoids 201-203. The results of the biological evaluation of the 
extracts are presented in detail in the next section.  
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5.1.7. Biological evaluation of the extracts  
5.1.7.1. Antibacterial activity.  
Increasing antibiotic resistance encourages the search for novel compounds and 
affordable treatments to effectively treat bacterial infections. In this regard, medicinal 
plants from the genus Cissus had shown antibacterial activities 118, 119, 204. Furthermore, 
the ethnomedical uses of C. trifoliata include the treatment of infections, thus, the extracts 
from the stems were evaluated against a panel of bacteria that represent the most 
common type of drug-resistant strains in the clinical setting 23 (Table 16). 
No antibacterial activity was observed against strains from the ATCC or clinical isolates 
at the highest concentration employed (500 µg/ml). Previous studies of the antibacterial 
activity of extracts from the stems of C. quadrangularis report MIC values between 0.93 
mg/ml to 6.25 mg/ml against P. aeruginosa, S. aureus and E. coli 118. However, according 
to the National Committee for Clinical Laboratory Standards, the concentration of the 
extracts evaluated should not exceed the range of 1 mg/ml. 
Furthermore, a MIC ≥ 30 µg/ml is considered negative for antibacterial activity 38, thus, 
the extracts from the stems of C. trifoliata were considered inactive for the inhibition of 
bacterial growth. We cannot discard that C. trifoliata possess activity against other 
microorganisms. Perhaps, infections managed successfully with C. trifoliata include 
dermatophytes, originated from bacteria and fungi. We speculate this based on the fact 
that the bacteria evaluated in the present study include pathogens of the respiratory and 
gastrointestinal tracts. Additionally, mycosis is common in places were C. trifoliata is still 
traditionally used 91, 205 and the metabolic profile predicts good antifungal properties 206. 
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Table 16. MIC of the extracts (µg/ml) of C. trifoliata stems and levofloxacin against bacteria 
 
Thus, C. trifoliata could exhibit good responses against infection originated from 
dermatophytes. It is worthy to mention that the production of stilbenes in Vitaceae 
increases when plants suffer from fungal infections and they exhibited good activity 
against dermatophytes 198. Thus, extracts from C. trifoliata could possess strong 
antifungal activities and should be considered for evaluation in further studies. 
 
Bacteria Hexane CHCl3-MeOH Aqueous Levofloxacin 
S. aureus (ATCC, 29213) ≥ 500 ≥ 500 ≥ 500 3.12 
S. epidermidis (ATCC,14990) ≥ 500 ≥ 500 ≥ 500 3.12 
E. faecium (ATCC, 2127) ≥ 500 ≥ 500 ≥ 500 3.12 
E. coli (ATCC, 25922) ≥ 500 ≥ 500 ≥ 500 3.12 
P. aeruginosa (ATCC, 27853) ≥ 500 ≥ 500 ≥ 500 3.12 
K. pneumoniae (ATCC, 19606) ≥ 500 ≥ 500 ≥ 500 3.12 
A. baumanni (ATCC, 13883) ≥ 500 ≥ 500 ≥ 500 3.12 
Methicillin-resistant S.aureus (14-2095) ≥ 500 ≥ 500 ≥ 500 12.5 
Linezolid-resistant S. epidermidis (14-583) ≥ 500 ≥ 500 ≥ 500 6.25 
Vancomycin-resistant E. faecium (10-984) ≥ 500 ≥ 500 ≥ 500 12.5 
Beta lactamic-resistant E.coli (14-2081) ≥ 500 ≥ 500 ≥ 500 25.0 
Carbapenem-resistant P. aeruginosa (13-1391) ≥ 500 ≥ 500 ≥ 500 12.5 
Oxacillin-resistant K. pneumoniae (17-1692) ≥ 500 ≥ 500 ≥ 500 6.25 
Beta lactamic-resistant K. pneumoniae (14-3335) ≥ 500 ≥ 500 ≥ 500 50.0 
Carbapenem-resistant A. baumannii (12-666) ≥ 500 ≥ 500 ≥ 500 12.5 
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5.1.7.2 Cytotoxic activity 
Results from the MTS assay showed that the hexane extract was the most active against 
the tested cancer cell lines. According to the NCI guidelines, an active crude extract must 
inhibit the 50% of cell proliferation (IC50) at a concentration of 30 µg/ml after the exposure 
time of 72 h to be considered cytotoxic 36. Therefore, the hexane extract from the stems 
of C. trifoliata was active against HepG2, Hep3b, and MCF7 cells and the aqueous extract 
against MCF7 cells (Table 17). Previously, the extracts from the stems of other plants 
from the genus Cissus have been evaluated against cancer cells. In the next section, this 
information is compared with the results from C. trifoliata.  
Table 17. MTS assay IC50 (µg/ml) of the extracts from the stems of C. trifoliata 
Cancer cell lines Hexane CHCl3-MeOH Aqueous Taxol 
HepG2 26±2* 80±8 79±5 64.0 x 10-3 
Hep3b 24±2* 81±4 81±7 33.0 x 10-3 
HeLa 35±3 82±4 90±8 5.12 x 10-3 
A549 51±4 85±3 94±9 5.12 x 10-3 
PC3 62±3 61±3 58±4 4.27 x 10-3 
MCF7 30±3* 78±5 30±2* 79.4 x 10-3 
*active according to NCI guidelines (IC50 ≤ 30 µg/ml) 
 
For example, the hexane extract from C. quadrangularis was inactive (IC50 of 200 µg/ml) 
against KB (keratin-forming tumor cell line HeLa) and A431 (epidermoid carcinoma) by 
MTT assay 124. Regarding polar extracts, the acetonic extract from C. quadrangularis 
showed an IC50 of 43 µg/ml against HepG2 207, whereas the ethanolic and ethyl acetate 
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extracts from C. sicyoides showed an IC50 of 50 µg/ml and 43 µg/ml against NCI-H292 
and HepG2 respectively 127. The methanolic extract of C. debilis displays an IC50 of 50 
µg/ml against CaCo-2 cells 125. Thus, previous results suggested that hexane and the 
aqueous extracts from C. trifoliata were more active than other Cissus plants. However, 
we cannot conclude that considering the variability in the results from the evaluation of 
cytotoxicity in vitro, such as the cellular phenotypes, the cell passages and the techniques 
used for the IC50 determination 208. In conclusion, the cytotoxic activity of the extracts 
provides evidence of the anti-tumor effects of C. trifoliata and encourages the realization 
of a bioassay-guided study to identify the bioactive compounds according to the 
recommendations of the NCI for plants that show promising anticancer effects 36. Despite 
the hexane and the aqueous extract showed more activity against cancer cells, the CHCl3-
MeOH was used in the bioassay guided study. One of the reasons obeyed to the small 
quantity that remains after the hexane extract column-fractionation for the isolation of the 
solids. Additionally, the high activity of the hexane extract might be related to the presence 
of plant sterols and triterpenes and their cytotoxicity and the mechanism of action in the 
cancer cell lines assayed is well described (discussed in the next section). In the case of 
the aqueous extract, their fractions were inactive against cancer cells (data not showed). 
The aqueous extract showed signs of decomposition and is reported its susceptibility of 
contamination and degradation 197. Thus, further studies were performed with the CHCl3-
MeOH extract. The next section provides a revision of the current literature of the 
antiproliferative effects of the bioactive molecules identified by the chemical analysis of 
the active extracts since they might contribute with their anti-tumor mechanisms against 
the liver and breast cancer cells. 
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5.1.8. Cytotoxic compounds identified in the stems of C. trifoliata.  
The overrepresentation of biosynthetic pathways of sterols, stilbenes, and flavonoids in 
the metabolomic profile of the stems of C. trifoliata might play a major role in their effects 
against HepG2, Hep3b, and MCF7 cells. The plant sterols campesterol, stigmasterol, and 
β-sitosterol have been previously evaluated against those cancer cell lines. For example, 
β-sitosterol showed cytotoxic activity against MCF7 (IC50 250 µg/ml) 209 and Hep3B (IC50 
25 µg/ml). β-Sitosterol increases caspase-8 activity 210 and affect sphingolipid 
metabolism, causing apoptosis and cell growth inhibition in a dose-dependent manner 157. 
Stigmasterol also showed cytotoxic activities against MCF7 (IC50 9.2 µg/ml) 209 and Hep3B 
cells (IC50 30 μM) 211. Both sterols modulate the estrogen receptor (ER), thus inhibiting 
the proliferation of MCF7 (ER-positive) 212. Pentacyclic triterpenes also exhibit potent 
anticancer activities; for example, lupeol showed cytotoxicity activity against MCF7 (IC50 
32 µg/ml), and HepG2 (IC50 48 µg/ml) 213. Lupeol induces apoptosis through mitochondrial 
cell death pathway and cell cycle arrest by inhibition of cyclin-dependent kinases (CDKs), 
and bcl-2 214, and suppression of STAT3 in parallel with the inhibition of the proteins cyclin 
D1, Bcl-2, the B-cell lymphoma extra-large protein (BclxL), the antiapoptotic protein 
survivin, the VEGF and the metalloprotease 9 215. The bioactivity of the aqueous extract 
might be related to its polyphenol content. Piceatannol, quercetin, and kaempferol may 
account for most of the effects in MCF7 cells. Piceatannol induces antiproliferative effects 
at IC50 of 30 μg/ml 216 and competes with the estradiol for binding the ER 217. Kaempferol 
is a flavonol, and its biological activities against cancer cells include disruption of the cell 
cycle process, angiogenesis and inflammation. Kaempferol decreased the cell viability in 
MCF7 cells cultured with 50-100 μM. The mechanism of action is also the modulation of 
the ER signaling acting as an anti-estrogen. The effect on cell cycle progression was 
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accompanied by a reduction of the protein expression of cyclin D1 and E, and increased 
p21 expression 218. Quercetin is a flavonol whose intake is associated with a reduced risk 
of mortality from chronic diseases including cancer. In MCF7 cells treated with 50 μM/ml 
reduces 50% in viability and proliferation was accompanied by changes in the expression 
of the proapoptotic protein caspase-3 219. Quercetin showed estrogen receptor 
antagonism 220, thus, the combination of polyphenols with antiestrogenic activities might 
account for the higher susceptibility of the breast cancer cells MCF7.  
Current knowledge of the anticancer bioactivities of the phytocompounds identified in the 
cytotoxic extracts partially explained the ethnomedical uses of C. trifoliata as an antitumor 
agent. However, a bioassay-guided study would indicate more precisely the bioactive 
secondary metabolites that accounts for most of the antiproliferative effects against 
cancer cells. In the next section, these results are presented in detail.  
 
5.2. Bioassay-guided study C. trifoliata stems 
The screening of the cytotoxic activity and the chemical content of the complete extracts 
demonstrated potential anticancer effects of the extracts from C. trifoliata. Following a 
bioassay-guided study, the CHCl3-MeOH extract was subjected to fractionation by column 
chromatography and biological evaluation by WST-1 to test the activity of the fractions 
against cancer cells. The CHCl3-MeOH extract was the most abundant (23g), and 
according to the mixture of solvents employed during the extraction it may possess a wider 
range of secondary metabolites 197. The fractions of the extract were tested against the 
cell lines MCF7 and PC3 that showed higher sensitivity (the lowest IC50 when exposed to 
the complete extract). The column fractionation of the CHCl3-MeOH extract yields 210 
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fractions pooled in 14 according to their TLC behavior (A to N). Fractions A to E were not 
included in the WST-1 assay, they were reminiscent of the fractions obtained in the 
hexane extract and were composed mainly of waxes (mixtures of alkanes, fatty acids, and 
fatty alcohols).  
 
Table 18. Results of cell viability expressed as a percentage of control mean viable cells (± standard 
deviation). Cancer cell lines were treated with three different concentrations of the fractions of the CHCl3-
MeOH extract from the stems of C. trifoliata and with taxol. 
PC3 cells 
Treatment 100 µg/ml 50 µg/ml 25 µg/ml 
F1 20.52 ± 0.57* 49.21 ± 9.64 156.79 ± 9.71 
F2 17.79 ± 1.55* 133.19 ± 10.04 158.36 ± 3.87 
F3 68.85 ± 5.73 150.72 ± 3.17 147.49 ± 5.49 
F4 96.26 ± 7.86 136.39 ± 8.81 108.22 ± 12.02 
F5 139.40 ± 4.12 145.19 ± 6.85 141.93 ± 3.21 
F6 139.31 ± 5.10 145.65 ± 4.20 143.24 ± 3.18 
F7 122.95 ± 7.31 128.42 ± 6.09 143.24 ± 3.18 
F8 83.42 ± 11.46 88.45 ± 6.29 108.91 ± 8.25 
F9 99.95 ± 0.58 118.89 ± 5.18 114.64 ± 5.59 
Taxol 40.15 ± 7.58 62.95 ± 10.43 70.32 ± 1.19 
MCF cells 
F1 6.50 ± 2.70* 27.67 ± 9.49 74.45 ± 9.49 
F2 10.29 ± 0.13* 89.07 ± 9.44 104.71 ± 2.12 
F3 89.11 ± 6.17 95.88 ± 3.05 96.57 ± 6.19 
F4 100.79 ± 1.16 105.20 ± 7.55 100.24 ± 4.78 
F5 101.74 ± 7.64 105.82 ± 4.96 105.73 ± 2.39 
F6 96.80 ± 3.44 104.41 ± 4.78 102.72 ± 2.84 
F7 97.74 ± 4.15 102.61 ± 1.77 102.06 ± 1.46 
F8 114.87 ± 2.47 103.98 ± 4.48 106.32 ± 8.52 
F9 93.99 ± 1.51 100.76 ± 5.62 102.17 ± 3.41 
Taxol 62.25 ± 3.06 67.68 ± 4.50 68.58 ± 0.78 
* Asterisks indicate significant differences in the analysis (ANOVA-LSD 
test, values of p < 0.05 
 
The anti-proliferative activity of the fractions F1 to F9 was studied by WST1 (for details of 
fraction polarity see table 4). Cancer cells were treated with doses of 100, 50 and 25 µg/ml 
for 48 hours. The resulting data were expressed as the percentage value of the cell growth 
respect to the control. Then, results were subjected to ANOVA-LSD test. Fractions F1 and 
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F2 showed a significative reduction (p > 0.05) in the cell viability of both cancer cell lines 
at the concentration of 100 µg/ml (Table 18). Therefore, the chemical composition of both 
fractions was analyzed by LC-MS to identify the compounds accountable for the 
antiproliferative activity of C. trifoliata against cancer cells.  
 
5.2.1. Chemical analysis of the active fractions by UPLC-QTOF-MS 
The fraction F1 of the CHCl3-MeOH extract was characterized by UPLC-QTOF-MS 
analysis using the negative mode. The figure 26 shows the chromatogram of the fraction 
F1.  
 Figure 26. Chromatogram of F1 from the CHCl3-MeOH stem extract of C. trifoliata by UPLC-QTOF-MS  
The tentatively identified compounds include simple phenolics, fatty acids, terpenes, 
flavonoids and stilbenes. The table 19 summarized them along with the retention time, the 
experimental m/z and the molecular formula. The phenolic compounds tentatively 
identified include the trans-p-coumaric acid and isoferulic acid. The polyphenolic 
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compounds include the flavonoids dihydrokaempferol, apigenin, kaempferol, chrysoeriol 
and naringenin, and the stilbene resveratrol. Regarding the terpenes, the hydroxyursolic 
acid, ursolic acid and betulic acid were identified along with the palmitic and stearic fatty 
acids. Fraction 2 showed similar TLC behavior and polarity, thus UPLC-QTOF-MS 
analysis were performed under the same conditions. 
 
Table 19. UPLC-QTOF-MS analysis of F1 from the CHCl3-MeOH extract from the stems of C. trifoliata 
Peak RT (min) 
Experimental m/z 
[M-H]- Molecular formula Tentatively identified compound 
1 6.785 163.0401 C9H8O3 Trans-p-coumaric acid 
2 7.908 193.0504 C10H10O4 Isoferulic acid 
3 8.541 287.0569 C15H12O6 Dihydrokaempferol 
4 8.567 227.0716 C14H12O3 Resveratrol 
5 9.103 269.0434 C15H10O5 Apigenin 
6 9.243 285.0404 C15H10O6 Kaempferol 
7 9.345 299.0561 C16H12O6 Chrysoeriol 
8 9.479 271.0612 C15H12O5 Naringenin 
9 11.699 471.3475 C30H48O4 2-alpha hydroxyursolic acid 
10 13.994 455.3515 C30H48O3 Ursolic acid 
11 14.071 455.3422 C30H48O3 Betulinic acid 
12 14.401 253.2161 C16H28O2 Hexadecadienoic acid 
13 14.582 279.2348 C16H32O2 Octadecadienoic acid 
 
The results of the analysis showed similar bioactive content and chromatogram of the 
fraction F2 (Figure 27). The phytocompounds tentatively identified include simple 
phenolics, flavonoids, stilbenes and terpenes. The phenolic compounds include the 
protocatechuic acid, the methylgallate, the isoferulic acid and the trans-p-coumaric acid. 
The flavonoids include the dihydrokaempferol, apigenin, kaempferol, and quercetin, 
whereas the only stilbene identified was the piceatannol glucoside. 
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 Figure 27. Chromatogram of F2 from the CHCl3-MeOH stem extract of C. trifoliata by UPLC-QTOF-MS  
Regarding the terpenes, the hydroxyursolic acid, ursolic acid and betulic acid were also 
present in F2. The table 20 summarizes them along with the retention time, the 
experimental m/z and the molecular formula.  
 
Table 20. UPLC-QTOF-MS analysis of F2 from the CHCl3-MeOH extract from the stems of C. trifoliata 
Peak RT  (min) 
Experimental m/z 
 [M-H]- Molecular formula Tentatively identified compound 
1 6.234 153.0192 C7H6O4 Protocatechuic acid 
2 6.836 183.0291 C8H7O5 Methylgallate 
3 6.785 163.0401 C9H8O3 Trans-p-coumaric acid 
4 7.751 431.1013 C21H20O10 Apigenin glucoside 
5 7.908 193.0504 C10H10O4 Isoferulic acid 
6 8.487 405.1198 C20H22O9 Piceatannol glucoside 
7 8.741 287.0569 C15H12O6 Dihydrokaempferol 
8 8.859 301.0367 C15H10O7 Quercetin 
9 9.103 269.0434 C15H10O5 Apigenin 
10 9.243 285.0404 C15H10O6 Kaempferol 
11 11.699 471.3475 C30H48O4 2-alpha hydroxyursolic acid 
12 13.994 455.3515 C30H48O3 Ursolic acid 
13 14.071 455.3422 C30H48O3 Betulinic acid 
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According with the chemical analysis by LC-MS both active fractions share similar 
composition. The most significative difference was the lack of fatty acid content in fraction 
F2 compared with F1, that may be explained based on their differences in polarity. 
However, bioactive fractions share the content of flavonoids, stilbenes, simple phenolics 
and terpenes. Thus, the antiproliferative activity against cancer cells can be inferred based 
on the bioactive content. A bioassay guided isolation from the stems of V. vinifera founded 
related results. They identified oleanolic acid, resveratrol, ε-viniferin, and daucosterol as 
the compounds responsible for the antiproliferative properties of the most active fractions 
221. 
 
The pentacyclic triterpenes tend to be more active than polyphenols at low concentration 
222. They are highly active against almost all cancer cell lines tested with an IC50 value 
lower than 15 μg/ml 209, 223, 224. Additionally, the betulic, ursolic, oleanolic and 
hydroxyursolic acids are commonly found as the most active compounds in studies of the 
bioassay-guided isolation of antiproliferative constituents from plant extracts 225, 226. 
Betulinic acid exhibits cytotoxic activity against all cancer cell lines tested including PC3 
and MCF-7 at IC50 value of 10 μg/ml. Furthermore, in vivo it decreases angiogenesis, 
proliferation and invasion 227. Ursolic acid decreased the proliferation of cancer cells 
including the MCF7 by 80% at doses of 10 μM 224. It exerts its action through the 
mitochondrial pathway 228, inhibits phosphorylation of JAK2 (Janus kinase 2) and STAT3 
downregulated Bcl-xl. The oleanolic acid showed significant inhibition on MCF7 with IC50 
of 15 μmol/l by reducing the expression of Bcl-2, Bcl-xL, and survivin. The oleanolic acid 
inhibits survival and proliferation of all the models of prostate cancer cells including the 
PC3 (15 μmol/l) by inhibition of the cancer pathway PI3k/Akt1 229. The 2α-hydroxyursolic 
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acid also shows growth inhibitory activity against tumor cell lines 223. In breast cancer cells, 
the 2α-hydroxyursolic acid inhibits the cell proliferation by the modulation of the p38/MAPK 
pathway 230. The phenolic acids, coumaric and isoferulic have been tested against PC3 
and MC7 cells and showed potential as chemopreventive agents. Coumaric acids showed 
apoptotic effects against MCF7 cells (IC50 40 mM) 231 and PC-3 cells (IC50 30 mM). Their 
mechanism of action includes downregulation of CDKs and increased expression of p53 
and ATM 232. Flavonoids and stilbenes were also founded in the bioactive fractions F1 and 
F2 of C. trifoliata stems. Their antitumor and cytotoxic activities have been previously 
reviewed (section 5.1.7).  
 
The bioactive fractions result in a mixture of anticancer compounds that may act in 
synergy to inhibit cancer cell proliferation. The extracts and the most active fractions were 
rich in triterpenes, sterols, phenolic compounds with known cytotoxic, antiproliferative and 
anti-estrogen activities. Altogether the metabolic profile and the observed antiproliferative 
activity could partially explain the traditional use of C. trifoliata as antitumor agent. 
Medicinal plants are often administered as a complete extract, composed of a complex 
mixture of phytocompounds. However, in natural product chemistry is tradition to reduce 
the complexity of plant extracts by isolating the most active compound. Then, the active 
constituents are subjected to evaluation of the molecular mechanisms and some of them 
will be used for drug development 233. Since most of the identified triterpenes and 
flavonoids in the cytotoxic fractions are widely distributed in plants 234, we opt to evaluate 
the bioactivity and mechanism of action of stilbenes. Resveratrol derivatives exhibit a 
narrow distribution and Vitaceae plants have been characterized by their content 198. 
Additionally, stilbenes have been isolated from the stems of other Cissus plants 133 and 
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the biosynthetic pathway of stilbenes characterized the metabolite profile of C. trifoliata 
stems. Given the results, we considered that some of the antitumoral properties of C. 
trifoliata may relate to its high content of stilbenes. Therefore, the stilbene profile of the 
most active fraction (F1) of C. trifoliata was analyzed by a targeted metabolomic approach. 
This method has been previously useful in the study of grape metabolomics with UPLC-
QTOF-MS technology and is called suspect screening analysis 235. This protocol uses the 
molecular formula and the isotopic pattern of stilbenes to extract them from the total ion 
chromatogram. The result is showed in figure 28. The extracted ion chromatogram (EIC) 
of the fraction F1 contained the stilbenes resveratrol, resveratrol glucoside, piceatannol, 
resveratrol methyl ether, piceatannol glucoside, ε-viniferin, δ-viniferin, pallidol, and 
caraphenol B. 
 
 
Figure 28. Extract-ion chromatogram of stilbene derivatives in fraction F1 
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5.3. Determination of the IC50 of stilbenes  
The antitumor activity of the most abundant stilbene in the active fraction F1, was 
examined in the cancer cells MCF and PC3. Resveratrol and its glucoside (piceid) were 
purchased as pure compounds from Sigma Aldrich. Cells were treated with 100, 50, 25, 
12.5 and 6.5 μg/ml for 24 hours and their effects on cell growth were evaluated by WST-
1 (Table 21). In the MCF7 cells, resveratrol caused marked growth inhibition, with an IC50 
value of 211 μM. Cells showed more resistance to piceid, thus the mechanism of action 
was assessed for resveratrol. The criteria for selecting the PC3 cells over the model of 
breast cancer was the well-characterized effects of resveratrol in MCF7 by several studies 
that include microarrays 236. In contrast, at present no reports of the effects of resveratrol 
by microarrays have been published in PC3 cells.  
Table 21. IC50 (μM) of stilbenes against the cancer cell lines. 
 
Regarding the elevated IC50 for stilbenes of our results in comparison with literature, we 
attributed most of the resistance to the process of subculture. One of the most common 
phenomena observed as the responsible of the increased tolerance of cell lines is the loss 
of markers of differentiation that occur along with the increased number of passages. Cell 
lines can experience alterations in morphology, response to stimuli, growth rate and 
sensibility to compounds. To avoid passage-dependent effects and increase the 
reproducibility of the results is recommended to start with well know characterized cell 
lines and test them genetically and morphologically as the passages increases 240. The 
Cancer Resveratrol Piceid 
cell line Calculated Reference Calculated Reference 
PC3 232 15 237 387 72 *238 
MCF7 211 80 236 593 103 239 
* The IC50 included as reference was performed in CaCo cells, no reports in PC3. 
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reproducibility of the IC50 of stilbenes does not represent an issue in the present study. 
Rather, one of the objectives was the identification of a novel mechanism of action of one 
of the compounds present in the active extracts from the stems of C. trifoliata. In this 
regard, the exposition to sublethal doses of phytocompounds (IC30 or IC25) has been 
successfully employed for the identification of new anticancer mechanism of action of well-
known anticancer compounds 156. Thus, gene expression changes of PC3 cells exposed 
to resveratrol (IC25) were determined by microarrays to explore a potential novel 
mechanism of action of resveratrol against prostate cancer cells.  
 
5.4. Mechanism of action of resveratrol in PC3 cells. 
5.4.1 Resveratrol influences gene expression in human prostate cancer cells  
The gene expression profile of a cell determines its phenotype, function, and response to 
the environment. The technique of DNA microarrays has a high performance and 
efficiency to measure the simultaneous expression of all the genes of the genome of an 
organism 241. Microarrays can be used to study the mechanism of drug action by 
examining the effect of gene expressions 242. Thus, microarrays have been previously 
used for the identification of the mechanisms of action of phytocompounds 243, 244. To 
identify the genes modulated by resveratrol, cDNA microarray hybridization analysis using 
the entire human genome was carried out. PC3 cells, a human prostate cancer cell line, 
were treated with resveratrol for 24 h at IC25 and the RNA was isolated. Figure 29 
illustrates the transcriptional changes according to the fold change of gene expression. 
The genes considered for the functional analysis were those with a z-score of ± 2 SD. The 
PC3 cells exposed to resveratrol undergone significative transcriptional changes (2-fold) 
in 847 genes (Fig 29, B).  
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A)        B) 
          
Figure 29. Z- score of microarrays. A) Z-score of all genes; B) Z-score ± 2 SD. In total 848 genes were affected. 
 
Resveratrol upregulated 526 genes and downmodulated 322. The full gene identifiers of 
the upregulated and downregulated genes are listed in tables 24 and 25 of the 
supplementary material. The table 22 showed the results of the genes upregulated. 
 
Table 22. Functional Annotation Chart of upregulated genes. 
Category Term Count % p-value Bonferroni 
UP_KEYWORDS Transcription regulation 53 20.8 3.10E-05 8.70E-03 
UP_KEYWORDS Nucleus 93 36.5 7.50E-05 2.10E-02 
GOTERM_BP_DIRECT Transcription RNA polymerase II 22 8.6 7.20E-06 9.90E-03 
UP_KEYWORDS DNA-binding 43 16.9 6.60E-04 1.70E-01 
UP_KEYWORDS Phosphoprotein 127 49.8 1.00E-03 2.50E-01 
UP_KEYWORDS Alternative splicing 154 60.4 2.30E-03 4.80E-01 
UP_KEYWORDS Hydrolase 30 11.8 3.80E-02 1.00E+00 
UP_KEYWORDS Ubl conjugation 30 11.8 4.70E-02 1.00E+00 
UP_KEYWORDS ATP-binding 25 9.8 5.90E-02 1.00E+00 
UP_KEYWORDS Differentiation 14 5.5 6.90E-02 1.00E+00 
INTERPRO Homeodomain-like 12 4.7 4.50E-03 9.20E-01 
GOTERM_MF_DIRECT Ubiquitin protein ligase binding 10 3.9 1.80E-02 1.00E+00 
GOTERM_CC_DIRECT Mitochondrial inner membrane 12 4.7 3.50E-02 1.00E+00 
GOTERM_BP_DIRECT Cell differentiation 11 4.3 1.00E-01 1.00E+00 
Functional annotation data derived from DAVID algorithm. Table derived from the functional annotation 
chart that shows all cellular functions associated with the number of genes affected by the treatment by 
resveratrol. The upregulated genes are showed. p value of 0.05 was considered significative. 
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The gene list was analyzed with the functional classification tool available in the 
bioinformatic software DAVID. The most significant changes were observed in the process 
associated with transcription, nuclear proteins, DNA-binding process, splicing, hydrolase 
and ubiquitin activities, ATP binding, cell differentiation, homeobox proteins, and 
mitochondrial membrane. The downregulated genes belong with process related to 
components and signaling of the cell membrane, cytoplasm and transport proteins, 
endoplasmic reticulum components and process, and the g-protein coupled receptor 
signaling pathways (Table 23). Overall, the microarrays indicate that resveratrol induces 
transcriptional responses in PC3 cells that impact their differentiation, stemness, 
metabolism, apoptosis, and metastatic potential. 
 
Table 23. Functional Annotation Chart of downregulated genes. 
Category Term Count % p-value Bonferroni 
UP_KEYWORDS Membrane 71 49.1 1.70E-03 3.10E-01 
UP_KEYWORDS Phosphoprotein 69 47.6 4.80E-02 1.00E+00 
GOTERM_CCDIRECT Integral component of membrane 51 35.2 2.00E-02 9.70E-01 
GOTERM_CCDIRECT Plasma membrane 44 30.3 9.60E-03 8.10E-01 
UP_SEQ_FEATURE Cytoplasmic 39 26.9 3.70E-03 8.60E-01 
UP_KEYWORDS Cell membrane 32 22.1 3.10E-02 1.00E+00 
UP_KEYWORDS Transport 27 18.6 1.20E-03 2.30E-01 
UP_KEYWORDS Receptor 22 15.2 5.30E-03 6.80E-01 
UP_KEYWORDS Transducer 15 10.3 4.30E-03 6.00E-01 
GOTERM_CCDIRECT Endoplasmic reticulum membrane 15 10.3 5.10E-03 5.80E-01 
GOTERM_BPDIRECT G-protein coupled receptor pathway 15 10.3 6.50E-03 9.90E-01 
UP_KEYWORDS Endoplasmic reticulum 14 9.7 3.70E-02 1.00E+00 
UP_KEYWORDS Ubl conjugation pathway 11 7.6 2.10E-02 9.90E-01 
Functional annotation data derived from DAVID algorithm. Table derived from the functional annotation chart that shows all cellular 
functions associated with the number of genes affected by the treatment by resveratrol. The downregulated genes are showed. p 
value of 0.05 was considered significative. 
 
In the next section the functional significance of the most important genes that were 
modulated is discussed, and how they interact and impact the cellular process and 
pathways that the functional analysis indicated.  
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5.4.2. Resveratrol influences cell differentiation  
Resveratrol upregulated the expression of 44 genes that codify transcription factors and 
6 epigenetic modifiers. Is have been shown that transcription factors are key players in 
orchestrating cell decisions, such as cell cycle, cell differentiation, cellular inflammation, 
apoptosis or autophagy 245. We found that resveratrol induced the expression of the 
homeobox genes, including the H6 family homeobox 2 (HMX2), homeobox A3 (Hox-A3), 
homeobox D12 (Hox D12), msh homeobox 2 (MSX-2), PBX/knotted homeobox 1 
(PKNOX1), and lim homeobox 8 (LHX8). Many of these proteins have reported 
deregulated in cancer, but their role in carcinogenesis remains unknown. In general, 
homeobox genes that are upregulated in cancer are normally expressed during 
development or in undifferentiated cells 246. In our experiment, it seems that the 
upregulation of Homeobox proteins is associated with antitumor effects of resveratrol by 
induction of cell differentiation and reduction of cell proliferation. In line with this 
hypothesis, we found high expression of other transcription factors involved with cellular 
differentiation and developmental pathways. For example, we also found upregulated the 
POU class 4 homeobox 2 (POU4F2) which is a transcription factor involved in the 
developmental process that activates the differentiation of cells. This protein is also 
involved in carcinogenesis, but their role is not well understood 247. The T-box 1 protein 
(TBX1) is also a transcription factor involved in development that acts as a negative 
regulator of tumor cell growth 248.  
The protein Cbp/p300-interacting trans activator 4 (CITED4) function as an inhibitor of 
hypoxia-induced factor 1 (HIF1A) and prevents their interaction with CREB binding protein 
(CREBBP). The functional consequences of this overexpression also seem to be related 
to the differentiation of cells and the prevention of tumor growth and angiogenesis 249. 
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Also, resveratrol induced the expression of the genes Kruppel-like Factor 14 (KLF14) and 
Ikaros is a DNA-binding zinc finger protein (IKZF1) also involved in differentiation. The 
KLF14 gene induces epigenetic reprogramming during cell differentiation. Thus, the 
overexpression of KLF14 also suggests cell differentiation via chromatin remodeling 250. 
Furthermore, IKZF1 regulates gene expression and chromatin remodeling with important 
tumor suppressor properties 251. The chromatin remodeling is possible by the activation 
of chromatin remodeling proteins. The antitumor effects of resveratrol have been 
associated with its influence in epigenetics 252. We found upregulation of jumonji domain 
containing 2B (JMJD2B), the methyltransferase mixed-lineage leukemia protein 3 (MLL3), 
and the histone lysine N-methyltranferase (SETD3). These enzymes regulate 
transcription by altering the epigenetic marks on histones but the pathologic roles in 
cancer remain to be elucidated 253. Likewise, the mitochondrial NAD-dependent protein 
deacylase sirtuin-5 (SIRT5) and the bifunctional heparan sulfate N-deacetylase/N-
sulfotransferase (NDST2), were upregulated by resveratrol. It is well documented that 
SIRT5 is upregulated by resveratrol and that their activation protects cells from oncogenic 
transformation 254. On the other hand, resveratrol downregulates a histone-lysine N-
methyltransferase (SETD1B) that showed to promote cell proliferation, migration, and 
invasion of cancer cell lines. Furthermore, the overexpression in carcinomas is associated 
with an unfavorable prognosis. Thus, downmodulation of the activities of SETD1B in the 
generation of trimethylated histone H3 at Lys4 is consistent with the anti-cancer activities 
of resveratrol 255. Resveratrol also induces high expression of the eukaryotic translation 
initiation factor 4H (eIF4H), an activator of the RNA helicase eIF4A, which is 
overexpressed in carcinomas although the exact role of eIF4H in tumorigenesis and the 
molecular mechanisms involved are unknown 256.  
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5.4.3. Resveratrol impair cancer stemness  
In line with the findings of induction of differentiation, resveratrol impairs biomarkers of 
pluripotency. We found that resveratrol downmodulates the homeobox protein Nanog 
(NANOG). This transcription factor maintains pluripotency in embryonic stem cells and 
cancer stem cells. The activity of Nanog is associated with many different types of cancer. 
It is considered an oncogene and its high expression correlates with poor survival, 
therapeutic resistance, relapse, and metastasis. Its upregulation enhances tumorigenicity 
both in vivo and in vitro whereas their repression inhibits tumor initiation 257. Thus, its 
downregulation is consistent with the upregulation of transcription factors related to cell 
differentiation. Recent evidence demonstrated that resveratrol inhibits Nanog, affecting 
the self-renewal capacity of pancreatic cancer stem cells reducing tumor growth and 
development in mice. Furthermore, the pancreatic cancer cells showed a lower capacity 
of invasion, migration, and resistance to chemotherapy and radiation 258.  
Furthermore, resveratrol also represses the expression of the recombining binding protein 
suppressor of hairless (RBPSUH), a transcriptional regulator of Notch signaling. This 
signaling pathway is involved in cell-cell communication and regulates cell-fate 
determination during embryonic development. The Notch signaling regulates Nanog and 
the insulin-like growth factor 1 (IGF1-R), and helps in maintain stemness by preventing 
cellular differentiation 259. In line with the induction of differentiation by resveratrol, it 
showed downregulation of the transcription factor (THRAP3). This protein is involved in 
the ability of prostate cancer cells to grow in an androgen‐independent manner 260. 
Therefore, this finding suggests that PC3 cells become less aggressive when exposed to 
resveratrol.  
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5.4.4. Resveratrol reduces metastatic potential 
Consistent with the previous assumption, resveratrol induces the upregulation of tight 
junction proteins and cell adhesion molecules. We found overexpression of the tight 
junction protein ZO-2 (TJP2), gap junction alpha-1 protein (GJA1), the tight junction 
partitioning defective 6 homolog gamma Gap (PARD6G), the gap junction alpha-10 
protein (NP115991), and the unconventional myosin-VIIb (MYO7B). Among the cell 
adhesion molecules syndecan-2 cell adhesion molecule (SDC2), the high-affinity 
immunoglobulin gamma Fc receptor (FCGR1A) and necdin (NDN). These proteins control 
cellular proliferation and differentiation and during cancer progression and metastasis are 
frequently deleted. Furthermore, induction of their expression in vitro promotes the 
abrogation of the metastatic potential of the cell lines 261.  
 
5.4.5. Resveratrol reprogram cell metabolism  
Resveratrol affects genes involved in cell metabolism and the process of autophagia on 
PC3 cells. The mitochondrial activity, and the electron transport chain were highly 
affected. Resveratrol downregulated ATPases, GTPases, DNA, and RNA polymerases, 
kinases, transferases, and n-methyltransferases. The metabolic pathways affected are 
involved with the metabolism of glucose, fatty acids, amino acids, ATP, NADPH, and 
cytochromes. We found downmodulation of 40 genes related to metabolism, including the 
mitochondrial cytochromes CYB561D2, the NAD(P) transhydrogenase (NNT), the 
NADPH P450 reductase (POR), and the c oxidase subunit 1 (MT-CO1). The lipid 
metabolism was affected as showed by the downregulation of the palmitoyltransferase 
specific of HRas (ZDHHC9) and the palmitoyltransferase (ZDHHC20), the fatty-acid 
amide hydrolase (FAAH2), the very-long-chain 3-hydroxyacyl-CoA dehydratase (PTPLA) 
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and the long-chain fatty acid transport protein 1 ligase (SLC27A1) and the acyl-coenzyme 
A thioesterase 11 (ACOT11). Furthermore, the tricarboxylate mitochondrial transport 
protein (SLC25A1), the sarcosine mitochondrial dehydrogenase (SARDH) and the 
creatine kinase M-type (CKM) were also affected. Taken together these changes in 
expression indicate disruption of cancer cell metabolism by resveratrol, particularly 
affecting mitochondrial functions. Recently, resveratrol has been to be shown to inhibit the 
mitochondrial electron transport chain proteins, NADH/ubiquinone oxidoreductase 
complex-1, F0-F1 ATPase, and cytochrome P450 isoenzymes such as CYP1A1, and 
quinone reductase-2 (QR-2) 262, which is consistent with our results. Furthermore, it has 
been proved that resveratrol suppresses the fermentative glycolysis in normoxia of tumors 
(Warburg effect). This high glycolytic phenotype results from the conjunction of 
uncontrolled growth signaling, deregulated c-Myc and HIF-1 activity leading to induction 
of glycolytic enzymes and inhibition of mitochondrial pyruvate oxidation 263. Resveratrol 
targets the pyruvate dehydrogenase complex in cancer cells and PI3K signaling pathway. 
Resveratrol also downregulate the glucose transporter GLUT1, phosphofructokinase, the 
hexokinase 2, the phosphoglycerate mutase, the glucose 6 phosphate dehydrogenase, 
the transketolase and the pyruvate kinase 2 264. Thus, resveratrol seems to normalize the 
metabolism and the altered mitochondria functions deregulated in cancer 265. 
 
5.4.6. Resveratrol abrogates cancer pathways 
Resveratrol was able to downmodulate key components of pathways involved in 
carcinogenesis such as the TGF-β, Notch, HIF-1α, PI3K/Akt and insulin/IGF-1 signaling. 
Several findings indicate that exists a cross-talk among the major signaling pathways 
involved in carcinogenesis 266. Our results support the integrated nature of the molecular 
98 
 
networks involved in cellular differentiation, growth, and metabolism. Resveratrol was able 
to affect those processes at the transcriptional level, but also showed changes in the 
cancer pathways. For example, the gene glucagon-like peptide 1 receptor (GLP1R) was 
downregulated on PC3 exposed to resveratrol. GLP-1 receptors are expressed in most 
cancer cells and upon activation exert proliferation via activation of PI3K and MAPK 
kinases 267. We found downmodulation of the phosphatidylinositol 3-kinase regulatory 
subunit beta (PIK3R2) which is considered an oncogene and is highly amplified in 
neoplasia. Additionally, resveratrol downmodulated the phospholipase C gamma 
(PLCG1), a member of the family of phosphoinositide specific PLC that converts 
phosphatidylinositol 4,5-bisphosphate into second messengers 1,2-diacylglycerol (DAG) 
and inositol 1,4,5-trisphosphate (IP3), thereby initiating and propagating proliferation.  
 
Resveratrol also increases the expression of negative regulators of proliferation. The 
insulin-like growth factor-binding protein 6 (IGFBP6) possess anticancer effects; its 
expression inhibits cell proliferation in PC-3 cells. IGFBP-6 blocks the IGF-II in a dose-
dependent manner 268 These genes are major components of the insulin/IGF-1 signaling 
which is frequently deregulated in cancer 269. We found upregulation of the protein called 
mothers against decapentaplegic homolog 7 (Smad7). This protein prevents TGF-β-
associated Smad signaling. Smad7 abrogates tumorigenesis in late stage cancers mainly 
through family E3 ubiquitin ligases 270. We found that another mechanism by which 
resveratrol abrogates TGF-β pathway is by the downregulation of the receptor of TGF-β, 
the bone morphogenetic protein receptor type-2 (BMPR2). The downregulation of the 
TGF-β pathway by resveratrol might implicate the inactivation of angiogenesis, the 
epithelial-mesenchymal transition (EMT) and the CSC properties of the PC3 cells 271. It 
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has been reported that sirtuins inactivates hypoxia-inducible factor (HIF)-1α, and inhibits 
β-catenin and cyclins 272. SIRT5 was upregulated by resveratrol. It normally resides in the 
mitochondrial matrix and catalyzes the removal of negatively charged lysine acyl 
modifications; succinyl, malonyl, and glutaryl groups. SIRT5 acts as a regulator of cellular 
homeostasis. SIRT5 regulates protein substrates involved in glycolysis, the TCA cycle, 
fatty acid oxidation, electron transport chain, ketone body formation, nitrogenous waste 
management, and ROS detoxification. Furthermore, SIRT5 is involved in tumor 
suppressor mechanisms and also explains the metabolic changes observed with 
resveratrol exposition 273.  
 
5.4.7. Resveratrol sensitizes to apoptosis 
The downregulation of the MDM4 gene suggests the induction of apoptosis by the 
reactivation of the p53 pathway. The protein p53 is the most frequently inactivated gene 
in human cancers, is mutated in more than half of human tumors. In response to various 
extra and intracellular stresses p53 functions as a transcriptional factor and transactivates 
a set of genes engaged in multiple cellular processes such as cell-cycle arrest, cellular 
senescence, energy metabolism, and apoptosis. p53 signaling is inactivated by high 
levels of p53 inhibitors, such as Mdm4. The upregulation of Mdm4 serves as an alternate 
means of inactivating the p53 pathway 274. Thus, resveratrol seems to reactivate p53 
pathway by suppressing MDM4 gene. Furthermore, we also found the upregulation of the 
apoptosis-inducing factor 1 (AIFM1). This mitochondrial protein indicates apoptosis and 
its overexpression in cancer cell lines is related to apoptosis mediated by caspase 3 275. 
To our knowledge, this is the first report of the study of the effects of resveratrol on PC3 
cells by microarrays. 
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Previously the LNCaP cells; another in vitro model of prostate cancer was studied by DNA 
microarrays. Upon exposition at 150 μM of resveratrol in DMSO (0.01%) for 24 h they 
analyzed the expression change (>2.0-fold) among 42,000 genes. They found that 
resveratrol inhibits 50% of cell growth by affecting 1656 genes. They found 37 genes 
upregulated and 63 downregulated related to stress, lipid metabolism, protein trafficking, 
androgen responsiveness and cell proliferation. The most affected genes were related to 
proliferation such as the p53-induced protein sestrin (PA26), the tumor susceptibility gene 
(TSG101), P300/CBP-associated factor (PCAF) and the histone deacetylase 3 (HDAC3). 
The proapoptotic genes induced were the transcription factor JunD (JUND), the 
phospholipase A2 (PLA2), p53 (TP53), the murine double minute 2 (MDM2), the 
programmed cell death 4 (PDCD4) and the serine/threonine kinase 17a (STK17A). They 
conclude that resveratrol elicits gene expression changes with anticancer activities in 
prostate cancer cells by regulation of the androgen axis and cell cycle 244.  It is important 
to clarify that the LNCaP is a cell line derived from a metastatic lymph node lesion of 
human prostate cancer which is AR-positive, thus exhibits androgen-sensitive growth. In 
contrast, PC3 cells are human prostate cancer cells derived from bone metastasis of 
grade IV prostate cancer. Thus, PC3 are useful in investigating biochemical changes in 
advanced prostate cancer cells, such as the mechanism of resistance to androgen 
ablation. PC3 have high metastatic potential compared to LNCaP cells, which have low 
metastatic potential. Thus, a direct comparison is not straightforward, and PC3 cells 
represent an advanced stage of the disease with more aggressive traits and a less 
differentiated phenotype 276. 
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CHAPTER VI 
6. CONCLUSIONS 
 
 
The metabolomic profile of Cissus trifoliata (L.) L was analyzed by the hyphenated techniques of 
GC-MS and LC-MS. The use of accurate mass spectrometry and spectral data led to the 
identification of C. trifoliata stems as a high producer of anticancer compounds of the class of 
terpenes, sterols, flavonoids, and stilbenes. The MTS and WST-1 antiproliferative assays with the 
cancer cells A549, HepG2, Hep3B, HeLa, MCF7, and PC3 provide insight on the antitumor activity 
of the plant. The hexane and aqueous extract showed high cytotoxic activity, and their bioactive 
triterpenes, sterols, and polyphenols suggested synergistic antiproliferative and antiestrogenic 
effects against the HepG2, Hep3B, and MCF7 cells. The combination of column chromatography, 
LC-MS, and WST-1 led to the identification of the fraction with the most anticancer properties in 
the CHCl3-MeOH extract. The bioassay-guided study showed that the content of the fraction F1 
includes the antitumor compounds 2-alpha hydroxyursolic acid, ursolic acid, betulinic acid, 
dihydrokaempferol, apigenin, kaempferol, chrysoeriol, naringenin, and resveratrol. The 
identification of resveratrol in the most active fraction encourages its selection for the evaluation 
of its mechanism of action. The findings of the microarray study indicated novel mechanisms of 
action of resveratrol against the proliferation of prostate cancer cells that include the 
downregulation of the transcription factor Nanog. Therefore, is suggested that resveratrol impairs 
the cancer stem cell characteristics of PC3 cells by induction of differentiation and the loss of 
malignancy. According to our results, the metabolic profile of Cissus trifoliata is enriched in 
anticancer compounds associated with its antiproliferative effects against cancer cells, and the 
molecular mechanism of an active constituent provides a better understanding of this medicinal 
plant used in the management of tumors. 
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CHAPTER VII 
7. PERSPECTIVES 
 
The metabolic profiling of C. trifoliata by advanced chromatography-spectrometry 
technology represented an effective tool to detect and identify its bioactive content and to 
understand its traditional use. Nonetheless, since comparison with databases was used 
for compound identification, the characterization at a higher level of confidence would 
require the inclusion of authentic standards. 
The microarray analysis suggested many anticancer properties of resveratrol including 
novel mechanisms of action against PC3 cells. The investigation of the mechanism 
underlying the inhibition of the pluripotency maintaining factors altogether with biological 
assays for the evaluation of cancer stem properties, migration, and invasion would provide 
additional evidence to support the findings. 
Proponents of the medicinal use of natural mixtures often claim that complete extracts are 
more effective than purified compounds due to the synergy that efficiently addresses the 
problematic of tumor resistance. Cissus trifoliata is traditionally used as an aqueous 
extract. The understanding of how the complex mixture of compounds acts in concert to 
achieve the biological effect would require the application of advanced analytical and 
molecular techniques. Additionally, the use of a murine model of tumorigenesis is required 
to provide a more comprehensive characterization of the systemic antitumor properties of 
C. trifoliata.  
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Supplementary Contents 
Table 24. Functional annotation of upregulated genes by resveratrol (IC25) on PC3 cells (part 1) 
No Gene ID Gene Name Biological function 
1 SNX12 Sorting nexin-12  
2 AHNAK Neuroblast differentiation-associated protein AHNAK  
3 ABCA12 ATP-binding cassette sub-family A member 12 ATP-binding cassette (ABC) transporter 
4 NP001025045 Rab15 effector protein  
5 CAV3 Caveolin-3 G-protein modulator 
6 ERCC6 DNA excision repair protein ERCC-6  
7 HMX2 Homeobox protein HMX2 transcription factor 
8 C7orf26 Uncharacterized protein C7orf26  
9 GABPB2 GA-binding protein subunit beta-1  
10 ALG1 beta-mannosyltransferase glycosyltransferase 
11 MAFA Transcription factor MafA basic leucine zipper transcription factor 
12 NP001073958 Glyoxalase domain-containing protein 5  
13 KITLG Kit ligand  
14 ACSS2 Acetyl-coenzyme A synthetase, cytoplasmic  
15 IKZF1 DNA-binding protein Ikaros KRAB box transcription factor 
16 DCHS2 Protocadherin-23  
17 ZNF524 Zinc finger protein 524 transcription factor 
18 PCDH18 Protocadherin-18  
19 EFHC2 EF-hand domain-containing family member C2  
20 HOXD12 Homeobox protein Hox-D12 transcription factor 
21 OGT UDP-N-acetylglucosamine N-acetylglucosaminyltransferase  
22 MON1A Vacuolar fusion protein MON1 homolog A  
23 KRBA2 KRAB-A domain-containing protein 2  
24 MTHFD2 Bifunctional methylenetetrahydrofolate  dehydrogenase, mitochondrial 
25 RBX1 E3 ubiquitin-protein ligase RBX1 ubiquitin-protein ligase 
26 IZUMO1 Izumo sperm-egg fusion protein 1  
27 UTP20 Small subunit processome component 20 homolog  
28 FAM124B Protein FAM124B  
29 UBADC1 Ubiquitin-associated domain-containing protein 1  
30 VAMP4 Vesicle-associated membrane protein 4  
31 ATP5H ATP synthase subunit d, mitochondrial ATP synthase 
32 MLL3 Histone-lysine N-methyltransferase 2C epigenetic modifier 
33 KDELR3 ER lumen protein-retaining receptor 3 membrane trafficking regulatory protein 
34 SERPINC1 Antithrombin-III serine protease inhibitor 
35 NP_056274 Atlastin-3 heterotrimeric G-protein 
36 CTSZ Cathepsin Z cysteine protease 
37 ATXN1 Ataxin-1  
38 MARCH7 E3 ubiquitin-protein ligase MARCH7  
39 LAGE3 EKC/KEOPS complex subunit LAGE3  
40 CITED4 Cbp/p300-interacting transactivator 4 transcription cofactor 
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Table 24. Functional annotation of upregulated genes by resveratrol (IC25) on PC3 cells (part 2) 
No Gene ID Gene Name Biological function 
41 NUSAP1 Nucleolar and spindle-associated protein 1  
42 SIRT5 NAD-dependent protein, sirtuin-5, mitochondrial chromatin deacylase  
43 CENTD3 Arf-GAP with Rho-GAP domain PH domain-containing protein 3 
44 GJA1 Gap junction alpha-1 protein gap junction 
45 ARSJ Arylsulfatase J  
46 DNM1L Dynamin-1-like protein hydrolase 
47 GABRA3 Gamma-aminobutyric acid receptor subunit alpha-3 GABA receptor 
48 CASP8AP2 CASP8-associated protein 2 transcription cofactor 
49 RYK Tyrosine-protein kinase RYK tyrosine kinase 
50 IRX5 Iroquois-class homeodomain protein IRX-5 homeodomain transcription factor 
51 ZNF750 Zinc finger protein 750 transcription factor 
52 TBX1 T-box transcription factor TBX1 Rel homology transcription factor 
53 ATP10D Probable phospholipid-transporting ATPase VD cation transporter 
54 VNN3 Vascular non-inflammatory molecule 3 hydrolase 
55 C12orf46 Endoplasmic reticulum resident protein 27  
56 AGBL3 Cytosolic carboxypeptidase 3 G protein, metalloprotease 
57 MCAT Mitochondrial carnitine acylcarnitine carrier protein 
58 LRRC37A Leucine-rich repeat-containing protein 37A extracellular matrix protein 
59 MRPS27 28S ribosomal protein S27, mitochondrial ribosomal protein 
60 TAF13 Transcription initiation factor TFIID subunit 13 transcription cofactor 
61 SSX2IP Afadin- and alpha-actinin-binding protein  
62 USP44 Ubiquitin carboxyl-terminal hydrolase 44 cysteine protease 
63 KCNK6 Potassium channel subfamily K member 6 channel protein 
64 TAF15 TATA-binding protein-associated factor 2N transcription cofactor 
65 MYOCD Myocardin  
66 MYB Transcriptional activator Myb transcription factor 
67 MAML3 Mastermind-like protein 3 transcription factor 
68 NP001017361 KHDC3-like protein  
69 DIP2A Disco-interacting protein 2 homolog A  
70 NP001004318 Acid phosphatase type 7 phosphatase 
71 KLF14 Transcription factor Sp6 transcription factor 
72 EEF1B2 Elongation factor 1-beta translation elongation factor 
73 ACOT4 Acyl-coenzyme A thioesterase 4 thioesterase 
74 STK3 Serine/threonine-protein kinase 24 kinase 
75 ZNF256 Zinc finger protein 256 transcription factor 
76 FAM78A Protein FAM78A  
77 ACSBG1 Long-chain-fatty-acid-CoA ligase ACSBG1 ligase 
78 CYP4A11 Cytochrome P450 4A11 oxygenase 
79 MCF2L Guanine nucleotide exchange factor DBS signaling molecule 
80 FCGR1A High affinity immunoglobulin gamma Fc receptor I cell adhesion molecule 
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Table 24. Functional annotation of upregulated genes by resveratrol (IC25) on PC3 cells (part 3) 
No Gene ID Gene Name Biological function 
81 DNAH2 Dynein heavy chain 2, axonemal hydrolase 
82 HSPA5 Endoplasmic reticulum chaperone BiP chaperone 
83 LCN2 Neutrophil gelatinase-associated lipocalin isomerase 
84 MARK1 Serine/threonine-protein kinase MARK1 serine/threonine protein kinase 
85 PROM1 Prominin-1 membrane traffic protein 
86 CALN1 Calcium-binding protein 8 binding protein 
87 MAK10 N-alpha-acetyltransferase 35, NatC auxiliary subunit acetyltransferase 
88 MAP2K5 Dual specificity mitogen-activated protein kinase kinase 5 kinase 
89 SCG3 Secretogranin-3  
90 DHX32 pre-mRNA-splicing factor ATP-dependent helicase  RNA helicase  
91 PDE4DIP Myomegalin  
92 ITPR3 Inositol 1,4,5-trisphosphate receptor type 3 ligand-gated ion channel 
93 OR52K2 Olfactory receptor 52K2  
94 SUSD5 Sushi domain-containing protein 5  
95 CCDC75 G patch domain-containing protein 11 G protein 
96 TFAP2C Transcription factor AP-2 gamma transcription factor 
97 C20orf186 BPI fold-containing family B member 4  
98 REPS2 RalBP1-associated Eps domain-containing protein 2 G-protein modulator 
99 PARD6G Partitioning defective 6 homolog gamma tight junction 
100 NAT8B Putative N-acetyltransferase 8B acetyltransferase 
101 EIF4H Eukaryotic translation initiation factor 4H translation initiation factor 
102 PLXNB3 Plexin-B3  
103 ANAPC2 Anaphase-promoting complex subunit 2  
104 UBE1L Ubiquitin-like modifier-activating enzyme 7 ligase 
105 SEMA3F Semaphorin-3F membrane-bound signaling molecule 
106 THAP6 THAP domain-containing protein 6  
107 RASSF2 Ras association domain-containing protein 2 G-protein modulator 
108 DEF6 Differentially expressed in FDCP 6 homolog nucleic acid binding 
109 DMRTC1 Doublesex- and mab-3-related transcription factor C1  
110 TMEM143 Transmembrane protein 143 transmembrane protein 
111 GTF2H1 General transcription factor IIH subunit 1 transcription factor  
112 RBM41 RNA-binding protein 41 Rna binding protein 
113 DPT Dermatopontin extracellular matrix protein 
114 HMGB3 High mobility group protein B3 HMG box transcription factor 
115 ZNF8 Zinc finger protein 8 transcription factor 
116 AIFM1 Apoptosis-inducing factor 1, mitochondrial dehydrogenase 
117 ALG1 Alpha-1,3/1,6-mannosyltransferase ALG2 transferase 
118 NP115991 Gap junction alpha-10 protein gap junction 
119 DEFB112 Beta-defensin 112  
120 ZNF782 Zinc finger protein 782 KRAB box transcription factor 
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Table 24. Functional annotation of upregulated genes by resveratrol (IC25) on PC3 cells (part 4) 
No Gene ID Gene Name Biological function 
121 JMJD2B Lysine-specific demethylase 4B zinc finger transcription factor 
122 UBE2J1 Ubiquitin-conjugating enzyme E2 J1  
123 MCAT Malonyl-CoA-acyl carrier protein transacylase, mitochondrial 
124 KLF14 Krueppel-like factor 14 transcription factor 
125 PCMT1 Protein-L-isoaspartate(D-aspartate) O-methyltransferase methyltransferase 
126 VPS4B Vacuolar protein sorting-associated protein 4B non-motor microtubule binding protein 
127 C17orf78 Uncharacterized protein C17orf78  
128 SRGAP2 SLIT-ROBO Rho GTPase-activating protein 2 G-protein modulator 
129 C9orf72 Guanine nucleotide exchange C9orf72  
130 CD74 HLA class II histocompatibility antigen gamma chain protease inhibitor 
131 FAM18B Golgi apparatus membrane protein TVP23 homolog B  
132 KIAA1602 Nck-associated protein 5-like  
133 FBXW11 F-box/WD repeat-containing protein 11  
134 POU4F2 POU domain, class 4, transcription factor 2 transcription factor 
135 SPTBN5 Spectrin beta chain, non-erythrocytic 5  
136 GRM1 Metabotropic glutamate receptor 1 G-protein coupled receptor 
137 ISCU Iron-sulfur cluster assembly enzyme ISCU, mitochondrial  
138 GUCA1B Guanylyl cyclase-activating protein 2  
139 C18orf17 Tetratricopeptide repeat protein 39C  
140 PHF11 PHD finger protein 11 DNA binding protein 
141 SUSD2 Sushi domain-containing protein 2  
142 NFAM1 NFAT activation molecule 1  
143 C4orf18 Protein FAM198B  
144 CRTAC1 Cartilage acidic protein 1  
145 GABPB2 GA-binding protein subunit beta-2  
146 TAF15 Transcription initiation factor TFIID subunit 12 transcription factor 
147 SDC2 Syndecan-2 cell adhesion molecule 
148 C1orf35 SDC2 extracellular matrix glycoprotein 
149 MMTAG2 Multiple myeloma tumor-associated protein 2  
150 LHX8 LIM/homeobox protein Lhx8 RNA binding protein 
151 CCL17 C-C motif chemokine 17 chemokine 
152 MYO7B Unconventional myosin-VIIb cell junction protein 
153 HOXA3 Homeobox protein Hox-A3 transcription factor 
154 TSSK2 Testis-specific serine/threonine-protein kinase 2 serine/threonine protein kinase 
155 EFS Embryonal Fyn-associated substrate  
156 YBX1 Nuclease-sensitive element-binding protein 1  
157 SLC9A10 Sodium/hydrogen exchanger 10  
158 DFFA DNA fragmentation factor subunit alpha  
159 TJP2 Tight junction protein ZO-2 tight junction 
160 PIK3AP1 Phosphoinositide 3-kinase adapter protein 1  
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Table 24. Functional annotation of upregulated genes by resveratrol (IC25) on PC3 cells (part 5) 
No Gene ID Gene Name Biological function 
161 ADRBK2 Beta-adrenergic receptor kinase 2 serine/threonine protein kinase 
162 KCNN2 Calcium-activated potassium channel protein 2 voltage-gated potassium channel 
163 MAFA Killer cell lectin-like receptor subfamily G member 1  
164 VPS33A Vacuolar protein sorting-associated protein 33A membrane trafficking regulatory protein 
165 ZBTB32 Zinc finger and BTB domain-containing protein 32  
166 CCDC107 Coiled-coil domain-containing protein 107  
167 NOB1 RNA-binding protein NOB1 RNA-binding protein 
168 SERPIND1 Heparin cofactor 2 serine protease inhibitor 
169 NDST2 Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 2 deacetylase 
170 NELFB_ Negative elongation factor B  
171 ELL3 RNA polymerase II elongation factor ELL3 transcription factor 
172 SLC17A3 Sodium-dependent phosphate transport protein 4 cation transporter 
173 IGFBP6 Insulin-like growth factor-binding protein 6 protease inhibitor 
174 XRRA1 X-ray radiation resistance-associated protein 1  
175 NFATC4 Nuclear factor of activated T-cells, cytoplasmic 4 Rel homology transcription factor 
176 C14orf179 Intraflagellar transport protein 43 homolog  
177 PDE8B cAMP-specific 3',5'-cyclic phosphodiesterase 8B phosphodiesterase 
178 SRFBP1 Serum response factor-binding protein 1  
179 MRPL27 39S ribosomal protein L27, mitochondrial ribosomal protein 
180 NUP93 Nuclear pore complex protein Nup93 transporter 
181 PSME4 Proteasome activator complex subunit 4  
182 VANGL1 Vang-like protein 1  
183 FAM114A1 Protein NOXP20  
184 PLCB4 1-PI, 4,5-bisphosphate phosphodiesterase beta-4 signaling molecule 
185 DEF6 Defensin-6  
186 GABPA GA-binding protein alpha chain nucleic acid binding 
187 OR5H1 Olfactory receptor 5H1  
188 SMAD7 Mothers against decapentaplegic homolog 7 transcription factor 
189 DUSP11 RNA/RNP complex-1-interacting phosphatase nucleotidyltransferase 
190 TRIM7 E3 ubiquitin-protein ligase TRIM7  
191 LCT Lactase-phlorizin hydrolase glycosidase 
192 NDN Necdin cell adhesion molecule 
193 C20orf94 Protein SLX4IP  
194 MAP3K1 Mitogen-activated protein kinase kinase kinase 1 kinase 
195 KIF23 Kinesin-like protein KIF23 microtubule binding motor protein 
196 PHKA2 Phosphorylase b kinase regulatory subunit alpha, liver isoform kinase activator 
197 PHYHIPL Phytanoyl-CoA hydroxylase-interacting protein-like  
198 TMPRSS3 Transmembrane protease serine 4 serine protease 
199 RECQL ATP-dependent DNA helicase Q1 DNA helicase 
200 SLC6A1 Sodium- and chloride-dependent GABA transporter 1 cation transporter 
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Table 24. Functional annotation of upregulated genes by resveratrol (IC25) on PC3 cells (part 6) 
No Gene ID Gene Name Biological function 
201 ARRDC2 Arrestin domain-containing protein 2  
202 ACTR3B Actin-related protein 3B actin and actin related protein 
203 KIAA0562 Centrosomal protein of 104 kDa  
204 MANBA Beta-mannosidase galactosidase 
205 UBE2U Ubiquitin-conjugating enzyme E2 U  
206 TLL2 Tolloid-like protein 2  
207 ZNF507 Zinc finger protein 507 KRAB box transcription factor 
208 LCN8 Epididymal-specific lipocalin-8 isomerase 
209 GPAM Glycerol-3-phosphate acyltransferase 1, mitochondrial acyltransferase 
210 CCDC113 Coiled-coil domain-containing protein 113  
211 ARMCX3 Armadillo repeat-containing X-linked protein 3  
212 SELK_HUMAN Selenoprotein K  
213 ANGPTL4 Angiopoietin-related protein 4 signaling molecule 
214 ZSCAN5 Zinc finger and SCAN domain-containing protein 5A transcription factor  
215 ZNF740 Zinc finger protein 740 transcription factor  
216 SAMSN1 SAM domain-containing protein SAMSN-1  
217 TMPRSS3 Transmembrane protease serine 3 serine protease 
218 ASPH Aspartyl/asparaginyl beta-hydroxylase hydroxylase 
219 RGPD3 RanBP2-like and GRIP domain-containing protein 3 G-protein modulator 
220 PPP1R16B Protein phosphatase 1 regulatory inhibitor subunit 16B phosphatase modulator 
221 NPAS4 Neuronal PAS domain-containing protein 4 basic helix-loop-helix transcription factor 
222 FAM11B Transmembrane protein 185B transmembrane protein 
223 UBQLNL Ubiquilin-like protein  
224 KLK7 Kallikrein-7 serine protease 
225 GLYATL2 GLYATL2  
226 TCFL5 Transcription factor-like 5 protein  
227 ATP6V1C2 V-type proton ATPase subunit C 2 ATP synthase 
228 PRAMEF10 PRAME family member 10  
229 IL7R Interleukin-7 receptor subunit alpha type I cytokine receptor 
230 ZNF662 Zinc finger protein 662 transcription factor 
231 NMBR Neuromedin-B receptor  
232 ZNF544 Zinc finger protein 544 transcription factor 
233 ANKRD10 Ankyrin repeat domain-containing protein 10  
234 GPBP1L1 Vasculin-like protein 1  
235 PKDREJ Polycystic kidney disease and receptor related protein G-protein modulator 
236 SRGAP2 SLIT-ROBO Rho GTPase-activating protein 3 G-protein modulator 
237 USF1 Upstream stimulatory factor 1  
238 ADAM8 Disintegrin domain-containing protein 8 metalloprotease 
239 MRPL27 39S ribosomal protein L41, mitochondrial ribosomal protein 
240 C9orf58 Allograft inflammatory factor 1-like annexin 
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Table 24. Functional annotation of upregulated genes by resveratrol (IC25) on PC3 cells (part 7) 
No Gene ID Gene Name Biological function 
241 ARRB1 Beta-arrestin-1 enzyme modulator 
242 CCDC57 CCDC57  
243 FPR1 fMet-Leu-Phe receptor G-protein coupled receptor 
244 STK3 Serine/threonine-protein kinase 3 kinase 
245 SERPINF1 Pigment epithelium-derived factor serine protease inhibitor 
246 LCORL Ligand-dependent nuclear receptor corepressor DNA-directed RNA polymerase 
247 CRAMP1L Protein cramped-like  
248 DCP2 m7GpppN-mRNA hydrolase  
249 ADAM29 Disintegrin domain-containing protein 29 metalloprotease 
250 ABHD4 Protein ABHD4  
251 BCAS3 Breast carcinoma-amplified sequence 3  
252 PSMD2 26S proteasome non-ATPase regulatory subunit 2 enzyme modulator 
253 SPIRE2 Protein spire homolog 2 actin family cytoskeletal protein 
254 TTC21B Tetratricopeptide repeat protein 21B  
255 KRTAP22-1 Keratin-associated protein 22-1  
256 KCNK18 Potassium channel subfamily K member 18  
257 CENPP Centromere protein P  
258 RPRM Protein reprimo  
259 PKNOX1 Homeobox protein PKNOX1 transcription factor 
260 CC2D1A Coiled-coil and C2 domain-containing protein 1A  
261 P2RXL1 P2RXL1  
262 C21orf2 Protein C21orf2  
263 PCDHA13 Protocadherin alpha-13  
264 FAM20C FAM20C  
265 PURG Purine-rich element-binding protein gamma transcription factor 
266 SPG21 Maspardin  
267 SETD3 Histone-lysine N-methyltransferase setd3 epigenetic modifier 
268 TNKS Tankyrase-1  
269 PGLYRP1 Peptidoglycan recognition protein 1  
270 SNAG1 Sorting nexin-18  
271 USP7 Ubiquitin carboxyl-terminal hydrolase 7 cysteine protease 
272 NP060223 Phospholipid phosphatase-related protein type 1 phoshatase 
273 BLK Tyrosine-protein kinase Blk kinase 
274 ANGPT4 Angiopoietin-4 signaling molecule 
275 CLPX ATP-dependent Clp protease  subunit clpX-like, mitochondrial 
276 MSX2 Homeobox protein MSX-2 transcription factor 
277 MYOM3 Myomesin-3  
278 LHX1 LIM/homeobox protein Lhx1 RNA binding protein 
279 C10orf25 Uncharacterized protein C10orf25  
280 NP612412 Myosin regulatory light chain 10 actin family cytoskeletal protein 
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Table 25. Functional annotation of downregulated genes by resveratrol (IC25) on PC3 cells (part 1) 
No Gene ID Gene Name Biological function 
1 RANBP2 E3 SUMO-protein ligase RanBP2  
2 C10orf49 Unique cartilage matrix-associated protein matrix-associated protein 
3 OR2AJ1 Olfactory receptor 2AJ1 receptor 
4 CYB561D2 Cytochrome b561 domain-containing protein 2 cytochrome  
5 RPL18 60S ribosomal protein L18 ribosomal protein 
6 CBL E3 ubiquitin-protein ligase CBL ligase 
7 PARP8 Poly [ADP-ribose] polymerase 8 - 
8 FBXO3 F-box only protein 3 - 
9 PIK3R2 Phosphatidylinositol 3-kinase regulatory subunit beta kinase modulator 
10 CCNF Cyclin-F kinase activator 
11 MDM4 Protein Mdm4 chromatin/chromatin-binding protein 
12 SFT2D1 Vesicle transport protein SFT2A - 
13 SLC7A14 Probable cationic amino acid transporter amino acid transporter 
14 ARSK Arylsulfatase K sulfatase 
15 TMCC1 Transmembrane and coiled-coil domains protein 1 - 
16 ADAMTSL4 ADAMTS-like protein 4 matrix-associated protein 
17 DOT1L Histone-lysine N-methyltransferase, H3 lysine-79 specific methyltransferase 
18 GALNT3 Polypeptide N-acetylgalactosaminyltransferase 3 glycosyltransferase 
19 SMPX Small muscular protein - 
20 RAB3D Ras-related protein Rab-3D - 
21 USP19 Ubiquitin carboxyl-terminal hydrolase 19 cysteine protease 
22 WDR53 WD repeat-containing protein 53 - 
23 NNT NAD(P) transhydrogenase, mitochondrial dehydrogenase 
24 MPP7 MAGUK p55 subfamily member 7 cell junction protein 
25 FCHO2 F-BAR domain only protein 2 - 
26 CALD1 Caldesmon - 
27 MS4A3 Membrane-spanning 4-domains subfamily A member 3 receptor 
28 WDR7 WD repeat-containing protein 7 - 
29 VN1R5 Vomeronasal type-1 receptor 5 - 
30 SLC6A6 Sodium- and chloride-dependent taurine transporter cation transporter 
31 ZNRF2 E3 ubiquitin-protein ligase ZNRF2 - 
32 RBPSUH Recombining binding protein suppressor of hairless nucleic acid binding 
33 MT1G Metallothionein-1G - 
34 BLOC1S2 Biogenesis of lysosome complex 1 subunit 2 - 
35 KRTAP9-3 Keratin-associated protein 9-3 - 
36 IL10 Interleukin-10 immune system 
37 MED12L Mediator of RNA polymerase II transcription subunit  nucleic acid binding 
38 SRPK1 SRSF protein kinase 1 non-receptor serine/threonine protein kinase 
39 RMND1 Required for meiotic nuclear division protein 1 homolog cell cycle 
40 PDIA6 Protein disulfide-isomerase A6 - 
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Table 25. Functional annotation of downregulated genes by resveratrol (IC25) on PC3 cells (part 2) 
No Gene ID Gene Name Biological function 
41 GABRR2 Gamma-aminobutyric acid receptor subunit rho-2 GABA receptor 
42 MAS1 Proto-oncogene Mas - 
43 LRRIQ2 Centrosomal protein of 97 kDa - 
44 ACTN2 Alpha-actinin-2 - 
45 NGFRAP1 Protein BEX3 - 
46 ATG9A Autophagy-related protein 9A autophagy 
47 STX19 Syntaxin-19 snare protein 
48 DDI2 Protein DDI1 homolog 2 aspartic protease 
49 PABPC5 Polyadenylate-binding protein 5 - 
50 GAS2L1 GAS2-like protein 1 - 
51 TRAF1 TNF receptor-associated factor 1 signaling molecule 
52 RTCD1 RNA 3'-terminal phosphate cyclase RNA binding protein 
53 SVOP Synaptic vesicle 2-related protein - 
54 GPX6 Glutathione peroxidase 6 peroxidase 
55 BMPR2 Bone morphogenetic protein receptor type-2 TGF-beta receptor 
56 CAMK1 Calcium/calmodulin-dependent protein kinase type 1 serine/threonine protein kinase 
57 OR10G4 Olfactory receptor 10G4 receptor 
58 SEC11B Putative signal peptidase complex catalytic subunit  serine protease 
59 MUT Methylmalonyl-CoA mutase, mitochondrial mutase 
60 ZDHHC9 Palmitoyltransferase ZDHHC9 - 
61 ZC3H7A Zinc finger CCCH domain-containing protein 7A nucleic acid binding 
62 C13orf33 Mesenteric estrogen-dependent adipogenesis protein - 
63 SIRPB1 Signal-regulatory protein beta-1 chemokine 
64 PNRC1 Proline-rich nuclear receptor coactivator 1 - 
65 OBP2A Odorant-binding protein 2a isomerase 
66 METT5D1 Probable methyltransferase-like protein 15 methyltransferase 
67 TRIM64 Tripartite motif-containing protein 64 - 
68 RBM34 RNA-binding protein 34 - 
69 ATP10B Probable phospholipid-transporting ATPase VB cation transporter 
70 SLC30A3 Zinc transporter 3 transporter 
71 ARCN1 Coatomer subunit delta vesicle coat protein 
72 HTR4 5-hydroxytryptamine receptor 4 G-protein coupled receptor 
73 SLC25A1 Tricarboxylate transport protein, mitochondrial - 
74 PTPLA Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 - 
75 SPAST Spastin non-motor microtubule binding protein 
76 SARDH Sarcosine dehydrogenase, mitochondrial dehydrogenase 
77 NXF2 Nuclear RNA export factor 2 RNA binding protein 
78 GNPDA1 Glucosamine-6-phosphate isomerase 1 hydrolase 
79 C4orf26 Odontogenesis associated phosphoprotein - 
80 KCNK2 Potassium channel subfamily K member 2 - 
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Table 25. Functional annotation of downregulated genes by resveratrol (IC25) on PC3 cells (part 3) 
No Gene ID Gene Name Biological function 
81 PTGER3 Prostaglandin E2 receptor EP3 subtype G-protein coupled receptor 
82 ODF2L Outer dense fiber protein 2-like - 
83 SETD1B Histone-lysine N-methyltransferase SETD1B chromatin/chromatin-binding protein 
84 SERPINB9 Serpin B9 serine protease inhibitor 
85 RAB36 Ras-related protein Rab-36 - 
86 CD2BP2 CD2 antigen cytoplasmic tail-binding protein 2 chromatin/chromatin-binding protein 
87 CKM Creatine kinase M-type amino acid kinase 
88 MPP7 Chromatin assembly factor 1 subunit B chromatin/chromatin-binding protein 
89 TBC1D20 TBC1 domain family member 20 - 
90 OPA3 Optic atrophy 3 protein - 
91 PNMA5 Paraneoplastic antigen-like protein 5 - 
92 NT5DC3 5'-nucleotidase domain-containing protein 3 nucleotide phosphatase 
93 SIAH1 E3 ubiquitin-protein ligase SIAH1 - 
94 TMEM68 Transmembrane protein 68 - 
95 ATP6V0D2 V-type proton ATPase subunit d 2 ATP synthase 
96 ZDHHC20 Palmitoyltransferase ZDHHC20 transferase 
97 KIAA0310 Protein transport protein Sec16A transporter 
98 NANOG Homeobox protein NANOG homeodomain transcription factor 
99 FAAH2 Fatty-acid amide hydrolase 2 hydrolase 
100 SLC19A3 Thiamine transporter 2 transporter 
101 CHMP5 Charged multivesicular body protein 5 transfer/carrier protein 
102 USP14 Ubiquitin carboxyl-terminal hydrolase 14 cysteine protease 
103 ACE Angiotensin-converting enzyme metalloprotease 
104 DCLRE1A DNA cross-link repair 1A protein - 
105 HERC4 Probable E3 ubiquitin-protein ligase HERC4 - 
106 FAM114A1 Protein NOXP20 - 
107 DUS2L tRNA-dihydrouridine(20) synthase [NAD(P)+]-like - 
108 SSX6 Putative protein SSX6 nucleic acid binding 
109 ZNF667 Zinc finger protein 667 transcription factor 
110 LYPD4 Ly6/PLAUR domain-containing protein 4 - 
111 THRAP3 Thyroid hormone receptor-associated protein 3 transcription factor 
112 OR4C46 Olfactory receptor 4C46 receptor 
113 LBH Protein LBH - 
114 C1orf122 Uncharacterized protein C1orf122 - 
115 TAAR1 Trace amine-associated receptor 1 - 
116 GPX6 Glutathione peroxidase 7 peroxidase 
117 MFSD3 Major facilitator superfamily protein 3 transporter 
118 TRPV1 Transient receptor potential cation channel ion channel 
119 OR2AG1 Olfactory receptor 2AG1 receptor 
120 FBXL18 F-box/LRR-repeat protein 18 - 
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Table 25. Functional annotation of downregulated genes by resveratrol (IC25) on PC3 cells (part 4) 
No Gene ID Gene Name Biological function 
121 OR5M9 Olfactory receptor 5M9 receptor 
122 GLP1R Glucagon-like peptide 1 receptor receptor 
123 OR7G2 Olfactory receptor 7G2 receptor 
124 UBE1 Ubiquitin-like modifier-activating enzyme 1 ligase 
125 ITGB3BP Centromere protein R - 
126 PTHR2 Parathyroid hormone 2 receptor - 
127 SLC27A1 Long-chain fatty acid transport protein 1 ligase 
128 EDG5 Sphingosine 1-phosphate receptor 2 G-protein coupled receptor 
129 NP_001073961 Inactive serine protease 54 annexin 
130 INSR Insulin receptor receptor 
131 FXYD2 Sodium/potassium-transporting ATPase subunit gamma cation transporter 
132 CRABP2 Cellular retinoic acid-binding protein 2 - 
133 RASL11B Ras-like protein family member 11B - 
134 IPO11 Importin-11 small GTPase 
135 ST13 Hsc70-interacting protein - 
136 JPH1 Junctophilin-1 - 
137 POR NADPH-cytochrome P450 reductase cytochrome 
138 CLRN1 Clarin-1 - 
139 STOML1 Stomatin-like protein 1 cytoskeletal protein 
140 S100PBP S100P-binding protein - 
141 RHBDD1 Rhomboid-related protein 4 serine protease 
142 C20orf24 Uncharacterized protein C20orf24 - 
143 UBOX5 RING finger protein 37 - 
144 PCM1 Pericentriolar material 1 protein - 
145 ZNF136 Zinc finger protein 136 transcription factor 
146 CRHR1 Corticotropin-releasing factor receptor 1 - 
147 CCDC129 Coiled-coil domain-containing protein 129 - 
148 PKIA cAMP-dependent protein kinase inhibitor alpha kinase inhibitor 
149 ZNF440 Zinc finger protein 440 KRAB box transcription factor 
150 TMPO Lamina-associated polypeptide 2, isoform alpha peptide hormone 
151 ACOT11 Acyl-coenzyme A thioesterase 11 esterase 
152 RFPL1 Ret finger protein-like 1 - 
153 AGPAT7 Lysophospholipid acyltransferase LPCAT4 acyltransferase 
154 CLDN14 Claudin-14 tight junction 
155 IL1R1 Interleukin-1 receptor type 1 type I cytokine receptor 
156 PLCG1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 calcium-binding protein 
157 SGOL2 Shugoshin 2 - 
158 OR2G3 Olfactory receptor 2G3 receptor 
159 CASC2 Protein CASC2, isoform 3 - 
160 MT-CO1 Cytochrome c oxidase subunit 1 oxidase 
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